MX2010009729A - Inhibitors of protein tyrosine kinase activity. - Google Patents
Inhibitors of protein tyrosine kinase activity.Info
- Publication number
- MX2010009729A MX2010009729A MX2010009729A MX2010009729A MX2010009729A MX 2010009729 A MX2010009729 A MX 2010009729A MX 2010009729 A MX2010009729 A MX 2010009729A MX 2010009729 A MX2010009729 A MX 2010009729A MX 2010009729 A MX2010009729 A MX 2010009729A
- Authority
- MX
- Mexico
- Prior art keywords
- optionally substituted
- substituted
- mmol
- group
- compound according
- Prior art date
Links
- 230000000694 effects Effects 0.000 title claims abstract description 55
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 title abstract description 27
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 title abstract description 27
- 239000003112 inhibitor Substances 0.000 title description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 222
- 239000000203 mixture Substances 0.000 claims abstract description 116
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 115
- 201000010099 disease Diseases 0.000 claims abstract description 93
- 230000005764 inhibitory process Effects 0.000 claims abstract description 57
- 238000000034 method Methods 0.000 claims abstract description 47
- 230000002062 proliferating effect Effects 0.000 claims abstract description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 80
- 125000000623 heterocyclic group Chemical group 0.000 claims description 77
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 60
- 125000003118 aryl group Chemical group 0.000 claims description 59
- 125000000217 alkyl group Chemical group 0.000 claims description 44
- 108091000080 Phosphotransferase Proteins 0.000 claims description 43
- 102000020233 phosphotransferase Human genes 0.000 claims description 43
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 37
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 36
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 35
- 125000004076 pyridyl group Chemical group 0.000 claims description 34
- 229910052757 nitrogen Inorganic materials 0.000 claims description 33
- 125000001424 substituent group Chemical group 0.000 claims description 33
- 125000001072 heteroaryl group Chemical group 0.000 claims description 32
- 230000002401 inhibitory effect Effects 0.000 claims description 29
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 20
- 230000033115 angiogenesis Effects 0.000 claims description 19
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 18
- 125000002883 imidazolyl group Chemical group 0.000 claims description 17
- 229940002612 prodrug Drugs 0.000 claims description 17
- 239000000651 prodrug Substances 0.000 claims description 17
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 239000012453 solvate Substances 0.000 claims description 11
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 10
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 150000001204 N-oxides Chemical class 0.000 claims description 8
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000004677 hydrates Chemical class 0.000 claims description 7
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 7
- 125000005942 tetrahydropyridyl group Chemical group 0.000 claims description 7
- 125000004953 trihalomethyl group Chemical group 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 6
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 6
- 125000000335 thiazolyl group Chemical group 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 5
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 4
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 4
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 4
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 6
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 230000011664 signaling Effects 0.000 abstract description 40
- 108091008605 VEGF receptors Proteins 0.000 abstract description 24
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 abstract description 21
- 208000035475 disorder Diseases 0.000 abstract description 20
- 102000005962 receptors Human genes 0.000 abstract description 15
- 108020003175 receptors Proteins 0.000 abstract description 15
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract description 11
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 215
- -1 tere-butyl Chemical group 0.000 description 207
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 186
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 171
- 239000000243 solution Substances 0.000 description 82
- 229910001868 water Inorganic materials 0.000 description 79
- 235000019439 ethyl acetate Nutrition 0.000 description 77
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 74
- 239000011541 reaction mixture Substances 0.000 description 72
- 239000007787 solid Substances 0.000 description 70
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 63
- 210000004027 cell Anatomy 0.000 description 56
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 51
- 206010028980 Neoplasm Diseases 0.000 description 38
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 34
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 33
- 241001465754 Metazoa Species 0.000 description 31
- 239000012074 organic phase Substances 0.000 description 31
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 29
- 150000003254 radicals Chemical class 0.000 description 29
- 239000003480 eluent Substances 0.000 description 27
- 239000000725 suspension Substances 0.000 description 26
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 24
- 239000012267 brine Substances 0.000 description 24
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 24
- 210000004204 blood vessel Anatomy 0.000 description 23
- 229920006395 saturated elastomer Polymers 0.000 description 23
- 238000011282 treatment Methods 0.000 description 23
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 22
- 241000124008 Mammalia Species 0.000 description 22
- 238000000746 purification Methods 0.000 description 22
- 230000002829 reductive effect Effects 0.000 description 22
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 21
- 125000004432 carbon atom Chemical group C* 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
- 125000000392 cycloalkenyl group Chemical group 0.000 description 19
- 230000012010 growth Effects 0.000 description 19
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 17
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- 239000004202 carbamide Substances 0.000 description 16
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 15
- 210000001508 eye Anatomy 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 238000004440 column chromatography Methods 0.000 description 13
- 150000002148 esters Chemical class 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 208000002780 macular degeneration Diseases 0.000 description 13
- 239000012044 organic layer Substances 0.000 description 13
- 125000004043 oxo group Chemical group O=* 0.000 description 13
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 150000001412 amines Chemical class 0.000 description 12
- 239000008346 aqueous phase Substances 0.000 description 12
- 230000004663 cell proliferation Effects 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 12
- 125000005843 halogen group Chemical group 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000011734 sodium Substances 0.000 description 12
- 125000003003 spiro group Chemical group 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 235000019270 ammonium chloride Nutrition 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 11
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 10
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N Vilsmeier-Haack reagent Natural products CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- 125000003342 alkenyl group Chemical group 0.000 description 10
- 125000003710 aryl alkyl group Chemical group 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 125000004429 atom Chemical group 0.000 description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 10
- WRIRWRKPLXCTFD-UHFFFAOYSA-N malonamide Chemical compound NC(=O)CC(N)=O WRIRWRKPLXCTFD-UHFFFAOYSA-N 0.000 description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
- 239000002244 precipitate Substances 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 208000007135 Retinal Neovascularization Diseases 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 9
- 206010064930 age-related macular degeneration Diseases 0.000 description 9
- 125000000304 alkynyl group Chemical group 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 9
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 9
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 9
- 238000000967 suction filtration Methods 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- LUBJCRLGQSPQNN-UHFFFAOYSA-N 1-Phenylurea Chemical compound NC(=O)NC1=CC=CC=C1 LUBJCRLGQSPQNN-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 125000004093 cyano group Chemical group *C#N 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 238000003818 flash chromatography Methods 0.000 description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 238000004007 reversed phase HPLC Methods 0.000 description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 229910052717 sulfur Inorganic materials 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- GYQUXKQLCNFKQT-UHFFFAOYSA-N 7-chlorothieno[3,2-b]pyridine Chemical compound ClC1=CC=NC2=C1SC=C2 GYQUXKQLCNFKQT-UHFFFAOYSA-N 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 7
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 7
- 239000007832 Na2SO4 Substances 0.000 description 7
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 125000001183 hydrocarbyl group Chemical group 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 7
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 6
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 6
- 241000288906 Primates Species 0.000 description 6
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 6
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 6
- 230000001594 aberrant effect Effects 0.000 description 6
- 125000002837 carbocyclic group Chemical group 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 229940043355 kinase inhibitor Drugs 0.000 description 6
- 210000005170 neoplastic cell Anatomy 0.000 description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 6
- 230000002207 retinal effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- XMRMXTPDVRPJNZ-UHFFFAOYSA-N 2-bromo-5-(1,3-dioxan-2-yl)pyridine Chemical compound C1=NC(Br)=CC=C1C1OCCCO1 XMRMXTPDVRPJNZ-UHFFFAOYSA-N 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 5
- 206010012689 Diabetic retinopathy Diseases 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 206010029113 Neovascularisation Diseases 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 235000011114 ammonium hydroxide Nutrition 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000004952 protein activity Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 description 5
- 210000001525 retina Anatomy 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 125000001544 thienyl group Chemical group 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 5
- GPWNWKWQOLEVEQ-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carbaldehyde Chemical compound NC1=NC=C(C=O)C(N)=N1 GPWNWKWQOLEVEQ-UHFFFAOYSA-N 0.000 description 4
- QWCGXANSAOXRFE-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanamine Chemical compound COCCOCCN QWCGXANSAOXRFE-UHFFFAOYSA-N 0.000 description 4
- DQTQYVYXIOQYGN-UHFFFAOYSA-N 2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethanamine Chemical compound COCCOCCOCCOCCN DQTQYVYXIOQYGN-UHFFFAOYSA-N 0.000 description 4
- AIIKUEAQCXSYFB-UHFFFAOYSA-N 3-dimethylphosphorylaniline Chemical compound CP(C)(=O)C1=CC=CC(N)=C1 AIIKUEAQCXSYFB-UHFFFAOYSA-N 0.000 description 4
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical class OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
- 108091008603 HGF receptors Proteins 0.000 description 4
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 239000000908 ammonium hydroxide Substances 0.000 description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 description 4
- WMSPXQIQBQAWLL-UHFFFAOYSA-N cyclopropanesulfonamide Chemical compound NS(=O)(=O)C1CC1 WMSPXQIQBQAWLL-UHFFFAOYSA-N 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 125000004404 heteroalkyl group Chemical group 0.000 description 4
- 125000001041 indolyl group Chemical group 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- ZLIBICFPKPWGIZ-UHFFFAOYSA-N pyrimethanil Chemical compound CC1=CC(C)=NC(NC=2C=CC=CC=2)=N1 ZLIBICFPKPWGIZ-UHFFFAOYSA-N 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- AEOIRUGFEFHTSK-UHFFFAOYSA-N 1-dimethylphosphoryl-3-nitrobenzene Chemical compound CP(C)(=O)C1=CC=CC([N+]([O-])=O)=C1 AEOIRUGFEFHTSK-UHFFFAOYSA-N 0.000 description 3
- QTTDOCZRNDCONI-UHFFFAOYSA-N 2-[5-(1,3-dioxan-2-yl)pyridin-2-yl]-7-(2-fluoro-4-nitrophenoxy)thieno[3,2-b]pyridine Chemical compound FC1=CC([N+](=O)[O-])=CC=C1OC1=CC=NC2=C1SC(C=1N=CC(=CC=1)C1OCCCO1)=C2 QTTDOCZRNDCONI-UHFFFAOYSA-N 0.000 description 3
- QAQJKDRAJZWQCM-UHFFFAOYSA-N 2-methoxyethyl carbamate Chemical compound COCCOC(N)=O QAQJKDRAJZWQCM-UHFFFAOYSA-N 0.000 description 3
- FOTZMWKVYASQBZ-UHFFFAOYSA-N 5-(1,3-dioxan-2-yl)-1-methylimidazole Chemical compound CN1C=NC=C1C1OCCCO1 FOTZMWKVYASQBZ-UHFFFAOYSA-N 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 3
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 3
- 208000001344 Macular Edema Diseases 0.000 description 3
- 208000022873 Ocular disease Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000004442 acylamino group Chemical group 0.000 description 3
- 125000002877 alkyl aryl group Chemical group 0.000 description 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 238000010533 azeotropic distillation Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- XRPPFMUYJVNXOU-UHFFFAOYSA-N ethyl n-cyclopropylsulfonylcarbamate Chemical compound CCOC(=O)NS(=O)(=O)C1CC1 XRPPFMUYJVNXOU-UHFFFAOYSA-N 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 102000058223 human VEGFA Human genes 0.000 description 3
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229910052738 indium Inorganic materials 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 206010023332 keratitis Diseases 0.000 description 3
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 3
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 125000000160 oxazolidinyl group Chemical group 0.000 description 3
- 239000006174 pH buffer Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 239000012264 purified product Substances 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000004644 retinal vein occlusion Diseases 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 3
- 230000005747 tumor angiogenesis Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 239000011592 zinc chloride Substances 0.000 description 3
- 235000005074 zinc chloride Nutrition 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- SZXBQTSZISFIAO-ZETCQYMHSA-N (2s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)OC(C)(C)C SZXBQTSZISFIAO-ZETCQYMHSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- VJPPLCNBDLZIFG-ZDUSSCGKSA-N 4-[(3S)-3-(but-2-ynoylamino)piperidin-1-yl]-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide Chemical compound C(C#CC)(=O)N[C@@H]1CN(CCC1)C1=C2C(=C(NC2=C(C=C1F)C(=O)N)C)C VJPPLCNBDLZIFG-ZDUSSCGKSA-N 0.000 description 2
- MXJQJURZHQZLNN-UHFFFAOYSA-N 4-amino-2-fluorophenol Chemical compound NC1=CC=C(O)C(F)=C1 MXJQJURZHQZLNN-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- ORPHLVJBJOCHBR-UHFFFAOYSA-N 403-19-0 Chemical compound OC1=CC=C([N+]([O-])=O)C=C1F ORPHLVJBJOCHBR-UHFFFAOYSA-N 0.000 description 2
- FKPXGNGUVSHWQQ-UHFFFAOYSA-N 5-methyl-1,2-oxazol-3-amine Chemical compound CC1=CC(N)=NO1 FKPXGNGUVSHWQQ-UHFFFAOYSA-N 0.000 description 2
- PVUKGNBRJFTFNJ-UHFFFAOYSA-N 6-bromopyridine-3-carbaldehyde Chemical compound BrC1=CC=C(C=O)C=N1 PVUKGNBRJFTFNJ-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000014882 Carotid artery disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 206010053759 Growth retardation Diseases 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 206010023845 Laryngeal oedema Diseases 0.000 description 2
- 201000008197 Laryngitis Diseases 0.000 description 2
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 206010025415 Macular oedema Diseases 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
- 208000003435 Optic Neuritis Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 201000010183 Papilledema Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010038886 Retinal oedema Diseases 0.000 description 2
- 206010039705 Scleritis Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 206010064996 Ulcerative keratitis Diseases 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 206010058990 Venous occlusion Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000004419 alkynylene group Chemical group 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229960004405 aprotinin Drugs 0.000 description 2
- 125000005140 aralkylsulfonyl group Chemical group 0.000 description 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 2
- 125000000732 arylene group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 125000003943 azolyl group Chemical group 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- 230000009400 cancer invasion Effects 0.000 description 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000005518 carboxamido group Chemical group 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 210000000695 crystalline len Anatomy 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- PQANGXXSEABURG-UHFFFAOYSA-N cyclohex-2-en-1-ol Chemical compound OC1CCCC=C1 PQANGXXSEABURG-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 206010014801 endophthalmitis Diseases 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 231100000001 growth retardation Toxicity 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
- 108010052968 leupeptin Proteins 0.000 description 2
- 201000010230 macular retinal edema Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
- 125000006525 methoxy ethyl amino group Chemical group [H]N(*)C([H])([H])C([H])([H])OC([H])([H])[H] 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- YFCUZWYIPBUQBD-ZOWNYOTGSA-N n-[(3s)-7-amino-1-chloro-2-oxoheptan-3-yl]-4-methylbenzenesulfonamide;hydron;chloride Chemical compound Cl.CC1=CC=C(S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl)C=C1 YFCUZWYIPBUQBD-ZOWNYOTGSA-N 0.000 description 2
- XWCCTMBMQUCLSI-UHFFFAOYSA-N n-ethyl-n-propylpropan-1-amine Chemical compound CCCN(CC)CCC XWCCTMBMQUCLSI-UHFFFAOYSA-N 0.000 description 2
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 201000003142 neovascular glaucoma Diseases 0.000 description 2
- 150000002828 nitro derivatives Chemical class 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 229950000964 pepstatin Drugs 0.000 description 2
- 108010091212 pepstatin Proteins 0.000 description 2
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical compound NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 2
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 201000011195 retinal edema Diseases 0.000 description 2
- 210000001210 retinal vessel Anatomy 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-M toluenesulfonate group Chemical group C=1(C(=CC=CC1)S(=O)(=O)[O-])C LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000759 toxicological effect Toxicity 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- NXMXETCTWNXSFG-BYPYZUCNSA-N (2s)-1-methoxypropan-2-amine Chemical compound COC[C@H](C)N NXMXETCTWNXSFG-BYPYZUCNSA-N 0.000 description 1
- DQUHYEDEGRNAFO-QMMMGPOBSA-N (2s)-6-amino-2-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CCCCN DQUHYEDEGRNAFO-QMMMGPOBSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- VXWBQOJISHAKKM-UHFFFAOYSA-N (4-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=C(C=O)C=C1 VXWBQOJISHAKKM-UHFFFAOYSA-N 0.000 description 1
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- WLXGQMVCYPUOLM-UHFFFAOYSA-N 1-hydroxyethanesulfonic acid Chemical class CC(O)S(O)(=O)=O WLXGQMVCYPUOLM-UHFFFAOYSA-N 0.000 description 1
- CBYAZOKPJYBCHE-UHFFFAOYSA-N 1-iodo-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(I)=C1 CBYAZOKPJYBCHE-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- PYHXGXCGESYPCW-UHFFFAOYSA-M 2,2-diphenylacetate Chemical compound C=1C=CC=CC=1C(C(=O)[O-])C1=CC=CC=C1 PYHXGXCGESYPCW-UHFFFAOYSA-M 0.000 description 1
- HNENEALJPWJWJY-UHFFFAOYSA-N 2,4-difluoro-1-isocyanatobenzene Chemical compound FC1=CC=C(N=C=O)C(F)=C1 HNENEALJPWJWJY-UHFFFAOYSA-N 0.000 description 1
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- RAAGZOYMEQDCTD-UHFFFAOYSA-N 2-fluorobenzoyl chloride Chemical compound FC1=CC=CC=C1C(Cl)=O RAAGZOYMEQDCTD-UHFFFAOYSA-N 0.000 description 1
- GSLTVFIVJMCNBH-UHFFFAOYSA-N 2-isocyanatopropane Chemical compound CC(C)N=C=O GSLTVFIVJMCNBH-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- 125000006087 2-oxopyrrolodinyl group Chemical group 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- 125000004610 3,4-dihydro-4-oxo-quinazolinyl group Chemical group O=C1NC(=NC2=CC=CC=C12)* 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- BNYKZFOZWZMEJD-UHFFFAOYSA-N 3-methylimidazole-4-carbaldehyde Chemical compound CN1C=NC=C1C=O BNYKZFOZWZMEJD-UHFFFAOYSA-N 0.000 description 1
- JAOINXWEFKZYIL-UHFFFAOYSA-N 4-(1-methyl-2-oxoquinolin-4-yl)oxy-n-(4-methylpyridin-2-yl)butanamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC1=CC=NC(NC(=O)CCCOC=2C3=CC=CC=C3N(C)C(=O)C=2)=C1 JAOINXWEFKZYIL-UHFFFAOYSA-N 0.000 description 1
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- WPDAVTSOEQEGMS-UHFFFAOYSA-N 9,10-dihydroanthracene Chemical compound C1=CC=C2CC3=CC=CC=C3CC2=C1 WPDAVTSOEQEGMS-UHFFFAOYSA-N 0.000 description 1
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- 125000004411 C5-C6 heterocyclyl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- 101100148606 Caenorhabditis elegans pst-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000003569 Central serous chorioretinopathy Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000033379 Chorioretinopathy Diseases 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 206010010736 Conjunctival ulcer Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010011715 Cyclitis Diseases 0.000 description 1
- 206010058202 Cystoid macular oedema Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 101001004391 Drosophila melanogaster Protein jim lovell Proteins 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010015084 Episcleritis Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 206010015153 Erythema annulare Diseases 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 208000009481 Laryngeal Edema Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000035719 Maculopathy Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 208000009857 Microaneurysm Diseases 0.000 description 1
- 108700027649 Mitogen-Activated Protein Kinase 3 Proteins 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 1
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 1
- 208000024599 Mooren ulcer Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 101150100019 NRDC gene Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000025047 Non-histaminic angioedema Diseases 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000008709 Retinal Telangiectasis Diseases 0.000 description 1
- 201000001949 Retinal Vasculitis Diseases 0.000 description 1
- 201000007527 Retinal artery occlusion Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 101150055528 SPAM1 gene Proteins 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 229920006328 Styrofoam Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 1
- 208000029977 White Dot Syndromes Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- BBAWTPDTGRXPDG-UHFFFAOYSA-N [1,3]thiazolo[4,5-b]pyridine Chemical compound C1=CC=C2SC=NC2=N1 BBAWTPDTGRXPDG-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 208000023564 acute macular neuroretinopathy Diseases 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 1
- 125000005910 alkyl carbonate group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000005116 aryl carbamoyl group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 210000001775 bruch membrane Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000005569 butenylene group Chemical group 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005622 butynylene group Chemical group 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000001721 carboxyacetyl group Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N cinnamic acid Chemical compound OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Chemical group 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- FWFSEYBSWVRWGL-UHFFFAOYSA-N cyclohex-2-enone Chemical compound O=C1CCCC=C1 FWFSEYBSWVRWGL-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- BFAIMMGBWGSCPF-UHFFFAOYSA-N cyclopenta-1,4-dien-1-ol Chemical compound OC1=CCC=C1 BFAIMMGBWGSCPF-UHFFFAOYSA-N 0.000 description 1
- FQQOMPOPYZIROF-UHFFFAOYSA-N cyclopenta-2,4-dien-1-one Chemical group O=C1C=CC=C1 FQQOMPOPYZIROF-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- 201000010206 cystoid macular edema Diseases 0.000 description 1
- 108091007930 cytoplasmic receptors Proteins 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 description 1
- 125000004987 dibenzofuryl group Chemical group C1(=CC=CC=2OC3=C(C21)C=CC=C3)* 0.000 description 1
- VILAVOFMIJHSJA-UHFFFAOYSA-N dicarbon monoxide Chemical group [C]=C=O VILAVOFMIJHSJA-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000004609 dihydroquinazolinyl group Chemical group N1(CN=CC2=CC=CC=C12)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- WQAWEUZTDVWTDB-UHFFFAOYSA-N dimethyl(oxo)phosphanium Chemical compound C[P+](C)=O WQAWEUZTDVWTDB-UHFFFAOYSA-N 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- TUEYHEWXYWCDHA-UHFFFAOYSA-N ethyl 5-methylthiadiazole-4-carboxylate Chemical compound CCOC(=O)C=1N=NSC=1C TUEYHEWXYWCDHA-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000004615 furo[2,3-b]pyridinyl group Chemical group O1C(=CC=2C1=NC=CC2)* 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000002315 glycerophosphates Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 229940089982 healon Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000034737 hemoglobinopathy Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical class CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical class CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- ZMPXGSYLKFAGOV-UHFFFAOYSA-N hydron;3-methylsulfonylaniline;chloride Chemical compound Cl.CS(=O)(=O)C1=CC=CC(N)=C1 ZMPXGSYLKFAGOV-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004926 indolenyl group Chemical group 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 150000002485 inorganic esters Chemical class 0.000 description 1
- 229910003480 inorganic solid Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 125000005438 isoindazolyl group Chemical group 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940073640 magnesium sulfate anhydrous Drugs 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000008747 mitogenic response Effects 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WFMJTCLDCCCFHE-UHFFFAOYSA-N n-(2-methoxyethyl)acetamide Chemical compound COCCNC(C)=O WFMJTCLDCCCFHE-UHFFFAOYSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical class C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 1
- 208000013441 ocular lesion Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- QNNHQVPFZIFNFK-UHFFFAOYSA-N oxazolo[4,5-b]pyridine Chemical compound C1=CC=C2OC=NC2=N1 QNNHQVPFZIFNFK-UHFFFAOYSA-N 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 208000026475 palpebral edema Diseases 0.000 description 1
- 208000010403 panophthalmitis Diseases 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical class CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 125000004928 piperidonyl group Chemical group 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 description 1
- 125000005547 pivalate group Chemical group 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004263 retinal angiogenesis Effects 0.000 description 1
- 210000001927 retinal artery Anatomy 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 239000000790 retinal pigment Substances 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000008261 styrofoam Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 210000001760 tenon capsule Anatomy 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
- GKTQKQTXHNUFSP-UHFFFAOYSA-N thieno[3,4-c]pyrrole-4,6-dione Chemical compound S1C=C2C(=O)NC(=O)C2=C1 GKTQKQTXHNUFSP-UHFFFAOYSA-N 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000006168 tricyclic group Chemical group 0.000 description 1
- 125000000169 tricyclic heterocycle group Chemical group 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical class CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions.
Description
INHIBITORS OF PROTEIN ACTIVITY TYROSINE KINASE
RELATED REQUESTS
This application claims the benefit of the Provisional Application for
E.U.A. Serial No. 61 / 034,005, filed March 5, 2008. All the teachings of the aforementioned application are incorporated herein for reference.
FIELD OF THE INVENTION
This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular, the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling.
BACKGROUND OF THE INVENTION
Tyrosine kinases can be classified as growth factor receptor (eg, EGFR, PDGFR, FGFR and erbB2) or non-receptor (eg c-src and bcr-abl) kinases. Receiver tyrosine kinases are composed of approximately 20 different subfamilies. Non-receptor type tyrosine kinases are composed of numerous families. These tyrosine kinases have different biological activity. Tyrosine kinase receptors are large enzymes that extend the cell membrane and possess an extracellular binding domain for growth factors, a transmembrane domain, and an intracellular portion that functions as a kinase to phosphorylate a specific tyrosine residue in proteins and by both to influence cell proliferation. Aberrant or inappropriate protein kinase activity may contribute to disease states associated with such aberrant kinase activity.
Angiogenesis is an important component of certain normal physiological processes such as embryogenesis and wound healing, but aberrant angiogenesis contributes to some pathological disorders and in particular to tumor growth. VEGF-A (vascular endothelial growth factor A) is a key factor that promotes neovascularization (angiogenesis) of tumors. VEGF induces endothelial cell proliferation and migration by means of signaling through two high affinity receptors, the fms-type tyrosine kinase receptor, Flt-1, and the receptor-containing kinase domain, KDR. These signaling responses are critically dependent on receptor dimerization and activation of intrinsic receptor tyrosine kinase (RTK) activity. The binding of VEGF as a disulfide-linked homodimer stimulates receptor dimerization and activation of the RTK domain. The kinase activity autophosphorylates the tyrosine residues of the cytoplasmic receptor, which then serves as binding sites for molecules involved in the propagation of a signaling cascade. ough multiple trajectories are linked to be clarified for both receptors, KDR signaling is studied more extensively, with a suggested mitogenic response to involve mitogen-activated protein kinases ERK-1 and ERK-2.
The interruption of VEGF receptor signaling is a very attractive therapeutic target in cancer, since angiogenesis is a prerequisite for all growth of solid tumors, and that mature endothelium remains relatively at rest (with the exception of female reproductive system and wound healing). Several experimental approaches to the inhibition of VEGF signaling have been examined, including the use of neutralizing antibodies, receptor antagonists, soluble receptors, antisense constructs and dominant-negative strategies.
Despite the attractiveness of anti-angiogenic therapy by inhibiting VEGF alone, several issues may limit this
focus. The levels of VEGF expression can be elevated by numerous diverse stimuli and perhaps most importantly, the state of hypoxia of the tumors derived from the inhibition of VEGFR, can lead to the induction of factors that promote tumor invasion and metastasis. , the potential to undermine the impact of VEGF inhibitors as cancer therapies.
HGF (hepatocyte growth factor) and the HGF receptor, c-met, are involved in the ability of tumor cells to undermine the activity of VEGF inhibition. HGF derived from any of the stromal fibroblasts that surround tumor cells or expressed from the tumor itself have been suggested to play a pivotal role in tumor angiogenesis, invasion and metastasis. For example, the growth of invasive cancer cells is drastically improved by the interactions of the stromal tumor that affect the HGF / c-Met (HGF receptor) pathway. HGF, which was originally identified as a potent mitogen for hepatocytes is mainly secreted by stromal cells and secreted HGF can promote the motility and invasion of several cancer cells that express c-Met in a paracrine form. The binding of HGF to c-Met leads to phosphorylation of the receptor and activation of the Ras / mitogen-activated protein kinase signaling pathway (MAPK), thus improving the malignant behavior of cancer cells. On the other hand, stimulation of the HGF / c-met pathway itself can lead to the induction of VEGF expression, contributing automatically
directly to the angiogenic activity.
Therefore, anti-angiogenic antitumor strategies or approaches that target VEGF / VEGFr signaling or HGF / c-met signaling may represent improved cancer therapies.
Tyrosine kinases also contribute to the pathology of ophthalmological diseases, diseases and conditions, such as age-related macular degeneration (AMD) and diabetic retinopathy (RD). The blindness of these diseases has been related to abnormalities in retinal neovascularization. The formation of new blood vessels is regulated by growth factors such as VEGF and HGF that activate tyrosine kinase receptors that result in the opening of signaling pathways that lead to the breakdown of plasma in the macula, causing vision loss. Kinases are attractive targets in this way for the treatment of ocular diseases involving neovascularization.
Therefore, there is a need to develop a strategy to control neovascularization of the eyes and develop a strategy for the treatment of eye diseases.
Small molecules that are potent inhibitors of tyrosine kinase protein activity are described below.
BRIEF DESCRIPTION OF THE INVENTION
The present invention provides novel compounds and methods for the treatment of a disease sensitive to the inhibition of kinase activity, for example a disease sensitive to inhibition of protein tyrosine kinase activity, for example a disease sensitive to inhibition of kinase activity. the protein tyrosine kinase activity of the growth factor receptors, for example a disease sensitive to the inhibition of receptor tyrosine kinase signaling, or for example, a disease sensitive to the inhibition of VEGF receptor signaling. In one embodiment, the disease is a proliferating cell disease. In another modality, the disease is an ophthalmological disease. The compounds of the invention are inhibitors of kinase activity, such as protein tyrosine kinase activity, for example protein tyrosine kinase activity of growth factor receptors, or for example receptor tyrosine kinase signaling.
In a first aspect, the invention provides compounds of formula (I) that are useful as kinase inhibitors:
and N-oxides, hydrates, solvates, pharmaceutically acceptable salts,
prodrugs and their complexes, and racemic and scala mixtures, diastereomers and enantiomers thereof, wherein D, M, Z, Ar and G are as defined herein. Because the compounds of the present invention are useful as kinase inhibitors, they are, therefore, useful research tools for studying the role of kinases in normal and disease states. In some embodiments, the invention provides compounds that are useful as inhibitors of VEGF receptor signaling and, therefore, are useful research tools for the study of VEGF function in normal and disease states.
The reference to "a compound of the formula (I)", (or equivalently, "a compound according to the first aspect", or "a compound of the present invention", and the like), hereinafter will be understood to include reference to N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and their complexes, and racemic and scala mixtures, diastereomers, enantiomers and tautomers thereof, unless otherwise indicated.
In a second aspect, the invention provides compositions comprising a compound according to the present invention and a pharmaceutically acceptable carrier, excipient or diluent. For example, the invention provides compositions comprising a compound that is an inhibitor of VEGF receptor signaling, or a pharmaceutically acceptable salt thereof, and a carrier
pharmaceutically acceptable, excipient or diluent.
In a third aspect, the invention provides a method of inhibiting kinase activity, for example protein tyrosine kinase, for example the activity of the tyrosine kinase of a growth factor receptor, including the contact method of the kinase with a compound according to the present invention, or with a composition according to the present invention. In some embodiments of this aspect, the invention provides a method of inhibiting tyrosine kinase receptor signaling, eg, inhibition of VEGF receptor signaling. The inhibition can be in a cell or a multicellular organism. If in a cell, the method according to this aspect of the invention comprises contacting the cell with a compound according to the present invention, or with a composition according to the present invention. If in a multicellular organism, the method according to this aspect of the invention comprises administering to the organism a compound according to the present invention, or a composition according to the present invention. In some embodiments the organism is a mammal, for example a primate, for example, a human being.
In a fourth aspect, the invention provides a method of inhibiting angiogenesis, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to the present invention, or a therapeutically effective amount of a composition according to the present invention.
In some embodiments of this aspect, the angiogenesis that must be inhibited is involved in the growth of the tumor. In some other forms of angiogenesis modality that will be inhibited is retinal angiogenesis. In some embodiments of this aspect, the patient is a mammal, for example a primate, for example, a human being.
In a fifth aspect, the invention provides a method for treating a disease sensitive to the inhibition of kinase activity, for example a disease sensitive to the inhibition of tyrosine kinase protein activity, for example a disease sensitive to the inhibition of protein activity. Thiosin kinase from growth factor receptors. In some embodiments of this aspect, the invention provides a method for treating a disease sensitive to inhibition of receptor tyrosine kinase signaling., for example a disease sensitive to inhibition of VEGF receptor signaling, the method comprising administering to an organism in need thereof a therapeutically effective amount of a compound according to the present invention, or a composition according to the present invention. In some embodiments of this aspect, the organism is a mammal, for example a primate, for example, a human being.
In a sixth aspect, the invention provides a method for treating a cell proliferative disease, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to the present invention, or a therapeutically effective amount of a composition. according to the present invention. In some embodiments of this aspect, the cell proliferation disease is cancer. In some embodiments, the patient is a mammal, for example a primate, for example, a human being.
In a seventh aspect, the invention provides a method for treating an ophthalmic disease, disorder or disease, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to the present invention, or a therapeutically effective amount of a composition according to the present invention. In some modalities of this aspect, the disease is caused by choroidal angiogenesis. In some embodiments of this aspect, the patient is a mammal, for example a primate, for example, a human being.
In an eighth aspect, the invention provides the use of a compound according to the present invention for or in the manufacture of a medicament for inhibiting kinase activity, for example, to inhibit protein tyrosine kinase activity, for example, to inhibit the protein tyrosine kinase activity of growth factor receptors. In some embodiments of this aspect, the invention provides the use of a compound according to the present invention for or in the manufacture of a medicament for inhibiting receptor tyrosine kinase signaling, for example, to inhibit receptor signaling. VEFG. In some embodiments of this aspect, the invention provides the use of a compound according to the present invention for or in the manufacture of a medicament for treating a disease responsive to inhibition of kinase activity. In some embodiments of this aspect, the disease is sensitive to the inhibition of tyrosine kinase protein activity, for example the inhibition of protein tyrosine kinase activity of growth factor receptors In some embodiments of this aspect, the disease is sensitive to inhibition of receptor tyrosine kinase signaling, for example the signaling of the VEGF receiver. In some embodiments, the disease is a cell proliferating disease, for example, cancer. In some embodiments of this aspect, the disease is an ophthalmic disease, disorder or condition. In some embodiments of this aspect, the ophthalmic disease, disorder or condition is caused by choroidal angiogenesis. In some modalities of this aspect, the disease is age-related macular degeneration, diabetic retinopathy or retinal edema.
In a ninth aspect, the invention provides the use of a compound according to the present invention, or a composition thereof, to inhibit kinase activity, for example, to inhibit receptor tyrosine kinase-like activity, for example, to inhibit protein tyrosine kinase activity of growth factor receptors. In some embodiments of this aspect, the invention provides the use of a compound according to the present invention, or a composition thereof, to inhibit tyrosine kinase receptor signaling, for example, to inhibit VEGF receptor signaling.
In a tenth aspect, the invention provides the use of a compound according to the present invention, or a composition thereof, for treating a disease sensitive to inhibition of kinase activity, for example a disease sensitive to activity inhibition. of protein tyrosine kinase, for example a disease sensitive to inhibition or protein tyrosine kinase activity of the growth factor receptor. In some modalities of this aspect, the invention provides the use of a compound according to the present invention, or a composition thereof, to treat a disease sensitive to the inhibition of receptor tyrosine kinase signaling, for example a disease sensitive to signaling inhibition of the receptor. VEGF. In some embodiments of this aspect, the disease is a cell proliferating disease, for example cancer. In some embodiments of this aspect, the disease is a disease, disorder or ophthalmic condition. In some embodiments of this aspect, the disease, disorder or ophthalmic condition is caused by choroidal angiogenesis.
The foregoing is limited to summarizing some aspects of the invention and is not intended to be limiting in nature. These aspects and other aspects and modalities are described in more detail below.
DETAILED DESCRIPTION OF THE INVENTION
The invention provides compounds, compositions and methods for inhibiting kinase activity, for example, protein tyrosine kinase activity, for example, the activity of the protein kinase receptor, for example, the KDR receptor of VEGF. The invention also provides compounds, compositions and methods for inhibiting angiogenesis, the treatment of a disease responsive to inhibition of kinase activity, treatment of cell proliferation diseases and the conditions and treatment of diseases, disorders and ophthalmic conditions. The patent and the scientific literature referred to here reflect the knowledge that is available to those with knowledge in the field. The granted patents, published patent applications and the references cited in this document are incorporated by reference to the same extent as if each is specific and individually indicated to be incorporated by reference. In the case of inconsistencies, the present description will prevail.
For the purposes of the present invention, the following definitions will be used (unless expressly stated otherwise):
For simplicity, chemical radicals are defined and referred to throughout the description primarily as univalent chemical radicals (eg, alkyl, aryl, etc.). However, such terms are also used to transmit corresponding multivalent radicals under the appropriate structural circumstances clear to those skilled in the art. For example, while an "alkyl" radical generally refers to a monovalent radical (eg, CH3-CH2-), under certain circumstances, a bivalent linking radical may be "alkyl", in which case those skilled in the art will understand the alkyl as a divalent radical (for example, -CH2-CH2-), which is equivalent to the term "alkylene". In the same way, in circumstances where a divalent radical is required and it is affirmed as "aryl", those skilled in the art will understand that the term "aryl" refers to the corresponding divalent radical, arylene. All atoms are understood to have their normal number of valences for bond formation (ie, 4 for carbon, 3 for N, 2 for O, and 2, 4 or 6 for S, depending on the oxidation state of S). ). Sometimes a radical can be defined, for example, as (A) a-B-, where a is 0 or 1. In these cases, when a is 0 the radical is B and when a is 1 the radical is A-B-.
For simplicity, the reference to a heterocyclyl "Cn-Cm" or "Cn-Cm" heteroaryl means a heterocyclyl or heteroaryl having "n" to "m" ring atoms, where "n" and "m" are integers . Thus, for example, a C5-C6heterocyclyl is a 5- or 6- membered ring with at least one heteroatom, and includes pyrrolidinyl (C5) and piperazinyl and piperidinyl (C6). Ceheteroaryl includes, for example, pyridyl and pyrimidyl.
The term "hydrocarbyl" refers to a straight or branched alkyl, alkenyl, or alkynyl each as defined herein. One co"
Hydrocarbyl is used to refer to a covalent bond. Thus, "C0-C3 hydrocarbyl" includes a covalent bond, methyl, ethyl, ethenyl, ethynyl, propyl, propenyl, propynyl and cyclopropyl.
The term "alkyl" designates a straight or branched chain aliphatic group having from 1 to 12 carbon atoms, alternatively 1 -8 carbon atoms, and, alternatively, 1-6 carbon atoms. In some embodiments, the alkyl groups have from 2 to 12 carbon atoms, alternatively 2-8 carbon atoms and alternatively 2-6 carbon atoms. Examples of alkyl groups include, without limitation, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec -butyl, tere-butyl, pentyl, hexyl, and the like. A "C0" alkyl (as in "C0-C3alkyl") is a covalent bond.
The term "alkenyl" is intended to refer to an unsaturated straight or branched chain aliphatic group with one or more carbon-carbon double bonds, with 2 to 12 carbon atoms, alternatively 2-8 carbon atoms, and alternatively, 2- 6 carbon atoms. Examples of alkenyl groups include, without limitation, ethenyl, propenyl, butenyl, pentenyl and hexenyl.
The term "alkynyl" is intended to refer to an unsaturated straight or branched chain aliphatic group with one or more carbon-carbon triple bonds, with 2 to 12 carbon atoms, alternatively 2-8 carbon atoms, and alternatively, 2- 6 carbon atoms. Examples of alkynyl groups include, without limitation, ethynyl, propynyl, butynyl, pentynyl and hexynyl.
The terms "alkylene", "alkenylene", or "alkynylene" as used herein are intended to mean an alkyl, alkenyl, alkynyl group, respectively, as defined herein above, which is placed between and serves to connect two chemical groups . Examples of alkylene groups include, without limitation, methylene, ethylene, propylene and butylene. Examples of alkenylene groups include, without limitation, ethenylene, propenylene, and butenylene. Examples of alkynylene groups include, without limitation, ethynylene, propynylene, and butynylene.
The term "carbocycle" as used herein means a cycloalkyl or aryl radical.
The term "cycloalkyl" designates a mono-, bi-, tri- or polycyclic, unsaturated or partially unsaturated, saturated hydrocarbon group having about 3 to 15 carbon atoms, alternatively having 3 to 12 carbon atoms, alternatively 3 to 8 carbon atoms, alternatively 3 to 6 carbon atoms, and alternatively 5 or 6 carbon atoms. In some embodiments, the cycloalkyl group is fused with an aryl, heteroaryl or heterocyclic group. Examples of cycloalkyl groups include, without limitation, cyclopenten-2-enone, cyclopenten-2-enol, cyclohex-2-enone, cyclohex-2-enol, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl. , etc.
The term "heteroalkyl" is intended to mean a straight or branched chain, saturated, partially unsaturated, or unsaturated aliphatic group, wherein one or more carbon atoms in the group
are replaced by a heteroatom selected from the group consisting of O, S, and N.
The term "aryl" is intended to designate a mono, bi, tri or polycyclic aromatic radical having one to three aromatic rings. In some embodiments the aryl is an aromatic C6-C14 radical, alternatively the aryl group is a C6-C10 group, alternatively an aryl Ce group. Examples of aryl groups include, without limitation, phenyl, naphthyl, anthracenyl and fluorenyl.
The terms "aralkyl" or "arylalkyl" are intended to refer to a group consisting of an aryl group covalently linked to an alkyl group. If an aralkyl group is described as "optionally substituted", it is intended that either or both aryl and alkyl radicals independently may be optionally substituted or unsubstituted. In some embodiments, the aralkyl group is (CrC6) alc (C6-C10) aryl, including, without limitation, benzyl, phenethyl and naphthylmethyl. For simplicity, when this term is written as "arylalkyl", and terms related thereto, it is intended to indicate the order of the groups in a compound such as "aryl-alkyl". Similarly, "alkyl-aryl" is intended to indicate the order of the groups in a compound such as "alkyl-aryl".
The terms "heterocyclyl", "heterocyclic" or "heterocycle" are intended to refer to a group that is a mono-, bi-, or polycyclic structure having from 3 to about 14 atoms, alternatively 3 to 8 atoms, alternatively 4 to 7 atoms, alternatively 5 or 6 atoms wherein one or more atoms, for example 1 or 2 atoms, are selected
independently of the group consisting of N, O and S, the rest of the atoms that make up the ring are carbon atoms. The ring structure can be saturated, unsaturated or partially unsaturated. In some embodiments, the heterocyclic group is non-aromatic, in which case the group is also known as a heterocycloalkyl. In a bicyclic or polycyclic structure, one or more rings may be aromatic; for example, a ring of a bicyclic heterocycle or one or two rings of a tricyclic heterocycle may be aromatic, as in indane and 9,10-dihydro anthracene. Examples of heterocyclic groups include, without limitation, epoxy, aziridinyl, tetrahydrofuranyl, pyrrolidinyl, piperidinyl, piperazinyl, thiazolidinyl, oxazolidinyl, oxazolidinonyl, morpholino, thienyl, pyridyl, 1,2-triazolyl, imidazolyl, isoxazolyl, pyrazolyl, piperazino, piperidyl, piperidino, morpholinyl, homopiperazinyl, homopiperazino, thiomorpholinyl, thiomorpholino, tetrahydropyrrolyl and azepanyl. In some embodiments, the heterocyclic group is fused with an aryl, heteroaryl, or cycloalkyl group. Examples of such fused heterocycles include, without limitation, tetrahydroquinoline and dihydrobenzofuran. Specifically excluded from the field of this term are compounds where an O or S ring atom is adjacent to another O or S atom.
In some embodiments, the heterocyclic group is a heteroaryl group. As used herein, the term "heteroaryl" is intended to designate a mono-, bi-, tri or polycyclic group having 5 to 14 ring atoms, alternatively 5, 6, 9 or 10 ring atoms; having, for example, 6, 10, or 14 pi electrons shared in a cyclic array, and having, in addition to carbon atoms, between one or more heteroatoms independently selected from the group consisting of N, O, and S. For example, a heteroaryl group include, without limitation, pyrimidinyl, pyridinyl, benzimidazolyl, thienyl, benzothiazolyl, benzofuranyl and indolinyl. Other examples of heteroaryl groups include, without limitation, thienyl, benzothienyl, furyl, benzofuryl, dibenzofuryl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, indolyl, quinolyl, isoquinolyl, quinoxalinyl, tetrazolyl, oxazolyl, thiazolyl and isoxazolyl.
The terms "arylene", "heteroarylene", or "heterocyclylene" mean an aryl, heteroaryl, or a heterocyclyl group, respectively, as defined herein above, which is placed between and serves to connect two other chemical groups.
Examples of heterocyclyls and heteroaryls include, but are not limited to, azepinyl, azetidinyl, acridinyl, azocinyl, benzidolyl, benzimidazolyl, benzofuranyl, benzofurazanyl, benzofuryl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzothienyl, benzthriazolyl, benzitetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, benzoxazolyl, benzoxadiazolyl, benzopyranyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, coumarinyl, decahydroquinolinyl, 1,3-dioxolane, 2H, 6H-1, 5,2-dithiazinyl, dihydrofuro [2,3-b] tetrahydrofuran, dihydroisoindolyl, dihydroquinazolinyl (such as 3,4-dihydro-4-oxo-quinazolinyl), furanyl, furopyridinyl (such as
fuor [2,3-c] pyridinyl, furo [3,2-b] pyridinyl or furo [2,3-b] pyridinyl), furyl, furazanyl, hexahydrodiazepinyl, imidazolidinyl, imidazolinyl, imidazolyl, indazolyl, 1 H- indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isoxazolinyl, isoxazolyl, methylenedioxyphenyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1, 2,3- oxadiazolyl, 1,4-oxadiazolyl, 1, 2,5-oxadiazolyl, 1,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, oxetanyl, 2-oxoazepinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxythinyl, phenoxyazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridin doimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolopyridyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydro-1,1-dioxotienyl, tetrahydrofuranyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrahydropyranyl, tetrazolyl, thiazolidinyl, 6H-1, 2,5-thiadiazinyl, thiadiazolyl (for example 1,2,3-thiadiazolyl, 1,4-thiadiazolyl, 1, 2,5-thiadiazolyl, 1, 3,4 thiadiazolyl), thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholyl sulfone, thiantrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, triazinilazepinyl, triazolyl (for example 1,2,3-triazolyl, 1,2,4-triazolyl) , 1, 2,5-triazolyl, 1,4-triazolyl), and xanthenyl.
The term "azolyl" as used herein is intended to mean a saturated or unsaturated five-membered heterocyclic group containing two or more heteroatoms, such as ring atoms, selected from the group consisting of nitrogen, sulfur and oxygen, wherein at least one of the heteroatoms is a nitrogen atom. Examples of azolyl groups include, but are not limited to, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,3,4-thiadiazolyl, 1,4-thiadiazolyl, 1,4-oxadiazolyl, and , Optionally substituted 3,4-oxadiazolyl.
As used herein, and unless otherwise indicated, when a moiety (eg, alkyl, heteroalkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, etc.) is described as "optionally substituted" it is understood that the group optionally alternatively one or two alternatively selected non-hydrogen substituents are selected from one to four, alternatively from one to three. Suitable substituents include, without limitation, halo, hydroxy, oxo (for example, a -CH-substituted ring with oxo is -C (O) -) nitro, halohydrocarbyl, hydrocarbyl, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, alkoxy, aryloxy, amino, acylamino, alkylcarbamoyl, arylcarbamoyl, aminoalkyl, acyl, carboxy, hydroxyalkyl, arenesulfonyl, alkanesulfonyl, alkanesulfonamido, arenesulfonamido, aralkylsulfonamido, alkylcarbonyl, acyloxy, cyano and ureido groups.
Examples of substituents, which in turn are not further substituted (unless expressly stated otherwise) are the
following:
(a) halo, cyano, oxo, carboxy, formyl, nitro, amino, amidino, guanidino,
(b) CrC5alkyl or alkenyl or arylalkyl, carbamoyl, azido, carboxamido, mercapto, hydroxy, hydroxyalkyl, alkylaryl, arylalkyl, Cr
C8alkyl, Ci-C8alquenilo, C C8alcoxi, CrCsalquiamino, d-C8alcoxicarbonilo, aryloxycarbonyl, C2-C8acilo, C2-C8acilamino, CrCealquiltio, arylalkylthio, arylthio, Ci-C8alquilsulfinilo, arylalkylsulfinyl, arylsulfinyl, d-C8alquilsulfonilo, arylalkylsulfonyl, arylsulfonyl, C0-C6 / V-alkyl carbamoyl, C2-C15 / /, / V-dialkylcarbamoyl, C3-C7 cycloalkyl, aroyl, aryloxy, arylalkyl ether, aryl, aryl fused to a cycloalkyl or heterocycle or other aryl ring, C3-C7heterocycle, C5- C-heteroaryl or any of these ring fused or spiro-fumes to a cycloalkyl, heterocyclyl, or aryl, wherein each of the above is optionally substituted with one or more radicals listed in (a), above; Y
(c) (CR32R33) S-NR30R31,
where s is 0 (case in which nitrogen is directly linked to the radical that is replaced) to 6,
R32 and R33 each independently is hydrogen, halo, hydroxyl or Ci-C4alkyl, and R30 and R31 each independently is hydrogen, cyano, oxo, hydroxyl, Ci-C8alkyl, Ci-C8heteroalkyl, d-C8alkenyl, carboxamido, CrC3alkylcarboxamido , carboxamido-Cr C3alkyl, amidino, C2-C8hydroxyalkyl, CrC3alkylaryl, aryl-Ci-C3alkyl, C
C3alkylheteroaryl, heteroaryl-Ci-C3alkyl, CrCalkalkheheterocyclyl, heterocyclic-Ci-C3alkyl CrCalkylcycloalkyl, cycloalkyl-Ci-C3alkyl, C2-C8alkoxy, C2-C8alkoxy-CrC4alkyl, Ci-C8alkoxycarbonyl, aryloxycarbonyl, aryl -CrC3alkoxycarbonyl, heteroaryloxycarbonyl, heteroaryl-C1-C3alkoxycarbonyl, C8-acyl, C0-C8alkylcarbonyl, aryl-C0-C8alkylcarbonyl, heteroaryl-Co-C8alkylcarbonyl, cycloalkyl-C0-C8alkylcarbonyl, Co-C8alkyl-NH- carbonyl, aryl-Co-C8alkyl-NH-carbonyl, heteroaryl-Co-Csalkyl-NH-carbonyl, cycloalkyl-C0-C8alkyl-NH-carbonyl, C0-C8alkyl-O-carbonyl, aryl-C0-C8alkyl-O-carbonyl, heteroaryl-C0-C8alkyl-O-carbonyl, cycloalkyl-C0-C8alkyl-O-carbonyl, d-Csalkylsu! fonyl, arylalkylsulfonyl, arylsulfonyl, heteroarylalkylsulfonyl, heteroarylsulphonyl, C8alkyl-NH-sulfonyl, arylalkyl-NH-sulfonyl, aryl-NH -sulfonyl, heteroarylalkyl-NH-sulfonyl, heteroaryl-NH-sulfonyl-aroyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, aryl-C-C3al quil-, C3-alkylcycloalkyl-, heterocyclyl-CrCalkyl-, heteroaryl-C-C3alkyl-, or protecting group, wherein each of the above is optionally further substituted with one or more radicals listed in (a), above; or
R30 and R31 taken together with the N to which they are attached form a heterocyclyl or heteroaryl, each of which is optionally substituted with 1 to 3 substituents selected from the group consisting of (a) above, a protecting group, and (X30- Y31-), wherein said heterocyclyl can also be bridged (forming a bicyclic radical with a methylene, ethylene or propylene bridge); where
X is selected from the group consisting of CrC8alkyl, C2-C8alkenyl-, C2-C8alkynyl-, -Co-C3alkyl-C2-C8alkenyl-Co-C3alkyl, C0-C3alkyl-C2-C8alkynyl-Co-C3alkyl, Co-C3alkyl-0 -C0-C3alkyl-, HO-C0-C3alkyl-, C0-C4alkyl-N (R30) -Co-C3alkyl-, N (R30) (R31) -C0-C3alkyl-, N (R30) (R31) -C0- C3alkenyl-, N (R30) (R3) -C0-C3alkynyl-, (N (R30) (R31)) 2-C = N-, Co-C3alkyl (O) o.2-Co-C3alkyl-, CF3 -C0-C3alkyl-, CrChesheteroalkyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, aryl-Ci-C3alkyl-, cycloalkyl-d-C3alkyl-, heterocyclyl-Ci-C3alkyl-, heteroaryl-CrC3alkyl-, N (R30) (R31) ) -heterocyclyl-CrC3alkyl-, wherein the aryl, cycloalkyl, heteroaryl and heterocyclyl are optionally substituted with 1 to 3 substituents of (a); Y
Y31 is selected from the group consisting of a direct bond, -O-, -N (R30) -, -C (O) -, -OC (O) -, -C (0) -0-, -N (R30 ) -C (O) -, -C (0) -N (R30) -, -N (R30) -C (S) -, -C (S) -N (R30) -, -N (R30) - C (O) -N (R31) -, -N (R30) -C (NR30) -N (R31) -, -N (R30) -C (NR31) -, -C (NR3) -N (R30) -, -N (R30) -C (S) -N (R31) -, -N (R30) -C (O) -O-, -0-C (0) -N (R31) -, -N ( R30) -C (S) -O-, -0-C (S) -N (R31) -, -S (O) 0.2-, -S02N (R31) -, -N (R31) -S02- and - N (R30) -SO2N (R31) -.
A radical that is substituted is one in which one or more (for example one up to four, alternatively from one to three and alternatively, one or two), hydrogens have been replaced independently with another chemical substituent. By way of non-limiting example, substituted phenyls include 2-flurophenyl, 3,4-dichlorophenyl-, 3-chloro-4-fluoro-phenyl, 2-fluoro-3-propylphenyl. As another non-limiting example, substituted n-octyls include 2,4-dimethyl-5-ethyl-octyl and 3-cyclopentyl-octyl.
Included within this definition are methylenes (-CH2-) substituted with oxygen to form carbonyl -CO-.
When there are two optional substituents attached to adjacent atoms of a ring structure, such as, for example, a phenyl, thiophenyl or pyridinyl, the substituents, together with the atoms to which they are attached, optionally form a 5 or 6 membered cycloalkyl or heterocycle having 1, 2, or 3 ring heteroatoms.
In some embodiments, a hydrocarbyl, heteroalkyl, heterocyclic and / or aryl group is unsubstituted.
In some embodiments, a hydrocarbyl, heteroalkyl, heterocyclic and / or an aryl group is substituted by 1 to 3 independently selected substituents.
Examples of substituents on the alkyl groups include, but are not limited to, hydroxyl, halogen (for example, an individual halogen substituent or multiple halo substituents, in the latter case, groups such as CF3 or an alkyl group having Cl3), oxo, cyano, nitro, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle, aryl, -ORa, -SRa,
-S (= 0) Re, -S (= 0) 2Re, -P (= 0) 2Re, -S (= O) 2ORe, -P (= O) 2ORe, -NRbRc, - NRbS (= 0) 2Re , -NRbP (= 0) 2Re, -S (= 0) 2NRbRc, -P (= 0) 2NRbRc, -C (= 0) ORe, -C (= O) Ra, -C (= O) NR Rc, -OC (= 0) Ra, -OC (= 0) NRbRc, -NRbC (= O) ORe, - NRdC (= 0) NRbRc, -NRdS (= 0) 2NRbRc, -NRdP (= 0) 2NRbRc, -NRbC (= 0) Ra or -NRbP (= 0) 2 Re, wherein Ra is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle or aryl; Rb, Rc and Rd are
independently hydrogen, alkyl, cycloalkyl, heterocycle or aryl, or said Rb and R ° together with the N to which they are attached optionally form a heterocycle; and Re is alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, heterocycle or aryl. In the aforementioned exemplary substituents, groups such as alkyl, cycloalkyl, alkenyl, alkynyl, cycloalkenyl, heterocycle and aryl can be optionally substituted by themselves
Examples of substituents on the alkenyl and alkynyl groups include, but are not limited to, alkyl or substituted alkyl, as well as those groups recited as examples of the alkyl substituents.
Examples of the substituents on the cycloalkyl groups include, but are not limited to, nitro, cyano, alkyl or substituted alkyl, as well as the groups recited above as examples of the alkyl substituents. Other examples of the substituents include, but are not limited to fused spiro-linked or cyclic substituents, for example, spiro-linked cycloalkyl, spiro-linked cycloalkenyl, spiro-linked heterocycle (excluding heteroaryl), fused cycloalkenyl, fused cycloalkyl, fused heterocycle, or fused aryl, wherein the above-mentioned substituents cycloalkyl, cycloalkenyl, heterocycle and aryl may be optionally substituted by themselves.
Examples of substituents on the cycloalkenyl groups include, but are not limited to, nitro, cyano, alkyl or substituted alkyl, as well as those groups recited as examples of the alkyl substituents. Other examples of substituents include, but are not limited to, spiro-linked cyclic substituents. or fused, for example spiro-linked cycloalkyl, spiro-linked cycloalkenyl, spiro-linked heterocycle (excluding heteroaryl), fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, wherein the above-mentioned cycloalkyl, cycloalkenyl, heterocycle and aryl substituents may be themselves optionally substituted.
Examples of substituents on the aryl groups include, but are not limited to, nitro, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, cyano, alkyl or substituted alkyl, as well as those groups recited above as an example of the alkyl substituents. Other examples of substituents include, but are not limited to, fused cyclic groups, such as fused cycloalkyl, fused cycloalkenyl, fused heterocycle, or fused aryl, wherein the aforementioned cycloalkyl, cylcoalkenyl, heterocycle, and aryl substituents may be optionally substituted automatically. Still other examples of the substituents on the aryl groups (phenyl, as a non-limiting example) include, but are not limited to, haloalkyl and those groups recited as examples of the alkyl substituents.
Examples of substituents on the heterocyclic groups include, but are not limited to, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, nitro, oxo (i.e., = 0), cyano, alkyl, substituted alkyl, as well as those groups recited as examples of alkyl substituents. Other examples of substituents in the groups
heterocyclics include, but are not limited to, spiro-linked cyclic substituents or fused at any available point or junction points, for example spiro-linked cycloalkyl, spiro-linked cycloalkenyl, spiro-linked heterocycle (excluding heteroaryl), fused cycloalkyl, cycloalkenyl, fused heterocycle and fused aryl, wherein the above-mentioned substituents cycloalkyl, cycloalkenyl, heterocycle and aryl can optionally be replaced by themselves.
In some embodiments, a heterocyclic group is substituted at carbon, nitrogen and / or sulfur at one or more positions. Examples of substituents on nitrogen, but not limited to alkyl, aryl, aralkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl, alkoxycarbonyl, or aralkoxycarbonyl. Examples of substituents on sulfur include, but are not limited to, oxo and C 1-6 alkyl. In some embodiments, nitrogen and sulfur heteroatoms independently can optionally be oxidized and nitrogen heteroatoms independently can optionally be quaternized.
In some embodiments, substituents on the ring groups, such as aryl, heteroaryl, cycloalkyl and heterocyclyl, include halogen, alkoxy and / or alkyl.
In some embodiments, the substituents on the alkyl groups are halogen and / or hydroxy.
A "halohydrocarbyl" as used herein is a hydrocarbyl radical, wherein one of all the hydrogens has been replaced with
one or more halo.
The term "halogen" or "halo" as used herein refers to chlorine, bromine, fluorine, or iodine. As used herein, the term "acyl" refers to an alkylcarbonyl or arylcarbonyl substituent. The term "acylamino" refers to an amide group attached at the nitrogen atom (i.e., R-CO-NH-). The term "carbamoyl" refers to an amide group attached to the carbonyl carbon atom (ie, NH2-CO-). The nitrogen atom of an acylamino or carbamoyl substituent is, in addition, optionally substituted. The term "sulfonamido" refers to a sulfonamido substituent attached either by the sulfur or the nitrogen atom. The term "amino" is intended to include NH 2, alkylamino, dialkylamino (where each alkyl may be the same or different), arylamino, and cyclic amino groups. The term "ureido" as used herein refers to a substituted or unsubstituted ureido radical.
The term "radical" as used herein means a chemical radical comprising one or more unpaired electrons.
When optional substituents are chosen from "one or several" groups it should be understood that this definition includes all substituents that are chosen within one of the specified groups or from the combination of all specified groups.
In addition, substituents on cyclic radicals (ie, cycloalkyl, heterocyclyl, aryl, heteroaryl) include mono-5- to 6-member radicals and 9- to 14-bi-cyclic members fused to the cyclic radical of origin to form a ring system fused bi- or tri-cyclic. The
Substituents on cyclic radicals also include mono-5- to 6-member radicals and 9- to 14-bi-cyclic members linked to the cyclic radical of origin by means of a covalent bond to form a bi- or tricyclic abi-ring system. For example, an optionally substituted phenyl includes, but is not limited to, the following:
An "unsubstituted" radical (eg, unsubstituted cycloalkyl, unsubstituted heteroaryl, etc.) means a radical as defined above that does not have any type of optional substituents.
A partially unsaturated or unsaturated carbocyclic ring of three to eight members is for example a saturated or unsaturated carbocyclic ring, of five to six members. Examples of three to eight membered saturated or unsaturated carbocyclic rings include phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
A saturated or unsaturated carboxylic and heterocyclic group can be condensed with another heterocyclic or saturated group to form a bicyclic group, for example a carbocyclic or heterocyclic, bicyclic group of nine to twelve members, saturated or unsaturated. The bicyclic groups include naphthyl, quinolyl, 1,2,3,4-tetrahydroquinolyl, 1,4-benzoxanyl, indanyl, indolyl and 1,2,4,4-tetrahydronaphthyl.
When a carbocyclic or heterocyclic group is substituted by two d-Cealkyl groups, the two alkyl groups can be combined together to form an alkylene chain, for example, a C3-alkylene chain. Carbocyclic or heterocyclic groups having this intertwined structure include bicyclo [2.2.2] octanyl and norbornyl.
The terms "kinase inhibitor" and "kinase activity inhibitor", and the like, are used to identify a compound that is capable of interacting with a kinase and inhibiting its enzymatic activity.
The term "inhibition of enzymatic kinase activity" is used to mean reducing the ability of a kinase to transfer a phosphate group from a donor molecule, such as ATP, to a specific target molecule (substrate). For example, the inhibition of kinase activity may be at least about 10%. In some embodiments of the invention, this reduction in kinase activity is at least about 25%, alternatively at least about 50%, alternatively at least about 75%, and alternatively at least about 90%. In other embodiments, the kinase activity is reduced by at least 95% and alternatively by at least 99%. The IC50 value is the concentration of kinase inhibitor that reduces the activity of a kinase to 50% of the uninhibited enzyme.
The terms "inhibitor of VEGF receptor signaling" are used to identify a compound having a structure as defined herein, which is capable of interacting with a VEGF receptor and inhibiting the activity of the VEGF receptor. In some embodiments, the activity reduction is at least about 50%, alternatively at least about 75%, and, alternatively at least about 90%. In some embodiments, the activity is reduced by at least 95% and alternatively by at least 99%.
The term "effective amount of inhibition" refers to designating a dose sufficient to cause inhibition of kinase activity. The amount of a compound of the invention that constitutes an "effective inhibiting amount" will vary depending on the compound, the kinase, and the like. The effective amount of inhibition can be determined routinely by those of ordinary skill in the art. The kinase can be in a cell, which in turn can be in a multicellular organism. The multicellular organism can be, for example, a plant, a fungus or an animal, for example, a mammal and, for example, a human being. The fungus may be infecting a plant or a mammal, for example, a human being, and therefore could be located in and / or in the plant or mammal.
In one embodiment example, such inhibition is specific, i.e., the kinase inhibitor reduces the ability of a kinase to transfer a phosphate group from a donor molecule, such as ATP, to a specific target molecule (substrate) at a lower concentration to the inhibitor concentration of what is required to produce another unrelated biological effect. For example, the concentration of the inhibitor required for the kinase inhibitory activity is at least two times lower, alternatively at least 5 times lower, alternatively at least 10 times lower, and, alternatively at least 20 times lower than the concentration required to produce an unrelated biological effect.
Thus, the invention provides a method for inhibiting the kinase enzyme activity, which includes contacting the kinase with an effective amount of inhibition of a compound or composition according to the invention. In some modalities, the kinase is found in an organism. Thus, the invention provides a method for inhibiting the enzymatic kinase activity in an organism, comprising administering to the organism an amount of effective inhibition of a compound or a composition according to the invention. In some embodiments, the organism is a mammal, for example a domesticated mammal. In some modalities, the organism is a human being.
The term "therapeutically effective amount" as used herein is an amount of a compound of the invention, which when administered to a patient, causes the desired therapeutic effect. The therapeutic effect depends on the disease to be treated and the desired results. As such, the therapeutic effect can be treatment of a disease state. In addition, the therapeutic effect may be inhibition of kinase activity. The amount of a compound of the invention that constitutes a "therapeutically effective amount" will vary depending on the compound, the state of the disease and its severity, the age of the patient to be treated, among others. The therapeutically effective amount can be determined routinely by those of ordinary skill in the art.
In some embodiments, the therapeutic effect is the inhibition of angiogenesis. The phrase "inhibition of angiogenesis" is used to denote a capacity of a compound according to the present invention to retard the growth of blood vessels, such as blood vessels in contact with the inhibitor as compared to uncontacted blood vessels. In some modalities, angiogenesis is tumor angiogenesis. The phrase "tumor angiogenesis" is intended to designate the proliferation of blood vessels that come into contact or other contact with a cancerous tumor, such as a tumor. In some modalities, angiogenesis is the abnormal formation of the blood vessels of the eye.
In one embodiment example, angiogenesis is delayed by at least 25% compared to angiogenesis of the uncontacted blood vessels, alternatively at least 50%, alternatively at least 75%, alternatively at least 90%, alternatively at least the 95%, and, alternatively, at least 99%. On the other hand, angiogenesis is inhibited by 100% (ie, the blood vessels do not increase in size or number). In some embodiments, the phrase "inhibition of angiogenesis" includes regression in the number or size of blood vessels, as compared to uncontacted blood vessels. Thus, a compound according to the invention that inhibits angiogenesis can induce growth retardation of blood vessels, arrest of the growth of blood vessels, or induce the regression of the growth of blood vessels.
Thus, the invention provides a method for inhibiting angiogenesis in an animal, comprising administering to an animal in need of such treatment, a therapeutically effective amount of a compound or a composition of the invention. In some embodiments, the animal is a mammal, for example a domesticated mammal. In some modalities, the animal is a human being.
In some embodiments, the therapeutic effect is the treatment of a disease, disorder or ophthalmic condition. The phrase "treatment of an ophthalmic disease, disorder or condition" is to be understood as the ability of a compound according to the present invention for the treatment of a disease, disorder or exudative and / or inflammatory condition, ophthalmic related alteration of permeability and / or integrity of the retinal vessels, a disorder related to the rupture of retinal microvessels leads to a focal hemorrhage, a disease of the back of the eye, a disease of the retina, or a disease of the front of the eye, or another disease Ophthalmic disorder or condition
In some embodiments, the disease, disorder or ophthalmic condition includes but is not limited to Age-Related Macular Degeneration (ARMD), exudative macular degeneration (also known as
"wet" or age-related neovascular macular degeneration (wet ARMD), macular edema, age-related discoidal macular degeneration, cystoid macular edema, palpebral edema, retinal edema, diabetic retinopathy, acute macular neuroretinopathy, central serous chorioretinopathy, chorioretinopathy , choroidal neovascularization, neovascular maculopathy, neovascular glaucoma, arterial and venous obstructive retinopathies (eg, retinal vein occlusion or retinal arterial occlusion), central retinal vein occlusion, disseminated intravascular coagulopathy, branched retinal venous occlusion, hypertensive background changes, of ocular ischemia, retinal arterial microaneurysms, coat disease, parafoveal telangiectasis, hemi-retinal vein occlusion, papilloflebitis, central retinal artery obstruction, branched retinal artery occlusion, carotid artery disease (CAD), branching angiitis frozen, retinopath a of sickle cell and other hemoglobinopathies, angioid striae, macular edema that occurs as a result of etiologies, such as disease (eg, diabetic macular edema), ocular lesions or eye surgery, retinal ischemia or degeneration caused for example by injury, trauma or tumors, uveitis, iritis, retinal vasculitis, endophthalmitis, panophthalmitis, metastatic ophthalmia, choroiditis, retinal pigment epitheliitis, conjunctivitis, cyclitis, scleritis, episcleritis, optic neuritis, retrobulbar optic neuritis, keratitis, blepharitis, exudative retinal detachment, ulcer corneal, conjunctival ulcer, chronic nummular keratitis, Tigeson keratitis, progressive Mooren ulcers, an inflammatory ocular disease caused by a bacterial or viral infection or by an ophthalmic operation, an inflammatory ocular disease caused by physical injury to the eye, and a symptom for an inflammatory eye disease including p icor, rash, edema and ulcers, erythema multiforme exudative, erythema nodosum, erythema annulare, sclerodema, dermatitis, angioneurotic edema, laryngeal edema, glottic edema, subglottic laryngitis, bronchitis, rhinitis, pharyngitis, sinusitis, laryngitis or otitis media.
In some embodiments, the disease, disorder or ophthalmic condition includes but is not limited to age-related macular degeneration, diabetic retinopathy, retinal edema, retinal venous occlusion, neovascular glaucoma, retinopathy of prematurity, retinal pigmentary degeneration, uveitis, neovascularization corneal or proliferative vitreoretinopathy.
In some embodiments, the disease, disorder or ophthalmic condition is age-related macular degeneration, diabetic retinopathy or retinal edema.
Thus, the invention provides a method for treating the disease, disorder or ophthalmic condition in an animal, which includes administering to an animal in need of said treatment a therapeutically effective amount of a compound or composition of the invention. In some embodiments, the animal is a mammal, for example a domesticated mammal In some embodiments, the animal is a
human.
In some modalities, the therapeutic effect is the inhibition of retinal neovascularization. The phrase "inhibition of retinal neovascularization" should be understood as the ability of a compound according to the present invention to retard the growth of the blood vessels of the eye, for example new blood vessels coming from the veins of the retina, for example, to retard the growth of new blood vessels from the veins of the retina and that extend along the inner (vitreous) surface of the retina.
In one embodiment example, retinal neovascularization is delayed by at least 25% compared to retinal neovascularization of uncontained blood vessels, alternatively at least 50%, alternatively at least 75%, alternatively at least 90%, alternatively at least 95% , and, alternatively, at least 99%. On the other hand, retinal neovascularization is inhibited by 100% (ie, blood vessels do not increase in size or number). In some embodiments, the phrase "inhibition of retinal neovascularization" includes regression in the number or size of blood vessels, as compared to uncontacted blood vessels. Thus, a compound according to the invention that inhibits retinal neovascularization can induce the retardation of the growth of blood vessels, arrest of the growth of blood vessels, or induce the regression of the growth of blood vessels.
Thus, the invention provides a method for inhibiting
retinal neovascularization in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a compound or composition of the invention In some embodiments, the animal is a mammal, e.g., a domesticated mammal In some modalities, the animal is a human being.
In some embodiments, the therapeutic effect is the inhibition of cell proliferation. The phrase "inhibition of cell proliferation" is used to denote a capacity of a compound according to the present invention to retard the growth of cells in contact with the inhibitor compared to uncontacted cells. An evaluation of cell proliferation can be done by counting contacted and uncontacted cells using a Coulter cell counter (Coulter, Miami, Fl.) Or a hemocytometer. When the cells are in solid growth (eg, a solid or organ tumor), an evaluation of cell proliferation can be made by measuring growth with tweezers or comparing the size of the growth of the cells in contact with the cells not contacted
In one embodiment example, the growth of the cells in contact with the inhibitor is delayed by at least 25% compared to the growth of the non-contacted cells, alternatively at least 50%, alternatively at least 75%, alternatively less 90%, alternatively at least 95%, and alternatively, at least 99%. By
On the other hand, cell proliferation is 100% inhibited (ie, the contacted cells do not increase in number). In some embodiments, the phrase "inhibiting cell proliferation" includes a reduction in the number or size of cells contacted, as compared to uncontacted cells. Thus, a compound according to the invention that inhibits cell proliferation in a contacted cell can induce the cell in contact to undergo growth retardation, to undergo growth arrest, to undergo programmed cell death (i.e., apoptosis) , or experience necrotic cell death.
In some embodiments, the cell in contact is a neoplastic cell. The term "neoplastic cell" is used to denote a cell that shows aberrant cell growth. In some embodiments, the aberrant cell growth of a neoplastic cell increases cell growth. A neoplastic cell can be a hyperplastic cell, a cell that exhibits a lack of inhibition by in vitro growth contact, a benign tumor cell that is incapable of metastasis in vivo, or a cancer cell that is capable of in vivo metastasis and that can be repeated after the attempted elimination. The term "tumorigenesis" is used to denote the induction of cell proliferation that leads to the development of neoplastic growth.
In some modalities, the cell contacted is in an animal. Thus, the invention provides a method for treating a disease or cell proliferation condition in an animal, which
comprises administering to an animal in need of such treatment a therapeutically effective amount of a compound or composition of the invention. In some embodiments, the animal is a mammal, for example a domesticated mammal. In some modalities, the animal is a human being.
The term "disease or condition of proliferating cells" is intended to refer to any condition that is characterized by aberrant cell growth, such as abnormally increased cell proliferation. Examples of such diseases or cell proliferative conditions treatable upon inhibition and treatment include, but are not limited to, cancer. Some examples of particular types of cancer include, but are not limited to, breast cancer, lung cancer, colon cancer, rectal cancer, bladder cancer, prostate cancer leukemia, and kidney cancer. In some embodiments, the invention provides a method for inhibiting the proliferation of neoplastic cells in an animal comprising administering to an animal having at least one neoplastic cell present in its body a therapeutically effective amount of a compound of the invention or a composition of the invention. same.
The term "patient" as used herein for purposes of the present invention includes humans and other animals, e.g., mammals, and other organisms. Thus, the compounds, compositions and methods of the present invention are applicable to both human therapy and veterinary applications. In some modalities the patient is a
mammal, for example, a human being.
The terms "treat", "treatment", or the like, as used herein, cover the treatment of a disease state in an organism, and include at least one of: (i) prevention of the disease state from occurring; in particular, when such an animal is predisposed to the state of disease state but has not yet been diagnosed with it; (ii) the inhibition of the disease state, that is, partial or total arrest of its development; (iii) alleviating the disease state, i.e., causing the regression of the symptoms of the disease state, or alleviating a symptom of the disease, and (iv) reversing or regression of the disease state, such as elimination. or cured of the disease. In some embodiments of the present invention the organism is an animal, for example, a mammal, for example a primate, for example, a human. As is known in the art, adjustments for systemic versus localized delivery, age, body weight, general health, sex, diet, time of administration, drug interaction, severity of the disease, etc., may be necessary, and will be find out with routine experimentation by those with common knowledge in the technique. In some embodiments, the terms "treat", "treatment", or the like, as used herein, cover the treatment of a disease state in an organism and include at least one of (ii), (iii) and (iv) above .
Administration for diseases, disorders or non-ophthalmic conditions can be by any means, including, without limitation,
parenteral, oral, sublingual, transdermal, topical, intranasal, intratracheal or intrarectal. In some embodiments, the compounds of the invention are administered intravenously in a hospital facility. In some modalities, the administration can be by oral route.
Examples of routes of administration of diseases, disorders and ophthalmic conditions include, but are not limited to, systemic, periocular, retrobulbar, intracanalicular, intravitral, topical injection (e.g., eye drops), subconjunctival injection, subtenon, transcleral, intracameral, subretinal, electroporation, and sustained release implant. Other routes of administration of other injection sites or other forms of administration for ophthalmic situations will be disclosed or contemplated by a person skilled in the art and are intended to be within the scope of the present invention.
In some embodiments of the present invention, routes of administration for diseases, diseases, and ophthalmic conditions include topical, subconjunctival, intravitreal, or other ocular routes, systemically, or other methods known to a person skilled in the art to a patient after administration. eye surgery.
In some other embodiments of the present invention, routes of administration of ophthalmic diseases, diseases and conditions include topical, intravitreal, transcleral, periocular, conjunctival, subtenon, intracameral, subretinal, subconjunctival, retrobulbar or intracanalicular.
In some embodiments of the present invention, routes of
Administration for diseases, diseases and ophthalmic conditions include topical administration (e.g., eye drops), systemic administration (e.g., oral or intravenous injection), subconjunctival injection, periocular injection, intravitreal injection, and surgical implant.
In some embodiments of the present invention, routes of administration for diseases, disorders and ophthalmic conditions include intravitreal injection, periocular injection, and sustained release implant.
In some embodiments of the present invention, an intraocular injection may be in the vitreous humor (intravitreal), below the conjunctiva (subconjunctival), behind the eye (retrobulbar), in the sclera, in the Tenon capsule (sub-Tenon) , or it may be in the form of a deposit.
The compounds of the present invention form salts that are also within the scope of the present invention. Reference to a compound of the invention, for example, a compound of formula (I), is hereinafter understood to include a reference to its salts, unless otherwise indicated.
The term "salt (s)", as used herein, denotes acidic and / or basic salts formed with inorganic and / or organic acids and bases. In addition, when a compound of the present invention comprises a base radical, such as, but not limited to a pyridine or imidazole and an acidic radical such as but not limited to a carboxylic acid, zwitterions ("inner salts") can be formed and are included within the term "salt (s)" as used herein. Pharmaceutically acceptable salts (ie, non-toxic (exhibiting minimal or no unwanted toxicological effects), physiologically acceptable) are preferred, although other salts are also useful, for example, in isolation or purification steps that can be employed during the preparation. The salts of the compounds of the invention can be formed, for example, by reaction of a compound of the present invention with an amount of acid or base, as an equivalent amount, in a medium such as one in which the salts precipitate or in an aqueous medium followed by lyophilization.
The compounds of the present invention which contain a basic radical, such as, but not limited to an amine or a pyridine or imidazole ring, can form salts with a variety of organic and inorganic acids. Examples of acid addition salts include acetates (such as those formed with acetic acid or trihaloacetic acid, eg, trifluoroacetic acid), adipates, alginates, ascorbates, aspartate, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, canforates , camphorsulfonates, cyclopentanopropionates, digluconates, dodecyl sulfates, ethanesulfonates, fumarates, glycoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, hydrochlorides, hydrobromides, hydroiodietrates, hydroxyethane sulfonates (eg, 2-hydroxyethane sulfonates), lactates, maleates, methanesulfonates, naphthalenesulfonates (for example, 2-naphthalenesulfonates), nichotinates,
nitrates, oxalates, pectinates, persulphates, phenylpropionates (eg, 3-phenylpropionates), phosphates, picrates, pivalates, propionates, salicylates, succinates, sulphates (such as those formed with sulfuric acid), sulfonates, tartrates, thiocyanates, such toluenesulfonates such as tosylates, undecanoates, and the like.
The compounds of the present invention which contain an acidic radical, such as but not limited to a carboxylic acid, can form salts with a variety of organic and inorganic bases.
Examples of basic salts include the ammonium salts, alkali metal salts such as sodium, lithium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as benzathines, dicyclohexylamines, hydramines (formed by N, N-bis (dehydroabiethyl) ethylenediamine), N-methyl-D-glucamines, N-methyl-D-glycamides, t-butyl amines, and salts with amino acids such as arginine, lysine and the like. Groups containing basic nitrogen can be quaternized with agents such as the lower alkyl halides (for example, methyl, ethyl, propyl and butyl chlorides, bromides and iodides), dialkyl sulfates (eg, dimethyl, diethyl, dibutyl and diamyl sulfates) ), long chain halides (e.g., decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides), aralkyl halides (e.g., benzyl and phenethyl bromides), and oth
As used herein, the term "pharmaceutically acceptable salts" is intended to designate salts that retain the desired activity
of the compounds identified above and show minimal or no unwanted toxicological effects. Examples of such salts include, but are not limited to, salts formed with inorganic acids (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), and salts formed with organic acids such as acetic acid. , oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, naphthalene disulfonic acid, methanesulfonic acid, p-toluenesulfonic acid and polygalacturonic acid. The other salts include pharmaceutically acceptable quaternary salts known to those skilled in the art, which specifically include the quaternary ammonium salt of the formula -NR + Z-, wherein R is hydrogen, alkyl, or benzyl, and Z is a counter ion, including chloride, bromide, iodide, -O-alkyl, toluenesulfonate, methylsulfonate, sulfonate, phosphate or carboxylate (such as benzoate, succinate, acetate, glycolate, maleate, malate, citrate, tartrate, ascorbate, benzoate, cinnamoate, mandeloate, benzyloate , and diphenylacetate).
Another aspect of the invention provides compositions comprising a compound according to the present invention. For example, in some embodiments of the invention, a composition comprises a compound, N-oxide, hydrate, solvate, pharmaceutically acceptable salt, complex or prodrug of a compound according to the present invention present in at least about 30% enantiomeric excess or
diastereomeric In some embodiments of the invention, the compound, N-oxide, hydrates, solvate, pharmaceutically acceptable salt, complexes or prodrug is present in at least about 50%, in at least about 80%, or even at least about 90 % enantiomeric or diastereomeric excess. In some embodiments of the invention, the compound, N-oxide, hydrate, solvate, pharmaceutically acceptable salt, complex or prodrug is present in at least about 95%, alternatively at least about 98% and, alternatively at least about 99% excess of enantiomeric or diastereomeric In other embodiments of the invention, a compound, the N-oxide, hydrate, solvate, pharmaceutically acceptable salt, complex or prodrug is present as a substantially racemic mixture.
Some compounds of the invention may have chiral centand / or isomeric geometric cent(E- and Z-isom, and it is to be undood that the invention embraces all optical, enantiomeric, diastereoisomeric and geometric isom The invention also encompasses all tautomeric forms of the compounds described herein. When the compounds of the invention include chiral cent the invention encompasses the enantiomerically and / or diastereomerically pure isomof these compounds, the enantiomerically and / or diastereomerically enriched mixtures of said compounds, and the racemic and scala mixtures of said compounds. For example, a
The composition may include a mixture of enantiomers or diastereomers of a compound of formula (I) in at least about 30% diastereomeric or enantiomeric excess. In some embodiments of the invention, the compound is present in at least about 50% enantiomeric or diastereomeric excess, in at least about 80% enantiomeric or diastereomeric excess, or even in at least about 90% enantiomeric excess or diastereomeric In some embodiments of the invention, the compound is present in at least about 95%, alternatively in at least about 98% enantiomeric or diastereomeric excess, and alternatively in at least about 99% enantiomeric or diastereomeric excess.
The chiral centers of the present invention can have the S or R configuration. The racemic forms can be resolved by physical methods, such as, for example, fractional crystallization, separation or crystallization of diastereomeric derivatives or separation by chiral column chromatography. The individual optical isomers can be obtained either from chiral / intermediate precursors or from the racemates by any appropriate method, including without limitation, conventional methods, such as, for example, the formation of the salt with an optically active acid followed of crystallization.
The present invention also includes prodrugs of compounds of the invention. The term "prodrug" is intended to
representing a compound covalently bound to a carrier, which prodrug is capable of releasing the active ingredient when the prodrug is administered to a mammal in question. The release of the active ingredient occurs in vivo. Prodrugs can be prepared by techniques known to one skilled in the art. These techniques generally modify appropriate functional groups in a given compound. These modified functional groups, however, regenerate original functional groups by routine or in vivo manipulation. Prodrugs of the compounds of the invention include compounds wherein a hydroxy, amino, carboxylic or a similar group has been modified. Examples of prodrugs include, but are not limited to esters (e.g., acetate, formate, and benzoate derivatives), carbamates (e.g., N, N-dimethylaminocarbonyl) of hydroxy or amino functional groups in compounds of the present invention) , amides (eg, trifluoroacetylamino, acetylamino, and the like), and the like.
The compounds of the invention can be administered, for example, as they are or as a prodrug, for example in the form of an in vivo hydrolysable ester or hydrolysable amide in vivo. An in vivo hydrolysable ester of a compound of the invention containing carboxy or hydroxy group is, for example, a pharmaceutically acceptable ester that is hydrolysed in the human or animal body to produce the acid or alcohol of origin. Suitable pharmaceutically acceptable esters for carboxy include esters of d-Ceralkoxymethyl (eg, methoxymethyl), CrCealkanoyloxymethyl esters (eg, pivaloyloxymethyl), phthalidyl esters, C3-Cecycloalkoxycarbonyloxy-CrCealkyl esters (eg, 1-cyclohexylcarbonyloxyethyl); 1,3-dioxolen-2-onylmethyl esters (e.g., 5-methyl-1,3-d-oxolen-2-onylmethoxy) and CrC6alkoxycarbonyloxyethyl esters (e.g. methoxycarbonyloxyethyl) and can be formed in any appropriate carboxy group in the compounds of this invention.
An in vivo hydrolysable ester of a compound of the invention containing a hydroxy group includes inorganic esters such as phosphate esters and α-acyloxyalkyl ethers and related compounds which as a consequence of the in vivo hydrolysis of the decomposition of the ester gives the hydroxyl group originally. Examples of the α-acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy. A selection of in vivo hydrolysable ester formation groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give esters of alkyl carbonate), dialkylcarbamoyl and N- (N, N-dialkylaminoethyl) -N-alkylcarbamoyl (to give carbamates), N, N-dialkylaminoacetyl and carboxyacetyl. Examples of substituents on benzoyl include morpholino and piperazino linked from a ring nitrogen atom through a methylene group to the 3- or 4- position of the benzoyl ring. A suitable value for a hydrolysable in vivo amide of a compound of the invention containing a carboxy group is, for example, an N-Cr Cealkyl or N, N-di-CrC6alkyl amide such as N-methyl, N-ethyl, N -propyl,?,? -dimethyl, N-ethyl-N-methyl, or?,? -diethyl amide.
Upon administration to a subject, the prodrug undergoes a chemical conversion by metabolic or chemical processes to give a compound of the present invention, for example, a salt and / or solvate thereof. Solvates of the compounds of the present invention include, for example, hydrates.
Throughout the specification, modalities of one or more chemical substituents are identified. Also included are combinations of different modalities. For example, the invention describes some embodiments of D in the compounds and describes some modalities of group G. Thus, as an example, compounds in which examples of D are as described and where examples are contemplated within the scope of the invention as well. of group G are as described.
Compounds
According to one embodiment, the invention provides compounds of formula (I):
D- M (1)
including N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and their complexes, and racemic and scala mixtures, diastereomers and enantiomers thereof, in which,
D is selected from the group consisting of an aromatic, heteroaromatic, cycloalkyl or heterocyclic ring system, each of which is optionally substituted with 1 to 5 R38 independently selected;
M is an optionally substituted heterocyclic fused radical;
Z is -O-;
Ar is a 5-7 membered aromatic ring system, which is optionally substituted with 0 to 4 R2 groups, and
G is a group B-L-T, where
B is -N (R 3) - or -C (= S) -;
L is selected from the group consisting of -C (= 0) N (R13) -, -C (= O) C0-Cialkyl-C (= O) N (R13) -, and -C (= 0) -, wherein an alkyl group of the aforementioned group L is optionally substituted, and
T is selected from the group consisting of -Co-C5alkyl, -C0. C5alkyl-Q, -O-C0-C5alkyl-Q, -O-C0-C5alkyl, -C (= S) -N (R13) -C0-C5alkyl-Q, -C0.C5alkyl-S (O) 2 -Q, and -C (= S) -N (R13) -C0-C5alkyl, wherein each C0. C5alkyl is optionally substituted;
where
each R38 is independently selected from the group consisting of halo, CrC6 optionally substituted alkyl, -Co-C6alkyl- (optionally substituted heterocycle), -C2-C6alkenyl = N-heterocycle-C6alkyl optionally substituted, -CH = N-optionally substituted heterocycle , - (CH2), NR39 (CH2) nR36, -C (0) (CH2) jNR39 (CH2) nR36,
(CH2) jNR39 (CH2) [O (CH2)]] (CH2)) R99, - (CH2) jNR39C (0) (CH2) jO (CH2) jOR3, - (CH2) jNR39 (CH2) i (CH ) (NH2) (COOH), - (CH2) jNR39CH (CH3) (CH2) jR99 and - (CH2) jNR39 (CH2) jCOOH;
where
each j is a whole number independently varying from 0 to 4, alternatively 1 -2,
n is an integer that varies from 0 to 6,
x is an integer that goes from 0-6, alternatively 2-3, each i is independent 2 or 3, and
the radicals - (CH2) n- of the above groups R38 are optionally substituted with C6alkyl;
R36 is H or - (CH2) n3OR37;
where
n3 is an integer that varies from 0 to 6;
with the proviso that when R36 and R39 are both bound to the same nitrogen, then R36 and R39 are not both bonded to the nitrogen directly through an oxygen;
each R37 is independently selected from H, C C6 alkyl, - (CH2) nO (CH2) aO-C C6alkyl, - (CH2) nCH (NH) (CH2) nO-C1-C6alkyl1 - (CH2) nCH (NH ) (CH2) nCrC6alkyl, - (CH2) nO (CH2) aO-C3-C10cycloalkyl, - (CH2) nCH (NH) (CH2) nO-C3-C10cycloalkyl and - (CH2) nCH (NH) (CH2) nC3- Cyclocycloalkyl, where each n is an integer independently ranging from 0 to 6 is already an integer ranging from 2 to 6, wherein the alkyl and cycloalkyl radicals of the above R37 groups are optionally substituted by one or more substituents selected from independently;
R39 is selected from the group consisting of H, C C6 alkyl, -SO2-C C6alkyl, -C (0) -C C6 alkyl, -C (0) 0-C C6alkyl, -C (0) -C C6alkyl-NR3R3, -d-Cealkyl-O-CrCealkyl, -CiOXCH ^ cMOICbb ^ OC Cealkyl, -C (0) -Ci-C6alkyl-OH, -C (O) -CF3 and -C (0) CH [CH (CrC6alkyl) 2] NR3R3 and a protecting group used to protect secondary amino groups with the proviso that when R36 and R39 are both bound to the same nitrogen, then R36 and R39 are not both bound to nitrogen directly through an oxygen;
R99 in each occurrence is independently -H, -NH2 or -OR3;
R2 at each occurrence is independently selected from -H and halogen;
each R3 is independently selected from the group consisting of -H and R4;
R 4 is (C C 6) alkyl;
each R13 is independently selected from the group consisting of -H, -C (0) NR3R3 and C C6 alkyl;
Q is a ring system of three to ten members, optionally substituted with between zero and four of R20; Y
each R20 is independently selected from the group
formed by -H, halogen, trihalomethyl, -OR3, -S (O) 0-2R3, -S (0) 2NR3R3, -C (O) OR3, -C (0) NR3R3, - (CH2) 0-5 ( heteroanl), CrC6alkyl, - (CH2) nP (= 0) (Cr C6alkyl) 2, wherein n is an integer ranging from 0 to 6, and the heteroaryl and C C6 alkyl are optionally substituted.
In some embodiments of the compounds according to the present invention D is an aromatic or heteroaromatic ring system, each of which is substituted with 1 or 2 independently selected R38 groups.
In some embodiments according to the present invention, D is a 5- or 6-membered heteroaromatic ring system, each of which is substituted with 1 or 2 independently selected R38 groups.
In some embodiments according to the present invention, D is a 6-membered aromatic ring or 6-membered aromatic ring system, each of which is substituted with 1 or 2 independently selected R38 groups.
In some embodiments according to the present invention, D is a 6-membered aromatic ring system, substituted with 1 or 2 independently selected R38 groups.
In some embodiments according to the present invention, D is a 6-membered heteroaromatic ring system, substituted by 1 or 2 independently selected R38 groups.
In some embodiments according to the present invention, D is a 5-membered heteroaromatic ring system, substituted by 1 or 2 independently selected R38 groups.
In some embodiments of the present invention, D is selected from the group consisting of
wherein the members of said group are substituted with 1 or 2 R38 groups selected independently.
In some embodiments of the present invention, D is selected from the group consisting of
wherein the members of said group are substituted with 1 or 2 R38 groups selected independently.
In some embodiments according to the present invention, D is replaced by a group R38.
In some embodiments of the present invention, D is phenyl, pyridyl, or imidazolyl or tetrahydropyridyl, each of which is substituted with 1 or 2 independently selected R38 groups.
In some embodiments according to the present invention,
R38 is
In some embodiments according to the present invention, D is phenyl, substituted by a group R38.
In some embodiments according to the present invention, D is pyridyl, substituted by 1 or 2 independently selected R38 groups.
In some embodiments according to the present invention, D is pyridyl, substituted with an R38.
In some embodiments according to the present invention, D is imidazolyl, substituted with one or two R38.
In some embodiments according to the present invention, D is imidazolyl, substituted by two R38.
In some embodiments of the present invention, D is tetrahydropyridyl substituted with 1 group R38.
In some embodiments of the present invention, each R38 is independently selected from the group consisting of C ^ Ce alkyl, - (CH2) jNR39 (CH2) j (CH) (NH2) (COOH), - (CH2) jNR39 (CH2) jCOOH,
(CH2) jNR39 (CH2) i [0 (CH2) ¡] x (CH2) jR99, - (CH2) jNR39 (CH2) nR36 and -C0-C6alkyl- (optionally substituted heterocycle).
In some embodiments of the present invention each R38 is independently selected from the group consisting of C C6 alkyl, - (CH2) jNR39 (CH2) ¡[0 (CH2) i] x (CH2) jR99, and - (CH2) jNR39 ( CH2) nR36
In some embodiments of the present invention, each R38 is independently - (CH2) jNR39 (CH2) ¡[0 (CH2) ¡] (CH2) jR99 or (CH2) jNR39 (CH2) nR36.
In some embodiments of the present invention, R38 is - (CH2) jNR39 (CH2) nR36, where] is 1 and n is 2.
In some embodiments of the present invention R38 is - (CH2) NR39 (CH2) 2OCH3.
In some embodiments of the present invention, R38 is - (CH2)) NR39 (CH2) i [0 (CH2) i] x (CH2) jR99.
In some embodiments of the present invention, R38 is - (CH2) jNR39 (CH2) l [0 (CH2) i] x (CH2) jR99, where j is 1, i is 2, and x is 2 or 3.
In some embodiments of the present invention, D is pyridyl substituted with a - (CH2) jNR39 (CH2) nR36, alternatively a (CH2) jNR39 (CH2) nR36, where j is 1 and n is 2.
In some embodiments of the present invention, D is pyridyl substituted with a - (CH2) jNR39 (CH2) ¡[0 (CH2) ¡] x (CH2) jR99, alternatively a - (CH2) jNR39 (CH2) i [0 ( CH2) i] x (CH2) jOMe, where j is 1, i is 2, and x is 2 or 3.
In some embodiments of the present invention, D is pyridyl substituted with a (CH2) jNR39 (CH2) j (CH) (NH2) (COOH).
In some embodiments of the present invention, D is pyridyl substituted with a -C0-C6alkyl- (optionally substituted heterocycle), for example -C0-C6alkyl- (heterocycle substituted with an oxo).
In some embodiments of the present invention, D is pyridyl substituted with a - (CH 2) j NR 39 (CH 2) JCOOH.
In some embodiments of the present invention, D is pyridyl substituted with a - (CH2) jNR39C (0) (CH2) 0 (CH2) ¡OR3.
In some embodiments of the present invention D is tetrahydropyridyl substituted with an optionally substituted -CH = N-heterocycle.
In some embodiments of the present invention D is tetrahydropyridyl substituted with a -C (0) (CH2) jNR39 (CH2) nR36.
In some embodiments of the present invention, D is imidazolyl substituted with a C6alkyl C and a - (CH2) jNR39 (CH2) rR36.
In some embodiments of the present invention, D is phenyl substituted with a - (CH2) jNR39 (CH2) ¡[0 (CH2) ¡] x (CH2) jR99
In some embodiments of the present invention, R39 is selected from the group consisting of H, -C (0) -CrC6 alkyl (e.g., -C (O) -Me), -C (0) -0-CrC6 alkyl, -C (0) -C -C6alkyl-NH2, -S02-Me, -C (0) (CH2) o-40 (CH2) i.40CrC6alkyl and -C (O) CH [CH (Ci-C6alkyl) 2] NR3R3 .
In another embodiment of the present invention, R39 is selected from the group consisting of H, -C (0) -e, C (O) (CH2) O (CH2) 20C1alkyl and -C (0) CH (CHMe2) NH2.
In some embodiments of the present invention, R39 is H or -C (0) -Me.
In some embodiments of the present invention, R39 is H. In some embodiments of the present invention R36 is -OMe.
In some embodiments of the present invention, R99 is -OMe.
In some embodiments of the present invention, M is
* represents the point of attachment to D, and
† represents the point of attachment to Z.
In some embodiments of the present invention, Ar is selected from the group consisting of phenyl, pyrazine, pyridazine, pyrimidine and pyridine, wherein each of said phenyl, pyrazine, pyridazine, pyrimidine and pyridine is optionally substituted by 0 to 4 groups R2.
In some embodiments of the present invention, Ar is phenyl, optionally substituted by 0 to 4 groups R2, alternatively with 1 or 2 groups R2, alternatively with 0, 1 or 2 halo.
In some embodiments of the present invention, Ar is phenyl substituted with a halo, for example, an F.
In some embodiments of the present invention, G is selected from the group consisting of
In some embodiments of the present invention, G is selected from the group consisting of
In some embodiments of the present invention, G is selected from the group consisting of
In some embodiments of the present invention, Q is selected from the group consisting of phenyl, cyclopropyl, isoxazolyl, cyclohexyl, thiazolyl, tetrahydrofuran, pyrazolyl, cyclobutyl and cyclopentyl, optionally substituted with between zero and two R20.
In some embodiments of the present invention, Q is phenyl, optionally substituted with one or two R20.
In some embodiments of the present invention, Q is cyclopropyl.
In some embodiments of the present invention Q is tetrahydrofuran.
In some embodiments of the present invention, Q is pyrazolyl optionally substituted with an R20.
In some embodiments of the present invention, each R20 is independently selected from the group consisting of -P (= 0) (Me) 2, methyl, halo (eg, F), trihalomethyl, methoxy, -C (0) NH2, heteroaryl, COOH, -S02NH2, -C (0) NH2, COOMe-, -C (0) N (H) (Me), -C (0) N (Me) 2 and -SO2Me.
In some embodiments of the present invention, Q is substituted with an R20 selected from -P (= 0) (Me) 2, methyl and methoxy.
In some embodiments of the present invention, Q is phenyl substituted with a -P (= 0) (Me) 2.
In some embodiments of the present invention, Q is pyrazolyl, isoxazolyl or thiazolyl substituted with a methyl.
In some embodiments of the present invention,
D is phenyl, pyridyl, imidazolyl or tetrahydropyridyl, each of which is substituted with 1 or 2 independently selected R38 groups;
Month
Z is -O-;
Ar is phenyl optionally substituted by 0 to 4 R2 groups, for example with between zero and four halo; Y
G is selected from the group consisting of
20 wherein Q is optionally substituted with from 0 to 4 R selected independently.
In some embodiments of the present invention,
D is pyridyl substituted with
(CH2) jNR39 (CH2) i [0 (CH2)]] x (CH2) jR99, -C0-C6alkyl- (heterocycle optionally substituted with one or two oxo), - (CH2) jNR39 (CH2) jCOOH, CH2) j (CH) (NH2) (COOH);
Month
Z is -O-,
Ar is phenyl optionally substituted by 0 to 4 groups R2, for example, an F, and
G is
wherein Q is optionally substituted with 0 to 4 R-independently selected.
In some embodiments of the present invention,
D is pyridyl substituted with - (CH2) iNR39 (CH2) nR36, - (CH2) jNR39 (CH2) ¡[O (CH2) ¡] x (CH2) jR99, -C0-C6alkyl- (heterocycle substituted with oxo), - (CH2) jNR39 (CH2) jCOOH or - (CH2) jNR39 (CH2) j (CH) (NH2) (COOH);
R "is OMe
Month
Z is -0-;
Ar is phenyl optionally substituted by 0 to 4 R2 groups, eg, phenyl substituted with an F, and
G is
where
R13 is H; Y
Q is phenyl optionally substituted with 1 or 2 R20 selected independently, wherein each R20 is independently selected from the group consisting of -P (= 0) (Me) 2, methyl, halo (eg, F), trihalomethyl, methoxy, -C (0) NH2, heteroaryl, -COOH, -S02HN2, -C (0) NH2, -COOMe, -C (0) N (H) (Me), -C (O) N (Me) 2 and -S02Me or Q is pyrazolyl optionally substituted with methyl, or Q is cyclopropyl, cyclobutyl or tetrahydrofuran, or Q is isoxazolyl substituted with methyl.
In some embodiments of the present invention,
D is pyridyl substituted with - (????? - ??? ^) ^ > 36
(CH2) jNR39 (CH2) i [0 (CH2) ¡] x (CH2) jR99, -C0-C6alkyl- (heterocycle substituted an oxo), (CH ^ NR ^ CH ^ COOH or - (CH2) jNR39 (CH2) J (CH) (NH2) (COOH);
R "is OMe;
Month
Z is -0-;
Ar is phenyl optionally substituted with 0 to 4 R2 groups, for example, phenyl substituted with an F, and
G is
where R13 is H; Y
Q is cyclopropyl.
In some embodiments of the present invention, D is pyridyl substituted with -C0-C6alkyl- (optionally substituted heterocycle);
Month
Z is -O-;
Ar is phenyl optionally substituted with 0 to 4 R2 groups, for example, phenyl substituted with an F, and
G is
R13 R13
o o
where
R1 J is H; Y
Q is cyclopropyl.
In some embodiments of the present invention,
D is pyridyl substituted with -C0-C6alkyl- (heterocycle optionally substituted with one or two oxo), for example -CH2- (5- or 6-membered heterocyclyl substituted with 0, 1 or 2 oxo);
Month
Z is -O-;
Ar is phenyl optionally substituted with 0 to 4 groups R2, for example, phenyl substituted with an F, and
G is
R13 R13
O o
where
R1JesH, and
Q is cyclopropyl.
In some embodiments of the present invention, D is pyridyl substituted with
Month
Z is -O-;
Ar is phenyl optionally substituted with 0 to 4 R groups, for example, phenyl substituted with an F, and
G is
R13 R13
0 or
where
R13 is H; Y
Q is cyclopropyl.
In some embodiments of the present invention,
D is pyridyl substituted with - (CH 2) j NR 39 (CH 2) i [0 (CH 2) i]) < (CH2) jR
R "is OMe;
Month
Z is -O-;
Ar is phenyl optionally substituted with 0 to 4 groups R2, for example, phenyl substituted with an F, and
G is
where
R13 is H; Y
Q is cyclopropyl.
In some embodiments of the present invention,
D is imidazolyl substituted with a C6alkyl and a (CH2) jNR39 (CH2) jR36;
Month
Z is -O-;
Ar is phenyl optionally substituted with 0 to 4 groups R2, example an F, and
G is
Where Q is optionally substituted with from 0 to 4 independently selected R20.
In some embodiments of the present invention,
D is imidazolyl substituted with a CrC6alkyl and a - (CH2) jNR39 (CH2) nR36;
Month
Z is -O-;
Ar is phenyl optionally substituted with 0 to 4 R groups, for example, phenyl substituted an F, and
G is
R13 R13
0 or 0)
where
R13 is H, and
twenty
Q is phenyl optionally substituted with 0 to 4 R selected independently,
In some embodiments of the present invention,
D is midazolyl substituted with a C6alkyl and a - (CH2) jNR39 (CH2) nR36;
Month
Z is -O-;
Ar is phenyl optionally substituted with 0 to 4 R2 groups, for example, phenyl substituted with an F and
G is
R 13 R 13
0 or 0;
where
R13 is H, and
Q is phenyl optionally substituted with one or two groups independently selected from the group consisting of -P (O) Me.sub.2, methyl, halo (for example, F), trihalomethyl (for example trifluoromethyl), methoxy, -C (O) NH.sub.2 and heteroaryl (for example, oxazoliium), or Q is cyclopropyl.
The compounds of the above formulas can generally be prepared according to the following schemes. Tautomers and solvates (eg, hydrates) of the compounds of the above formulas are
also in the scope of the present invention. Solvation methods are generally known in the art. Accordingly, the compounds of the present invention may be in free form, hydrate or salt form, and may be obtained by methods exemplified by the following schemes below.
The following examples and preparations describe the manner and process for making and using the invention and are illustrative rather than limiting. It should be understood that there may be other embodiments that fall within the spirit and scope of the invention as defined in the appended claims.
Compounds according to the invention include, but are not limited to those described in the following examples. Compounds are named with Chemdraw Ultra version 10.0 or version 8.0.3, which are available through Cambridgesoft.com, 100 Park Drive Cambridge, Cambridge, MA 02140, or are derived from it.
The data presented here demonstrate the inhibitory effects of the kinase inhibitors of the invention. These data lead us to reasonably expect that the compounds of the invention be useful not only for the inhibition of kinase activity, the protein tyrosine kinase activity, or modalities thereof, such as VEGF receptor signaling, but also as therapeutic agents for the treatment of proliferating diseases, such as cancer and the growth of tumors and diseases, diseases and ophthalmological conditions.
Synthesis schemes and experimental procedures
The compounds of the invention can be prepared according to the reaction schemes or the examples illustrated below using methods known to those of ordinary skill in the art. These schemes serve to exemplify some procedures that can be used to make the compounds of the invention. One skilled in the art will recognize that other general synthetic methods can be used. The compounds of the invention can be prepared from starting components that are commercially available. Any type of substitutions can be made to the starting components to obtain the compounds of the invention according to procedures that are well known to those skilled in the art.
SPECIFIC EXAMPLES
SCHEME 1
46
(2- (7- (4-amino-2-fluorophenoxy) thieno [3,2-b1pyridin-2-yl) -1-methyl-1 H-imidazol-5-yl) methyl (2-methoxyethyl) carbamate tere -butyl (46)
Stage 1 . 5- (1, 3-dioxan-2-yl) -1-methyl-1 H-imidazole (38) fShafiee A., N. Rastkary, M. Jorjani, M., Shafaqhi B., Arch. Pharm. Pharm Med Chem. 2002, 2, 69 -761
To a solution of 1-methyl-1 H-imidazole-5-carbaldehyde (2.9 g, 26.3 mmol) in toluene (20 mL) is added propane-1,3-diol (4.01 g, 52.7 mmol) and CSA (0.306 g). , 1317 mmol) and the reaction mixture is heated to reflux with the azeotropic removal of the developed water for 24 hours. The reaction mixture is cooled to RT, diluted with DCM and washed with NaHCO3 solution. It was then dried over Na 2 SO 4, filtered and concentrated. Purification by column chromatography (80% EtOAc in hexane to EtOAc) yields 38 (2.53 g, 57% yield) as a yellow oil which solidifies on standing to a yellow solid.
MS (m / z): 169.2 (M + H).
Step 2. 5- (1, 3-D-oxane-2-yl) -2-iodo-1-methyl-1 H -amidazole (39) To a solution of 38 (295 g, 1754 mmol) in dry TF (10 ml) at -78 ° C n-BuLi (0.772 ml, 1.929 mmol, 2.5 M in hexanes solution) is added and the reaction mixture is stirred for 20 minutes. Iodine (445 mg, 1754 mmol) in THF (2 mL) is added dropwise slowly while maintaining the temperature at -78 ° C and the reaction mixture is stirred for another 30 minutes.
minutes, and quenched by the addition of water and then extracted with EtOAc. The organic phase is washed with sodium thiosulfate solution, separated, dried over Na 2 SO 4, filtered and concentrated. Purification by column chromatography (20% EtOAc / hexane) yields 39 (305 mg, 59% yield) as a white solid.
MS (m / z): 294.1 (M + H).
Step 3. 2- (5- (1,3-dioxan-2-yl) -1-methyl-1 H-imidazol-2-yl) -7-chlorothienof3,2-blpyridine (40)
To a solution of 7-chlorothieno [3,2-b] pyridine (1) [Klemm, L.H .;
Louris, J.N; Boisvert, W. Higgins, C; Muchiri, D.R .; J. Heterocyclic Chem., 22, 1985, 1249-1252] (11.7 g, 69.0 mmol) in THF (300 mL) is added, at -78 ° C, a solution of n-BuLi (30.46 mL, 76 mmol , 2.5 M in hexanes) and the reaction mixture is stirred for 10 minutes. A solution of ZnCl2 (76.15 mL, 76 mmol, 1.0 M in Et20) is added and the mixture is stirred at room temperature for 10 minutes. Pd (PPh3) 4 (2287 mg, 0.104 mmol) is added together with a solution of 39 (5.82 g, 19.79 mmol) in THF (20 mL) and the reaction mixture is refluxed under N2 gas atmosphere for 4 hours . The reaction is then cooled to RT, and diluted with ammonium hydroxide and EtOAc. The organic phase is collected, dried over Na 2 SO 4, filtered and concentrated. The resulting material is triturated with Et20 to yield the title compound 40 (5.79 g, 87% yield) as a white solid.
MS (m / z): 336.1 (M + H).
Step 4. 2- (5- (1,3-dioxan-2-yl) -1-methyl-1 H-imidazol-2-yl) -7- (2-fluoro-4-nitrophenoxy) thieno [3,2 -blpyridine, (41)
A mixture of 40 (5.9 g, 17.57 mmol), 2-fluoro-4-nitrophenol (5.52 g, 35.1 mmol) and NaHCO 3 (1346 g, 16.02 mmol) in Ph20 (7 mL) is heated at 180 ° C for 4 hours. The reaction mixture is cooled to RT and diluted with DCM, filtered and concentrated. Purification of the residue by column chromatography (eluent EtOAc) gives 41 (2.5 g, 31% yield) as a yellow solid.
MS (m / z): 457.1 (M + H).
Step 5. 2- (5- (D-Methoxymethyl) -1-methyl-1 H-imidazol-2-yl) -7- (2-fluoro-4-nitrophenoxy) thienof3,2-b1-pyridine (42)
To a solution of 41 (2.5 g, 5.48 mmol) in MeOH (200 mL) is added CSA (127 mg, 0.548 mmol) and the reaction mixture is refluxed for 5 hours. It is then cooled to RT and solid NaHCO 3 is added. The mixture is filtered and the filtrate is concentrated to dryness. The solid residue is dissolved in DCM, washed with water, dried over Na2SO, filtered and concentrated. The resulting solid is triturated with Et2O to yield 42 (1.8 g, 74% yield) which is used without further purification.
MS (m / z): 445.1 (M + H).
Step 6. 2- (7- (2-fluoro-4-nitrophenoxy) thienor3,2-blpyridin-2-yl) -1-methyl-1 H-imidazole-5-carbaldehyde (43)
To a solution of 42 (1.8 g, 4.05 mmol) in acetone (100 mL) and water (100 mL) is added diluted HCl (20 mL, 2 M, 40.0 mmol) and the reaction mixture is stirred at room temperature night. It is then concentrated until dry. The solid residue is dissolved in DCM, washed with water, dried over Na 2 SO 4, filtered and concentrated. The resulting solid is triturated with Et20 to yield 43 (1.3 g, 81% yield), which is used without further purification.
MS (m / z): 399.2 (M + H).
Step 7. N - ((2- (7- (2-fluoro-4-nitrophenoxy) thieno [3,2-blpyridin-2-yl) -1-methyl-1 H-imidazol-5-yl) methyl) - 2-methoxyethamine (44)
To a suspension of 43 (1.3 g, 3.26 mmol) in dry DCM (50 ml) at room temperature is added 2-methoxyethamine (1226 g, 16.32 mmol), acetic acid (0.98 g, 16.32 mmol) and sodium triacetoxyborohydride (3.46). g, 16.32 mmol), and the reaction mixture is stirred at room temperature for 24 hours. It is then diluted with additional DCM and washed with saturated NaHCO3 solution, dried over Na2SO4, filtered and concentrated to dryness to give 44 (1.5 g, 100% yield) as a yellow oil which is used as a crude oil. the next stage without further purification.
MS (m / z): 458.2 (M + H).
Step 8. (2- (7- (2-fluoro-4-nitrophenoxy) thienof3,2-blpyridin-2-yl) -1-methyl-1 H-imidazol-5-yl) methyl (2-methoxyethyl) tere-butyl carbamate (45)
To a solution of 44 (1.5 g, 3.28 mmol) in DCM (50 mL) at room temperature is added Boc20 (1073 mg, 4.92 mmol) and the reaction mixture is stirred at room temperature overnight. The mixture is concentrated to dryness and the residue is purified by column chromatography (eluent EtOAc) to yield 45 (1.3 g, 71% yield) as a yellow solid.
MS (m / z): 558.2 (M + H).
Step 9. (2- (7- (4-amino-2-fluorophenoxy) thienor3,2-blpyridin-2-yl) -1-methyl-1 H-imidazol-5-yl) methyl (2-methoxyethyl) carbamate of tere -butyl (46)
To a solution of 45 (1.1 g, 0.717 mmol) in eOH (30 mL) and water (10 mL) is added ammonium chloride (211 mg, 3.95 mmol) and zinc (1.61 g, 17.76 mmol) and the mixture of reaction is heated at reflux for 24 hours. The reaction mixture is cooled to RT then concentrated to dryness. The residue is partitioned between DCM and water and the organic phase is collected, dried over Na 2 SO 4, filtered and concentrated to yield the title compound 46 (1.04 g, 100% yield), which is used crude in the next stage without further purification.
MS (m / z): 528.1 (M + H).
SCHEME 9
126
(6- (7- (4-amino-2-fluorophenoxy) thienof3,2-b1pyridin-2-yl) pyridin-3-yl) methyl (2-methoxyethyl) carbamate tere-butyl (126)
Step 1. N - ((6-Bromopyridin-3-yl) methyl) -2-methoxyethamine (143) To a solution of 6-bromopyridine-3-carbaldehyde (5 g, 26.9 mmol) in DCM (40 ml), add 2-methoxyethylamine (2.80 ml, 32.3 mmol). After 10 minutes, sodium triacetoxyborohydride (7.98 g, 37.6 mmol) is added to the mixture and stirred at RT for 17 hours. DCM (100 mL of water (50 mL and NH4CI (50 mL) is added to the reaction mixture.The organic phase is collected and the aqueous layer is extracted with DCM (3 x 100 mL) .The combined organic solutions are washed with Brine and concentrate under reduced pressure The residue is purified by flash column chromatography, eluent 98/2 to 95/5 DCM / MeOH, to give titer 143 (2958 g, 45% yield) as a brown oil.
1 H NMR (400 MHz, DMSO-d 6) d (ppm): 8.31 (dd, J = 2.6, 0.6 Hz, 1 H), 7.70 (dd, J = 8.2, 2.6 Hz, 1 H), 7.58 (d, J = 8.4 Hz, 1 H), 3.69 (s, 2H), 3.37 (t, J = 5.8 Hz, 2H), 3.22 (s, 3H), 2.60 (t, J = 5.8 Hz, 2H).
MS (m / z): 245.1 (M + H).
Stage 2. Tere-Butyl (6-Bromopyridin-3-yl) methyl (2-methoxyethyl) carbamate (144)
To a solution of 143 (13,072 g, 53.3 mmol) in TF (40 mL) is added di-tert-butyl dicarbonate (14.86 mL, 64.0 mmol). The mixture is stirred at room temperature for 16 hours and concentrated under reduced pressure. The residue is purified by flash column chromatography, eluent hexane / EtOAc: 7/3, 6/4, 5/5, to give the title compound 144 (16.196 g, 88% yield) as a yellow oil.
H NMR (400 MHz, DMSO-d6) d (ppm): 8.26 (dd, J = 2.4, 0.8 Hz, 1 H), 7.64-7.58 (m, 2H), 4.39 (s, 2H), 3.40-3.33 ( m, 4H), 3.20 (s, 3H), 1 .41 -1.31 (m, 9H).
MS (m / z): 345.2 (M + H).
Step 3. (6- (7-chlorothieno [3,2-blpyridin-2-yl) pyridin-3-yl) methyl (tere-butylcarbamate-2-methoxyethylcarbamate (145)
To a solution of 7-chlorothieno [3,2-b] pyridine (1) (8.84 g, 52.1 mmol) in TF (100 mL) at -78 ° C is added n-butyllithium (20.86 mL, 52.1 mmol) . After 30 minutes, zinc chloride (52.1 ml, 52.1 mmol) (1 M in ether) is added at -78X and the reaction mixture is warmed to room temperature. After 1 hour, tetrakistriphenylphosphine palladium (1,004 g, 0.869 mmol) and 144 (6 g, 17.38 mmol) in THF (25 ml) are added and the mixture is heated at reflux for 1 hour. This is then partitioned between saturated aqueous solution NaHCO 3 and EtOAc. The organic layer is collected and the aqueous layer is extracted with EtOAc (3x100 ml). The combined organic layers are washed with brine and evaporated under reduced pressure. The residue is purified by flash column chromatography, hexane / EtOAc: 5/5, 3/7, 0/10, to give compound 145 (5.41 g, 72% yield).
1 H NMR (400 MHz, DMSO-d 6) d (ppm): 8.65 (d, J = 5.1 Hz, 1 H), 8.52 (d, J = 1.6 Hz, 1 H), 8.39 (s, 1 H), 8.27 (d, J = 8.0 Hz, 1 H), 7.80 (dd, J = 8.1, 2.1 Hz, 1 H), 7.58 (d, J = 5.1 Hz, 1 H), 4.48 (s, 2H), 3.43-3.35 (m, 4H), 3.22 (s, 3H), 1.43-1.33 (m, 9H).
MS (m / z): 434.2 (M + H).
Step 4. (6- (7- (4-Amino-2-fluorophenoxy) thienof3,2-blpyridin-2-yl) pyridin-3-yl) methyl (2-methoxyethyl) carbamate tere-butyl (126)
To a solution of 4-amino-2-fluorophenol (1.933 g, 15.21 mmol) in DMSO (30 mL) is added potassium tert-butoxide (2.017 g, 17.97 mmol). After 30 minutes, chloride 145 (6 g, 13.83 mmol) is added and the reaction mixture is heated at 100 ° C for 45 minutes. The mixture is cooled and then poured into water (250 ml) at 40-45X and stirred for 30 minutes. The precipitate is collected by filtration, washed with water (2 x 30 ml) and dried overnight. The crude solid is triturated with Et2O (50 ml) for 1 hour to give the title compound 126 (4.18 g, 58% yield) as a brown solid.
MS (m / z): 525.2 (M + H).
SCHEME 14
+ g.Me Pd2 (dba) 3. xanlfos M
_ "N ° 2 H Me Cs2C03, Dioxane
90 ° C, 3 hours 287
289: example 179
EXAMPLE 179
1 - . 1 - (3- (Dimethylphosphoryl) phenyl) -3- (3-fluoro ^ - (2- (5 - ((2-methoxyethylamino) methyl) -pyridin-2-yl) thienor 3,2-b1pyridin-7 ilox!) phenyl) urea (289)
Step 1. 1 - (dimethylphosphoryl) -3-nitrobenzene (286)
Dimethylphosphine oxide is added to a solution of 1-iodo-3-nitrobenzene (2.4 g, 9.6 mmol) in dry 1,4-dioxane (24 mL) in a pressure vessel with nitrogen at room temperature [WO 2005/009348] (1.5 g, 19.2 mmol), Pd2 (dba) 3 (0.44 g, 0.48 mmol), Xantphos (0.56 g, 0.96 mmol) and cesium carbonate (4.38 g, 13.5 mmol). The mixture is degassed by bubbling nitrogen into the solution for 10 minutes. The pressure bottle is closed and heated to 90 ° C for 3 hours. The solvent is removed under reduced pressure and the residue is purified with Biotage (linear gradient 0-20%, methanol / ethyl acetate, 25 M column) to yield the title compound 286 as a brown solid (1.52 g, 7.63 mmol, 79%).
MS (m / z): 200.1 (M + H).
Step 2. 3- (dimethylphosphoryl) aniline (287)
To a solution of compound 286 (1.5 g, 7.5 mmol) in methanol
(62 ml) and water (12 ml) under nitrogen at room temperature are added ammonium chloride (0.604 g, 11.3 mmol) and iron (1.68 g, 30.1 mmol). The resulting mixture is refluxed for 30 minutes then filtered through celite. The celite pad is rinsed with methanol. The filtrate and washings are combined and concentrated and the residue is purified with Biotage (linear gradient 0-20%, methanol / dichloromethane, 25 M column) to yield compound 287 as a yellow solid (1.27 g, 7.51 mmol, quantitative).
MS (m / z): 170.1 (M + H).
Step 3. (6- (7- (4- (3- (3- (dimethylphosphoryl) phenyl) ureido) -2-fluorophenoxy) thienof3,2-blpyridin-2-yl) pyridn-3-yl) methyl (2- tert-butyl methoxyethyl) carbamate (288)
To a solution of compound 126 (schemes 6 or 9) (200 mg, 0.381 mmol) in dry tetrahydrofuran (8 ml) under nitrogen at -20 ° C is added 4-nitrophenyl chloroformate (115 mg, 0.572 mmol). The reaction mixture is stirred at -20 ° C for 2 hours. A solution of 3- (dimethylphosphoryl) aniline 287 (97 mg, 0.57 mmol) and?,? '-diisopropylethylamine (0.200 mL, 1.14 mmol) in a mixture of dry tetrahydrofuran (2 mL) and dry?,?' - dimethylformamide ( 2 ml) are added at -20 ° C, the reaction mixture is allowed to warm to room temperature slowly, and the stirring is maintained for an additional 16 hours. The solvent is removed under reduced pressure, the residue is diluted with ethyl acetate, washed with a saturated aqueous solution of ammonium chloride, dried over anhydrous sodium sulfate and concentrated. Purification through Biotage (linear gradient 0-20%, methanol / dichloromethane, column 25M) yields compound 288 (230 mg, 0.32 mmol, 84%).
MS (m / z): 720.4 (M + H).
Step 4. 1- (3- (dimethylphosphoryl) phenyl) -3- (3-fluoro-4- (2- (5 - ((2-methoxyethylamino) methyl) pyridin-2-yl) thieno [3,2 -blpyridin-7-yloxy) phenyl) urea (289)
To a solution of compound 288 (30 mg, 32 mmol) in dichloromethane (7 ml) under a nitrogen atmosphere at room temperature is added trifluoroacetic acid (2.5 ml, 32 mmol). The reaction mixture is
Stir for 16 hours at room temperature. The solvent is removed under reduced pressure and a saturated aqueous solution of sodium bicarbonate is added. The aqueous phase is extracted with ethyl acetate (3X), the combined organic layers are concentrated. The residue is purified with Biotage (linear gradient 0-20%, methanol / dichloromethane, 25 M column) to give 289 as a whitish compound (75.3 mg, 0.122 mmol, 38.0%).
1 H NMR (400 MHz, DMSO-d 6) d (ppm): 9.15 (s, 1 H), 9.06 (s, 1 H), 8.57 (d, J = 1.6 Hz, 1 H), 8.53 (d, J = 5.6 Hz, 1 H), 8.31 (s, 1 H), 8.23 (d, J = 8.0 Hz, 1 H), 7.92-7.83 (m, 2H), 7.76 (dd, J = 13.2, 2.4 Hz, 1 H ), 7.67-7.62 (m, 1 H), 7.49-7.42 (m, 2H), 7.41 -7.33 (m, 1 H), 7.32-7.26 (m, 1 H), 6.67 (d, J = 5.6 Hz, 1 H), 3.78 (s, 2H), 3.54-3.34 (2H, hidden under the water signal), 3.24 (s, 3H), 2.65 (t, J = 5.6 Hz, 2H), 1.65 (d, J = 13.2 Hz, 6H)
MS (m / z): 620.4 (M + H).
EXAMPLE 180
1- (4- (Dimethyl-phospho-phenyl) -3- (3-fluoro ^ - (2- (5 - ((2-methoxyethylamino) methy1) pyridin-2-yl) thienof3,2-b1-pyridin-7-yloxy) phenyl )urea
(290)
Compound 290 is obtained by following the procedures described above for compound 289 (Example 179). Characterization of compound 290 and compounds 295-300 are presented in table 1
TABLE 1
SCHEME 16
315: example 202
EXAMPLE 202
Step 1. (2- (7- (2-fluoro-4- (3-isopropylureido) phenoxy) thienof3,2-b1-pyridin-2-yl) -1-methyl-H-imidazol-5-yl) methyl (2- tert-butyl methoxyethyl) carbamate (314)
The reaction mixture of aniline 46 (200 mg, 0.379 mmol) and 2-isocyanatopropane (64.5 mg, 0.758 mmol) is heated at 100X for 15 minutes in a microwave reactor. The reaction mixture is loaded directly into Biotage (Silicycle, HR, column 12g, 50-100% EA / hexane, then MeOH / EA, 0-20%). The collected fractions yield the desired product 314 (150 mg, 0.245 mmol, 64.6% yield) as a white solid. MS: 613 (MH) +, very weak signal.
Step 2. 1 - (3-Fluoro-4- (2- (5 - ((2-methoxyethylamino) methyl) -1-methyl-H-imidazol-2-yl) thienof3,2-b1pyridin-7-yloxy ) pheny1) -3-isopropylurea (315)
The solution of urea 314 (150 mg, 0.245 mmol) and TFA (1 mL, 12.98 mmol) in DCM (20 mL) is stirred 4 hours at room temperature and concentrated. The residue is partitioned between EtOAc / saturated solution aHC03. The solid is collected by filtration and combined with organic layer. The mixture is concentrated and the residue is purified through Biotage (EA / MeOH 0-40%, column 12g Silicycle HR). Collected fractions give the desired product 315 (70 mg, 0.137 mmol, 55.8% yield) as a white solid.
1 H NMR (dmso-d 6) 5 (ppm) 1 H: 8.67 (s, 1 H), 8.48 (d, 1 H,
J = 5.5Hz), 7.91 (s, 1 H), 7.65 (dd, 1 H, J1 = 13.7Hz, J2 = 2.6Hz), 7.32 (t, 1 H, J = 9.0Hz), 7.07 (m, 2H ), 6.63 (d, 1 H, J = 5.5Hz), 6.13 (d, 1 H, J = 7.6Hz), 4.04 (s, br, 2H), 3.08 (s, 3H), 3.72 (m, 1 H) ), 3.47 (t, 2H, J = 5.2Hz), 3.24 (s, 3H), 2.94 (m, 2H), 1.07 (s, 3H, 1.05 (s, 3H) (presumably urn salt mono-TFA). : 513.4 (MH) +.
SCHEME 17
Step 4. 4- (2- (5- (1,3-dioxane-2-yl) thienof3,2-blpyridin-7-yloxy) -3-fluoroaniline (319)
Step 1. 2-Bromo-5- (1,3-dioxan-2-yl) pyridine (316)
To a solution of 6-bromopyridine-3-carbaldehyde (25 g, 134 mmol) in toluene (130 mL) is added 1,3-propanediol (20.45 g, 269 mmol) and 10-camphorsulfonic acid (3.12 g, 13.44 mmol). . The reaction mixture is heated to reflux, with azeotropic removal of the developed water, for 50 minutes, cooled to room temperature and concentrated. The residue is partitioned between EtOAc (150 mL) and saturated aqueous NaHCO3 solution (100 mL). The organic phase is collected and the aqueous phase is extracted with EtOAc (2 x 150 mL). The combined organic fractions are washed with brine (100 ml), dried over Na 2 SO 4, filtered and concentrated to give a brown solid which is triturated with Et 2 O and hexane (10/200 ml) to give intermediate 316 (27.7 g). , 84% yield) as a beige solid.
MS (m / z): 244.1, 246.1 (M + H).
1 H NMR (400 MHz, DMSO-d 6) d (ppm): 8.40 (d, J = 2.4 Hz, 1 H), 7.35 (dd, J = 8.0, 2.4 Hz, 1 H), 7.66 (dd, J = 8.0 , 0.4 Hz, 1 H), 5.61 (s, 1 H), 4.15 (ddd, J = 11.8, 5.0, 1.2 Hz, 2H), 3.98-3.91 (m, 2H), 2.028-1.95 (m, 1 H) , 1 .46 (d quintuplet, J = 13.2, 1.2 Hz, 1 H).
Step 2. 2- (5- (1,3-dioxane-2-yl) pyridin-2-yl) -7-chlorothienof3.2-blpyridine (317)
To a solution of 7-chlorothieno [3,2-b] pyridine (1) (13.33 g, 79 mmol) in THF (204 ml) at -5 ° C / -10 ° C is added n-BuLi (2.5 M in hexanes, 31.6 mL, 79 mmol) for 50 minutes. After 30 minutes, a solution of zinc chloride in ether (1 M, 79 mL, 79 mmol) is added at -5 ° C / -10 ° C for 50 minutes and the reaction mixture is allowed to warm to room temperature. After 45 minutes, 2-bromo-5- (1, 3-dioxan-2-yl) pyridine (316) (15.98 g, 65.5 mmol) and tetrakistriphenylphosphine palladium (2.27 g, 1.964 mmol) in THF (28 ml. ) are added and the mixture is heated at reflux for 2 hours, cooled to room temperature, and concentrated. The residue is diluted with DCM (600 mL), H2O (500 mL) and NH4OH (100 mL), stirred at rt. for 1 hour and the phases are separated. The aqueous phase is extracted with DCM (2 x 100 mL); The combined organic phases are dried over anhydrous Na2SO4, filtered and concentrated. The residue is triturated with MTBE (150 mL), to provide intermediate 317 (12.796 g, 59% yield) as a beige solid.
1 H NMR (400 MHz, DMSO-d 6) d (ppm): 8.66-8.65 (m, 2 H), 8.43 (d, J = 0.8 Hz, 1 H), 8.30 (d, J = 8.4 Hz, 1 H), 7.94 (d, J = 8.4 Hz, 1 H), 7.59 (dd, J = 5.0, 0.6 Hz, 1 H), 5.68 (s, 1 H), 4.19 (dd, J = 11.6, 4.8 Hz, 2H ), 3.99 (t, J = 11.4 Hz, 2H), 2.07-2.01 (m, 1 H), 1.49 (d, J = 13.2 Hz, 1 H).
MS (miz): 333.1 (M + H).
Step 3. 2- (5- (1,3-dioxane-2-yl) pyridin-2-yl) -7- (2-fluoro-4-nitrophenoxy) thieno [3,2-b] pyridine (318)
To a suspension of 317 (22.48 g, 67.5 mmol) in phenyl ether (65 ml) is added sodium carbonate (14.32 g, 135 mmol) and 2-fluoro-4-nitrophenol (15.92 g, 101 mmol). The reaction mixture is heated at 180 ° C for 2 hours, cooled to 40 ° C, diluted with DCM (300 ml), stirred at room temperature for 15 minutes and filtered. The filtrate is collected and concentrated to a minimum volume; Et20 (200 ml) is added and the formed suspension is stirred for 30 minutes. The solid material is collected by filtration, to provide intermediate 318 (25.20 g, 55.6 mmol, 82% yield) as a beige solid.
H NMR (400 MHz, DMSO-d6) d (ppm): 8.63-8.62 (m, 2H), 8.48 (dd, J = 10.6, 2.6 Hz, 1 H), 8.43 (s, 1 H), 8.31 (d , J = 8.0 Hz, 1 H), 8.21 (dt, J = 8.8, 1.2 Hz, 1 H), 7.94 (d, J = 8.4, 2.0 Hz, 1 H), 7.71 (t, J = 8.6 Hz, 1 H), 6.98 (d, J = 5.2 Hz, 1 H), 5.67 (s, 1 H), 4.19 (dd, J = 10.8, 5.2 Hz, 2H), 3.98 (td, J = 12.0, 2.0 Hz, 2H ), 2.08-1.99 (m, 1 H), 1.46 (d, J = 13.6 Hz, 1 H).
MS (m / z): 454.2 (M + H).
Step 4. 4- (2- (5- (1 .3-dioxan-2-yl) pyridin-2-yl) thienof3.2-blpyridin-7-yloxy) -3-fluoroaniline (319)
Method A
To a suspension of 318 (10 g, 22.05 mmol) in EtOH (216 ml) and water (108 ml) is added iron powder (10.47 g, 187 mmol) and ammonium chloride (1015 g, 18.97 mmol). The mixture is refluxed for 30 minutes, filtered hot and the solids washed with ether (200 ml). The filtrate and washings are combined and concentrated to give the title compound 319 (9.62 g, 99% yield) as a beige solid. This material is used in the next step (Scheme 18) without further purification.
1 H NMR (400 MHz, DMSO-d 6) d (ppm): 8.64 (d, J = 2.0 Hz, 1 H),
8. 51 (dd, J = 5.6, 2.0 Hz, 1 H), 8.34 (s, 1 H), 8.28 (dd, J = 8.0, 0.8 Hz, 1 H), 7.93 (dd, J = 8.4, 2.0 Hz, 1 H), 7.13 (t, J = 9.0 Hz, 1 H), 6.61 (dd, J = 5.4, 0.6 Hz, 1 H), 6.54 (dd, J = 13.2, 2.4 Hz, 1 H), 6.46 (ddd, J = 8.8, 2.8, 0.6 Hz, 1 H), 5.67 (s, 1 H), 5.56 (s, 2H), 4.19 (dd, J = 10.6, 5.0 Hz, 2H), 3.98 (td, J = 12.0, 2.5 Hz, 2H), 2.09-1.99 (m, 1 H), 1.49 (dt, J = 13.2, 1.3 Hz, 1 H).
MS (m / z): 424.1 (M + H).
, Method B
To a solution of 4-amino-2-fluorophenol (7.42 g, 58.4 mmol) in DMSO (65 mL) is added potassium tert-butoxide (7.75 g, 69.0 mmol). After 30 minutes, intermediate 317 (17.67 g, 53.1 mmol) is added and the reaction mixture is heated at 100 ° C for 1.5 hours, cooled to room temperature, poured into water (300 ml) at 40-45 ° C and stirred for 30 minutes. The solid is collected by filtration, washed with water (2 x 30 ml) and dried for 2 hours. This material is triturated with ether (60 ml), to give the title compound 319 (19.80 g, 88% yield) as a brown solid.
MS (m / z): 424.1 (M + H).
SCHEME 18
EXAMPLE 203
1 - . 1 - (4- (2- (5-5,8,11,14-Tetraoxa-2-azapentadecylpyridin-2-yl) thienof312-blpyridin-7-yloxy) -3-fluorophenyl) -3-cyclopropylurea (323)
Step 1: 1- (4- (2- (5- (1,3-dioxane-2-yl) pyridin-2-yl) thieno [3,2-blpyridin-7-yloxy) -3-fluorophenyl) -3 -cyclopropylurea (320)
A 100 ml round bottom flask is charged with 319 (0.55 g, 1.3 mmol) and DIPEA (0.91 ml, 5.2 mmol) in dry tetrahydrofuran (55 ml) to give a colorless solution. The reaction mixture is cooled to 0 ° C and then triphosgene (0.154 g, 0.520 mmol) is added. The reaction mixture is stirred for 1 hour at 0 ° C and then cyclopropylamine (1.8 ml, 26 mmol) is added. Finally, the reaction mixture is stirred at room temperature for 3 hours then concentrated. The residue is partitioned between water and ethyl acetate, resulting in the formation of a white, thick solid. This is isolated by suction filtration, rinsed with water and ethyl acetate, and dried in vacuo to give the crude 320 (0.65 g, 1.2 mmol, 99% yield) which is used without further purification.
MS: 507.2 (M + H).
Step 2: 1-Cyclopropyl-3- (3-fluoro-4- (2- (5-formylpyridin-2-yl) thieno [3,2-blpyridin-7-yloxy) phenyl) urea (321)
A suspension of 320 (0.65 g, 1.3 mmol) in 5: 2: 1 acetone / water / TFA (100 mL) is heated at reflux for 6 hours. The mixture is then cooled and concentrated. The resulting solid residue is suspended in water, isolated by suction filtration, washed with ethyl acetate and dried under vacuum to give 321 (0.49 g, 1.1 mmol, 85% yield) which is used without further purification in the next stage.
MS: 449.0 (M + H).
Step 3. 2,5,8,11-Tetraoxatridecan-13-amine (322)
Tetraethylene glycol monomethyl ether (10.0 ml, 47.5 mmol), phthalimide (7.20 g, 48.9 mmol) and triphenylphosphine (12.8 g, 48.8 mmol) is suspended in dry tetrahydrofuran (200 ml) to obtain a colorless suspension. Diethyl azodicarboxylate (8.0 ml, 50.5 mmol) is added dropwise with a syringe, and the mixture is stirred at room temperature for 18 hours. Then ethanol (50 ml) is added, the mixture is stirred for another 30 minutes and then concentrated under reduced pressure. The residue is dissolved in 1: 1 ethyl acetate / hexanes (100 ml), stirred at 0 ° C for 2 hours, and the resulting white precipitate is removed by suction filtration. The filtrate is concentrated (13.5 g, 40.0 mmol, 84% yield) and used in the next step without further purification.
The above crude product is dissolved in ethanol (100 ml) to give a colorless solution. Hydrazine hydrate (2.3 ml, 40 mmol) is added and the mixture is refluxed for 4 hours. After cooling, concentrated HCl (10.0 ml) is added, and the mixture refluxes for an additional 1 hour. Then it is allowed to cool to room temperature, the white precipitate is removed by filtration by suction, and the filtrate is concentrated. The residue is divided between water and diethyl ether. The aqueous phase is extracted with ether (organic phase, which mostly contains PPh3 by EM, is discarded), then basified with 3M NaOH (50 ml) at pH = 13. The aqueous phase is saturated with sodium chloride and extract several times with dichloromethane (-10 x 50 mL). The organic extract is dried (MgSO4) and concentrated to yield 322 (7.0 g, 33.8 mmol, 84% yield, 71% in 2 steps). This is used without further purification in the next step.
MS (m + 1) = 208.1.
Step 4: 1 - (4- (2- (5-5,8,11,14-Tetraoxa-2-azapentadecylpyridin-2-yl) thienof3,2-blpyridin-7-yloxy) -3-fluorophenyl) -3- cyclopropylurea (323)
To a suspension of carboxaldehyde 321 (0.45 g, 1.0 mmol) and amine 322 (1.4 g, 6.75 mmol) in dichloromethane (75 ml) is added acetic acid (0.12 ml, 2.0 mmol). The reaction mixture is stirred for 1 hour, and then sodium triacetoxyborohydride (0.64 g, 3.0 mmol) is added and the resulting mixture is stirred for 18 hours. The mixture is then partitioned between water and dichloromethane, washed with 1 M NaOH and brine, dried (MgSO4), filtered and concentrated under reduced pressure. The residue is purified by Gilson reverse phase HPLC (35-75% MeOH / H2O, Aquasil CiB, 30 minutes) and lyophilized. The purified product (containing a little formic acid from the HPLC) is partitioned between hot dichloromethane and 1 M NaOH. The organic phase is dried (MgSO4), filtered and concentrated to give the title compound 323 (0.264 g, 0.413 mmol, 41.1% yield).
1 H NMR (DMSO-d 6) 6 (ppm) 1 H: 8.80 (s, 1 H); 8.57 (s, 1 H); 8.51 (d, J = 5.5, 1 H); 8.31 (s, 1 H); 8.23 (d, J = 8.0, 1 H) 7.89 (dd, J = 8.0, 1.5, 1 H); 7.73 (dd, J = 1 3.5, 2.2, 1 H); 7.38 (t, J = 9.0, 1 H) 7.20 (d, J = 8.2, 1 H); 6.67 (d, J = 2.7, 1 H); 6.64 (d, J = 5.5, 1 H); 3.78 (s, 2H); 3.56-45 (m, 12H); 3.41 (t, J = 5.7, 2H); 3.21 (s, 3H); 2.66 (d, J = 5.7, 2H); 2.58-2.51 (m, 1 H); 0.66-0.62 (m, 2H) ¡0.44-0.41 (m, 2H).
LREM: 640.5 (M + H).
SCHEME 19
324: example 204
EXAMPLE 204
Acid (S) -2-amino-6 - ((6- (7- (4- (3-cyclopropylureido) -2-fluorophenoxy) thienor3.2-b1pyridin-2-yl) pyridin-3-yl) methylamino hexanoic)
Í324J
To a suspension of 321 (0.26 g, 0.58 mmol) and N-Boc-lysine (1.1 g, 4.6 mmol) in dichloromethane (75 ml) and acetic acid (0.066 ml, 1.2 mmol) is added. The reaction mixture is stirred for 1 hour, then sodium triacetoxyborohydride (0.37 g, 1.7 mmol) is added and the mixture
The resulting mixture is stirred for 18 hours. The mixture is then partitioned between water and dichloromethane, and the precipitated solid removed by suction filtration through celite. The product is mainly in the filter cake of solids, so it is solubilized by washing with 1: 1 dichloromethane / methanol. This solution is concentrated and the residue is purified by Gilson reverse phase HPLC (35-75% MeOH / H2O, Aquasil C18, 30 min) and lyophilized to give the BOC-protected product. This is dissolved in dichloromethane (75 ml) and trifluoroacetic acid (3 ml), and stirred at room temperature for 3 hours. The mixture is concentrated and the residue is purified by Gilson reverse phase HPLC (35-75% MeOH / H20, Aquasil C18, 30 min) and lyophilized to give the title compound 324 (44 mg, 69% yield).
1 H NMR (DMSO-de) 6 (ppm) 1 H: 9.02 (s, 1 H); 8.66 (s, 1 H); 8.53 (d, J = 5.3, 1 H); 8.35 (s, 1 H); 8.28 (d, J = 8.4, 1 H) 7.98 (d, J = 6.3, 1 H); 7.72 (dd, J = 13.5, 2.3, 1 H); 7.37 (t, J = 9.0, 1 H); 7.21 (d, J = 10.0, 1 H); 6.89 (s, 1 H); 6.68 (d, J = 5.3, 1 H); 4.00 (s, 2H); 2.75-2.70 (m, 2H) 2.55-2.52 (m, 1 H); 2.45 (m, 1 H); 1.70-1.30 (m, 6H); 0.67-0.62 (m, 2H); 0.44-0.40 (m, 2H).
LREM: 579.5 (M + H).
Faith; NH4CI; eOH / H20
329
330
331: example 205 EXAMPLE 205
1-Cyclopropyl-3- (3-fluoro-4- (2- (5 - ((2- (2-methoxyethoxy) ethylamino) methyl) pyridin-2-yl) thieno [3,2-b] pyridine-7- iloxy) phenyl) urea
Step 1: 6- (7- (2-fluoro-4-nitrophenoxy) thieno [3,2-blpyridin-2-D-nicotinaldehyde (325)
A suspension of 318 (2.64 g, 5.82 mmol) in 80% aqueous acetic acid (42 ml) is heated at 90 ° C for 18 hours. The reaction mixture is cooled to room temperature and diluted with water. The resulting precipitate is collected by suction filtration. The solid is transferred to a round bottom flask, the remaining water is removed by azeotropic distillation with toluene (4 times), and the dry solid under vacuum produces 325 (1.76 g, 76%). .
LREM: (M + H) 396.3
Step 2: 2- (2-methoxyethoxy) ethanamine (326)
Diethylene glycol monomethyl ether (9.8 ml, 83 mmol), phthalimide (14.7 g, 100 mmol), and triphenylphosphine (26.2 g, 100 mmol) is suspended in dry tetrahydrofuran (200 ml) to obtain a colorless suspension (see scheme 18, step 3). Dietl azodicarboxylate (15.8 ml, 100 mmol) is added dropwise with a syringe, and the mixture is stirred at room temperature for 18 hours. Then ethanol (50 ml) is added, the mixture is stirred for another 30 minutes and then concentrated under reduced pressure. The residue is dissolved in ethyl acetate / hexanes 1: 1 (100 ml), stirred at 0 ° C for 2 hours, and the resulting white precipitate is removed by suction filtration. The filtrate is concentrated and used in the next step without further purification.
The above crude product is dissolved in ethanol (200 ml) to give a colorless solution. Hydrazine hydrate (5.1 ml, 104 mmol) is added and the mixture is refluxed for 4 hours. It is then cooled, concentrated HCl (16 ml) is added, and the mixture is refluxed for an additional 1 hour. Then it is cooled to room temperature, the white precipitate is removed by filtration with suction, and the filtrate is concentrated. The residue is partitioned between water and ethyl acetate. The aqueous phase is extracted with ethyl acetate (organic phase, which mostly contains PPhaO with MS, is discarded), then basified with 3M NaOH (50 ml) at pH = 13. The aqueous phase is saturated with sodium chloride and extracted several times with dichloromethane (-10 x 50 ml). The organic extract is dried (MgSO4) and concentrated to yield 326 (6.6 g, 56 mmol, 67% yield in 2 steps). This is used without further purification in a subsequent reaction.
MS (m + I) = 120.2.
Step 3: N - ((6- (7- (2-fluoro-4-nitrophenoxy) thieno [3,2-blpyridin-2-yl) pyridin-3-yl) methyl) -2- (2-methoxyethoxy) Ethanamine (327)
A suspension of carbaldehyde 325 (0.50 g, 1 .3 mmol), amine
326 (0.30 g, 2.5 mmol) and acetic acid (0.14 mL, 2.5 mmol) in dichloromethane (20 mL) is stirred for 1 hour at room temperature. Then sodium triacetoxyborohydride (0.80 g, 3.8 mmol) is added and stirred at room temperature for 16 hours. An additional amount of sodium triacetoxyborohydride (1.0 g) is then added and the stirring is continued for 2 hours. The reaction mixture is partitioned between dichloromethane and 1 N NaOH. The yellow suspension is filtered off and rinsed with dichloromethane and 1 N NaOH. The organic extract is dried over anhydrous sodium sulfate, filtered and concentrated. The organic residue is purified with Biotage (linear gradient 0-20%, methanol / dichloromethane, column 100g Snap) to produce 327 (280 mg, 0.562 mmol, 44%) as a yellow solid.
LREM: (M + H): 499.4.
Step 4: (6- (7- (2-fluoro-4-nitrophenoxy) thieno [3,2-b1pyridin-2-yl) pyridin-3-yl) methyl (2- (2-methoxyethoxy) ethyl) carbamate tere -butyl (328)
To compound 327 (0.28 g, 0.56 mmol) in dichloromethane (100 ml) at room temperature is added (0.25 ml, 1.7 mmol), DMAP (0.017 g, 0.14 mmol) and Boc2O (0.26 g, 1.1 mmol). The reaction mixture is stirred at room temperature for 2 hours, then the mixture is washed sequentially with water, saturated ammonium chloride, and brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue is purified by silica gel chromatography (ethyl acetate) to yield compound 328 (0.20 g, 60% yield).
LREM: (M + H): 599.5.
Step 5: (6- (7- (4-amino-2-fluorophenoxy) thienof3.2-b1pyridin-2-yl) pyridin-3-yl) methyl (2- (2-methoxyethoxy) ethyl) tertiary carbamate -butyl (329)
To the nitro compound 328 (0.20 g, 0.33 mmol) in MeOH (75 ml) is added iron powder (0.37 g, 6.7 mmol) and ammonium chloride (0.089 g, 1.7 mmol) in water (5 ml). The resulting mixture is refluxed for 4 hours, then cooled, filtered through celite and concentrated. The residue is partitioned between ethyl acetate and water, washed with brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The product 329 (0.18 g, 95%) is used crude in the next stage.
LREM: (M + H): 569.5.
Step 6: (6- (7- (4- (3-cyclopropylureido) -2-fluorophenoxy) thieno [3,2-b | pyridin-2-yl) pyridin-3-yl) methyl (2- (2-methoxyethoxy) Ethyl) tert-butyl carbamate (330)
To amine 330 (0.17 g, 0.30 mmol) and DIPEA (0.16 mL, 0.12 g, 0.90 mmol) in tetrahydrofuran (25 mL) is added at 0 ° C triphosgene (0.035 g, 0.12 mmol) and the resulting solution is stirred for 1 hour. hour at 0 ° C. Cyclopropylamine (0.26 g, 4.6 mmol) is added and the mixture is warmed to room temperature and stirred for 18 hours, then concentrated under reduced pressure. The residue is partitioned between dichloromethane and water, the organic phase is washed with saturated NH 4 Cl (aC) and brine, dried over MgSO 4,
it is filtered and concentrated, yielding 330 crude (0.15 g, 77% yield). LREM: (M + H): 652.6.
Step 7: Cyclopropyl-3- (3-fluoro-4- (2- (5 - ((2- (2-methoxyethoxy) ethylamino) methyl) pyridin-2-yl) thieno [3,2-blpyridin-7] -iloxy) phenyl) urea (331)
Compound 330 (0.15 g, 0.23 mmol) is dissolved in dichloromethane (20 ml) and trifluoroacetic acid (0.9 ml) and the reaction mixture is stirred for 12 hours at room temperature. The mixture is concentrated and the residue is purified by Gilson reverse phase HPLC (40-80% MeOH / H20, Aquasil C 8, 30 minutes) and lyophilized. The purified product (containing a little formic acid of HPLC) is divided between hot dichloromethane and 1 M NaOH. The organic phase is dried (MgSO 4), filtered and concentrated to give the title compound 331 (0.110 g, 72 % yield) (a mono-TFA salt despite treatment with NaOH).
1 H NMR (DMSO-de) 6 (ppm) 1 H: 8.84 (s, 1 H); 8.65 (d, J = 1 .3, 1 H); 8.53 (d, J = 5.5, 1 H); 8.37 (s, 1 H); 8.30 (d, J = 8.2, 1 H); 7.99 (dd, J = 8 2, 2.0, 1 H); 7.73 (dd, J = 13.7, 2.5, 1 H); 7.38 (t, J = 9.0, 1 H); 7.22-7.18 (m, 1 H); 6.68-6.64 (m, 2H); 4.03 (s, 2H); 3.60-3.52 (m, 4H); 3.48-3.44 (m, 2H); 3.25 (s, 3H) 2.92-2.88 (m, 2H); 2.55 (septet, J = 3.1, 1 H); 0.69-0.62 (m, 2H); 0.44-0.40 (m, 2H).
LREM: (M + H): 552.5.
SCHEME 21
332: example 206 333: example 207
EXAMPLES 206 and 207
4 - ((6- (7- (4- (3-Cyclopropylureido) -2-fluorophenoxy) thienor3,2-b1pyridin-2-yl) pyridin-3-yl) methylamino) butanoic acid (332), and 1 -cyclopropyl-3- (3-fluoro-4- (2- (5 - ((2-oxopyrrolidin-1-yl) methyl) pyridin-2-yl) thienor3,2-b1pyridin-7-yloxy) phenylurea (333)
To a suspension of carbaldehyde 321 (0.20 g, 0.45 mmol) and 4-aminobutytic acid (1.0 g, 9.7 mmol) in dichloromethane (75 ml) and acetic acid (0.051 ml, 0.89 mmol) is added. The reaction mixture is stirred for 1 hour, then sodium triacetoxyborohydride (0.38 g, 1.8 mmol) is added and the resulting mixture is stirred for 18 hours. The mixture is partitioned between water and dichloromethane, and the precipitated solid is removed by suction filtration through celite. EM analysis indicates that the cyclized product 333 is in the filtrate, while the acid product 332 is mostly in the solid filter cake. The organic phase from the filtrate is concentrated and the residue is purified by silica gel chromatography (10% MeOH / ethyl acetate) to provide 333 purified (35 mg, 15% yield). The product in the celite filter cake is solubilized by washing with 1: 1 dichloromethane / methanol. This solution is concentrated and the residue is purified by Gilson reverse phase HPLC (35-75% MeOH / h <0>, Aquasil Ci <8>, 30 minutes) and lyophilized to give acid 332 (44 mg, 69% yield). Characterization of compounds 332 and 333 is provided below.
Compound 332 (example 206): 1 H NMR (DMSO-d 6) or (ppm) 1 H: 9.23 (s, 1 H); 8.58 (s, 1 H); 8.51 (d, J = 5 4, 1 H); 8.36 (s, 1 H); 8.32 (s, 1 H); 8.24 (d, J = 8.2, 1 H); 7.91 (dd, J = 8.4, 2.0, 1 H); 7.74 (dd, J = 13.7, 2.3, 1 H); 7.37 (t, J = 9.0, 1 H); 7.22 (d, J = 9.0, 1 H); 6.63 (d, J = 5.3, 1 H); 3.79 (s, 2H) 2.56 (t, J = 5.1, 2H); 2.47-2.43 (m, 1 H); 2.27 (t, J = 7.2, 2H) 1.65 (quintuplet, J = 6.7, 2H); 0.66-0.61 (m, 2H); 0.44-0.40 (m, 2H).
LREM: (M + H) 536.4.
Compound 333 (example 207): 1 H NMR (DMSO-d 6) or (ppm) 1 H: 8.76 (s, 1 H); 8.52 (s, 1 H) 8.52 (d, J = 5.5, 1 H); 8.35 (s, 1 H); 8.26 (d, J = 8.2, 1 H); 7.79 (dd, J = 8.2, 2.1, 1 H); 7.73 (dd, J = 13.5, 2.5, 1 H); 7.38 (t, J = 9.2, 1 H); 7.20 (d, J = 8.4, 1 H); 6.65 (d, J = 5.3, 1 H); 6.62 (s, 1 H); 4.46 (s, 2H); 3.30-3.20 (t, 2H, darkened by peak water?); 2.55 (quintuplet, J = 3.3, 1 H); 2.31 (t, J = 7.8, 2H); 1 .95 (quintuplet, J = 7.6, 2H); 0.67-0.62 (m, 2H); 0.45-0.40 (m,
LREM: (M + H) 518.4
SCHEME 22
335: example 209
EXAMPLES 208 and 209
Step 1: (S) -1-cyclopropyl-3- (3-fluoro-4- (2- (5 - ((1-methoxypropan-2-ylammon) methyl) -pyridin-2-yl) thieno [3 , 2-b1-pyridin-7-yloxy) phenyl) urea (334)
To a stirred suspension of carbaldehyde 321 (336 mg, 0.749 mmol), (S) -1-methoxy-2-aminopropane (200 mg, 2248 mmol) and acetic acid (68 mg, 1124 mmol) in DCM (20 mL) a Room temperature under nitrogen is added NaBH (OAc) 3 (418 mg, 1873 mmol). The reaction mixture is stirred at room temperature overnight and quenched with a 1.0% HCl solution. The layers are separated, the aqueous layer is collected, washed twice with DCM and basified with 4N NaOH (pH 12) to form a suspension which is stirred for 30 minutes. The solid is collected by filtration, dried with water and dried with air and purified by flash column chromatography on silica gel (eluent 2% ammonium hydroxide in MeOH / DCM: 10/90) to produce the title 334 (182 mg, 0.35 mmol, 46% yield) as a yellow fluffy solid.
H NMR (400 MHz, DMSO-d6) d (ppm): 8.71 (s, 1 H), 8.58 (d, J = 1.6 Hz, 1 H), 8.51 (d, J = 5.5 Hz, 1 H) , 8.31 (s, 1 H), 8.23 (d, J = 8.2 Hz, 1 H), 7.91 (dd, J = 8.2, 2.2 Hz, 1 H), 7.73 (dd, J = 13.6, 2.4 Hz, 1 H ), 7.38 (t, J = 9.0 Hz, 1 H), 7.23-7.17 (m, 1 H), 6.64 (d, J = 5.5 Hz, 1 H), 6.57 (bd, J = 2.7 Hz, 1 H) , 3.84 (d, J = 14.5 Hz, 1 H), 3.78 (d, J = 14.5 Hz, 1 H), 3.27 (d, J = 9.4, 6.3 Hz, 1 H), 3.24 (s, 3 H), 3.19 (dd, J = 9.2, 5.5 Hz, 1 H), 2.81 -2.71 (m, 1 H), 2.59-2.51 (m, 1 H), 2.36-2.10 (m, 1 H), 0.98 (d, J = 6.3 Hz, 3H), 0.69-0.62 (m, 2H), 0.46-0.40 (m, 2H).
MS (m / z): 522.4 (M + H).
Step 2j (S) -N - ((6- (7- (4- (3-cyclopropylureido) -2-fluorophenoxy) thieno [3,2-b1-pyridin-2-yl) pyridin-3-yl) methyl) -N - (1-methoxypropan-2-D-acetamide (335)
A suspension of urea 334 (66 mg, 0.127 mmol) in acetic anhydride (2 mL) is stirred at room temperature for 2 days. The reaction mixture is quenched by the addition of methanol and water, and divided with
AcOEt. After separation, the organic layer is collected, washed with water, 1 N NaOH (x4) water and brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The crude solid is purified by flash column chromatography on silica gel (eluent 2% ammonium hydroxide in MeOH / DCM: 05/90 to 10/90) to yield the title compound 335 (46 mg, 0.08 mmol, 64%). % yield) as a whitish fluffy solid.
1 H NMR (400 MHz, DMSO-d 6) d (ppm): mixture of rotamers, 8.70 (s, 1 H), 8.58-8.48 (m, 2 H), 8.34 and 8.30 (2 s, 1 H), 8.27 and 8.19 ( 2d, J = 8.3 Hz, 1 H), 7.85-7.69 (m, 2H), 7.38 (t, J = 9.0 Hz, 1 H), 7.20 (bd, J = 9.0 Hz, 1 H), 6.67-6.54 ( m, 2H), 4.74-4.16 (m, 3H), 3.41 -3.22 (m, 2H), 3.15 and 3.13 (2s, 3H), 2.59-2.52 (m, 1 H), 2.16 and 1.96 (2s, 3H) , 1.09 and 1 .04 (2d, J = 6.9 Hz, 3H), 0.72-0.58 (m, 2H), 0.50-0.36 (m, 2H).
MS (m / z): 564.4 (M + H).
SCHEME 23
EXAMPLE 210
N- (3-Fluoro-4- (2- (5 - ((2-methoxyethylamino) methyl) pyridin-2-intienor3,2-b] pyridin-7-yloxy) phenyl) cyclopropanecarboxamide (337)
Step V. (6- (4- (Cyclopropanecarboxamido) -2-fluorophenoxy) thieno [3,2-blpyridin-2-yl) pyridin-3-yl) methyl (2-methoxyethyl) tert-butyl carbamate (336)
To a solution of aniline 126 (200 mg, 0.36 mmol) in DCM (10 mL) under nitrogen at 0 ° C is added DIPEA (127 μ ?, 0.72 mmol) and cyclopropylcarbonyl chloride (50 μ ?, 0.54 mmol). The reaction mixture is allowed to warm to room temperature slowly and is stirred overnight at room temperature. The reaction mixture is diluted in AcOEt, and washed successively with saturated aqueous solution of ammonium chloride (x4), 1 N NaOH (x2), washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrate The crude residue is co-precipitated at a minimum of AcOEt in hexanes. The solid is collected by filtration, rinsed with hexanes, dried with air and dried under high vacuum to yield the title compound A (quantitative yield) as a pale brown solid.
MS (m / z): 593.4 (M + H).
Step 2: N- (3-Fluoro-4- (2- (5 - ((2-methoxyethylamino) methyl) pyridin-2-yl) thienof3,2-b1-pyridin-7-yloxy) phenyl) cyclopropanecarboxamide (337)
To a solution of amide 336 (215 mg, crude mixture) in DCM (10 mL) is added TFA (2 mL). The reaction mixture is stirred at room temperature for 2 hours, concentrated, partitioned between water and AcOEt, and basified with 1 N NaOH solution. After layer separation, the organic layer is collected, washed with NaOH 1 N (x2), water and brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue is purified by flash column chromatography on silica gel (eluent 2% ammonium hydroxide in MeOH / DCM: 05/95 to 15/95) to yield the title compound 336 (87 mg, 0.177 mmol, 48 % yield) as a sticky salmon solid.
H NMR (400 MHz, D SO-d6) d (ppm): 10.57 (s, 1 H), 8.57 (d, J = 1.6, 1 H), 8.52 (d, J = 5.5 Hz, 1 H), 8.32 (s, 1 H), 8.23 (d, J = 8.0 Hz, 1 H), 7.93-7.83 (m, 2H), 7.47 (t, J = 8.9 Hz, 1 H), 7.41 (dd) , J = 8.9, 2.0, 1 H), 6.66 (d, J = 5.3 Hz, 1 H), 3.78 (s, 2H), 3.41 (t, J = 5.6 Hz, 2H), 3.24 (s, 3H), 2.66 (t, J = 5.7 Hz, 2H), 1.79 (quint., J = 6.2 ??, 1 H), 0.90-0.80 (m, 4H), an NH is lost.
MS (m / z): 493.4 (M + H).
SCHEME 24
THF
339 34 Example 211
341: Example 212
EXAMPLE 340 AND 341
(6- (7- (4- (3-cyclopropylureido) -2-fluorophenoxy) thienoi3,2-blpyrdin-2-yl) pyridin-3-yl) methyl (2-methoxyethyl) carbamate I340) and (R ) -2-amino-N - ((6- (7- (4- (3-cyclopropylureido) -2-fluorophenoxy) thienor3,2-blpyridin-2-yl) pyridin-3-yl) metin-N- (2 -methoxyethyl) -3-methylbutanamide (341)
Stage 1: (6- (7- (4- (3-cyclopropylureido) -2-fluorophenoxy) thieno [3,2-b1pyridin-2-yl) pyridin-3-yl) methyl (2-methoxyethyl) carbamate of tere- Butyl (338)
Amine 126 (0.24 g, 0.46 mmol) in tetrahydrofuran (60 ml) at 0 ° C is added with triphosgene (0.054 g, 0.18 mmol) and the resulting solution is stirred for 1 hour at 0 ° C. DIPEA (0.40 ml,
0. 30 g, 2.3 mmol) and cyclopropylamine (0.26 g, 4.6 mmol) and the mixture is warmed to room temperature and stirred for 3 hours, then concentrated under reduced pressure. The residue is partitioned between dichloromethane and water, the organic phase is collected, washed with saturated NH 4 Cl (aq), and brine, dried over MgSO 4, filtered and concentrated. The residue is purified by flash chromatography on silica gel (ethyl acetate to 5% methanol / ethyl acetate), yielding 338 (0.19 g, 67% yield).
MS (m / z) 608.4 (M + H).
Step 2j 1-Cyclopropyl-3- (3-fluoro-4- (2- (5 - ((2-methoxyethylamino) methyl) pyridin-2-yl) thienof3,2-blpyridin-7-yloxy) phenyl) urea (339 )
To 338 (0.19 g, 0.31 mmol) in dichloromethane (40 mL) is added TFA (3 mL). The solution is stirred for 6 hours, then concentrated. The residue is partitioned between 98: 2 dichloromethane / methanol and 1 M NaOH (aq) mixture, washed with brine, dried over MgSO4, filtered and concentrated. The resulting oil is triturated with diethyl ether and ethyl acetate yields 339 (0.13 g, 82% yield).
1 H NMR (400 MHz, DMSO-d 6) d (ppm): 1 H: 8.80 (s, 1 H); 8.57 (s, 1 H); 8.51 (d, J = 5.5, 1 H); 8.31 (s, 1 H); 8.23 (d, J = 8.0, 1 H); 7.89 (dd, J = 8.0, 1.5, 1 H); 7.73 (dd, J = 13.5, 2.2, 1 H); 7.38 (t, J = 9.0, 1 H); 7.20 (d, J = 8.2, 1 H); 6.66-6.62 (m, 2H); 3.78 (s, 2H) 3.41 (t, J = 5.7, 2H); 3.24 (s, 3H); 2.65 (d, J = 5.7, 2H); 2.57-2.51 (m, 1 H), 0.66-0.62 (m, 2H); 0.44-0.41 (m, 2H).
MS (m / z): 508.3 (M + H).
Step 3: (6- (7- (4- (3-cyclopropylureido) -2-fluorophenoxy) thieno [3,2-blpyridin-2-yl) pyridin-3-yl) methyl (2-methoxyethyl) carbamate (340)
To a solution of compound 339 (220 mg, 0.433 mmol) and methyl chloroformate (50.2 μ ?, 0.65 mmol) in THF (4 mL) is added DIPEA (227 μ ?, 1.30 mmol) and the mixture is stirred at room temperature for 18 hours. The solvent is removed under reduced pressure, the residue is triturated with MeOH and the solid suspension is collected by filtration and purified via Biotage (linear gradient 0-20% methanol / dichloromethane; Snap column 25 g) to produce compound 340 ( 123.1 mg, 0.218 mmol, 50.2% yield) as a beige solid.
1 H NMR (400 MHz, DMSO-d 6) d (ppm): 8.70 (s, 1 H), 8.56-8.50 (m, 2H), 8.33 (s, 1 H), 8.25 (d, J = 8.0 Hz, 1 H), 7.84-7.77 (m, 1 H), 7.73 (dd, J = 13.6, 2.4 Hz, 1 H), 7.38 (t, J = 9.2 Hz, 1 H), 7.20 (dd, J = 8.8, 1.2 Hz, 1 H), 6.65 (d, J = 5.6 Hz, 1 H), 6.56 (d, J = 2.8 Hz, 1 H), 4.54 (s, 2H), 3.64 (s, 2H), 3.44 (s, 3H), 3.22 (s, 2H), 2.59-2.51 (m, 1 H), 0.69-0.62 (m, 2H), 0.46-0.40 (m, 2H).
MS (m / z): 566.4 (M + H).
Step 4: (R) -2-amino-N - ((6- (7- (4- (3-cyclopropylureido) -2-fluorophenoxy) thienof3,2-blpyrdin-2-yl) pyridin-3-yl ) methyl) -N- (2-methoxyethyl) -3-methylbutanamide (341)
To a solution of 339 (48 mg, 0.095 mmol), N-Boc-valine (41 mg, 0.19 mmol), and DIPEA (0.083 mL, 0.47 mmol) in DMF (20 mL) is added HATU (90 mg, 0.236 mmol). ). The resulting solution is stirred at room temperature for 3 hours. The reaction mixture is partitioned between ethyl acetate and water, washed with 1 M HCl and brine, dried (MgSO 4), filtered and concentrated to yield the crude BOC-protected product. This material is dissolved in dichloromethane (75 ml) and trifluoroacetic acid (3 ml) and stirred at room temperature for 3 hours. The mixture is then concentrated and the residue is purified by reverse phase HPLC (35-95% MeOH / (H20, Aquasil Ci8, 30 minutes) and lyophilized The residue (containing some formic acid HPLC) is divided. between dichloromethane and 1 M NaOH. The organic phase is dried (MgSO) filtered and concentrated to provide 341 (18 mg, 50% yield) as a 7: 3 mixture of rotamers per 1 H NMR.
1 H NMR (DMSO-d 6) d (ppm) 1 H. 8.73 (s, 1 H); 8.57-8.51 (m, 2H); 8.36 (s, 0.3H); 8.32 (s, 0.7H); 8.29-8.24 (m, 1 H) 7.84-7.71 (m, 2H); 7.38 (t, J = 8.8, 1 H); 7.21 (d, J = 8.3, 1 H); 6.66-6.64 (m, 1 H); 6.59 (s, 1 H) 4.90 (d, J = 17.6, 0.3H); 4.73 (d, J = 15.6, 0.7H); 4.64 (d, J = 17.1, 0.3H); 4.53 (d, J = 15.6, 0.7H); 3.73-3.39 (m, 5H); 3.25 (s, 2.2H); 3.22 (s, 1 .1 H); 2.58-2.52 (m, 1 H); 1.80-1.70 (m, 1 H); 0.89-0.84 (m, 6H); 0.68-0.64 (m, 2H); 0.45-0.41 (m, 2H).
LREM: (M + H) 607.5.
SCHEME 25
EXAMPLE 213 AND 214
N1- (3-fluoro ^ - (2- (5 - ((2-methoxyethylamino) methyl) pyridin-2-yl) thienof3,2-blpyridin-7-yloxy) phenyl) -N3- (3-methylsulfonyl) phenyl) malonamide (345 and N-3-fluoro ^ - (2- (5 - ((N- (2-methoxyethyl) acetamide) methyl) pyridin-2-yl) thienor 3,2-blpyridin-7-yloxy) phenyl) -N 3 - (3-methylsulfonyl) phenyl) malonamide (346)
Step 1j 3- (4- (2- (5- (tert-Butoxycarbonyl (2-methoxyethoamino) methylpyridin-2-yl-thienor-3-bp-pyridin-7-yloxy) -3-fluorophenylamino) -3-oxopropanoate methyl (342)
To a solution of compound 126 (480 mg, 0.915 mmol) and DIPEA (479 μ ?, 2.74 mmol) in DCM (9 ml) at room temperature is added methyl chloride (196 μl, 1.83 mmol). The mixture is stirred at room temperature for 18 hours. A saturated aqueous solution of ammonium chloride is added and the aqueous phase is extracted twice with DCM. The combined organic layers are dried over anhydrous sodium sulfate and concentrated. The residue is purified via Biotage (linear gradient 0-20% methanol / dichloromethane; Snap column 50 g) to yield compound 342 (540 mg, 0.86 mmol, 94% yield) as a yellow oil.
MS (m / z): 625.5 (M + H).
Step 2: 3- (4- (2- (5 - ((tert-butoxycarbonyl) amino) methyl) pyridin-2-yl) thieno [3,2-blpyridin-7-yloxy) -3-fluorophenylamino -3-oxopropanoic (343)
To a solution of compound 342 (540 mg, 0.864 mmol) in THF (12 mL) and water (6 mL) is added LiOH monohydrate ((363 mg, 8.64 mmol) .The mixture is stirred 48 hours at room temperature and THF The mixture is stirred under reduced pressure for 48 hours at room temperature and THF is removed under reduced pressure.The aqueous solution is diluted with water (10 ml) and acidified to pH 4 using 1 N HCl. the precipitate is dried under high vacuum to yield compound 343 (485 mg, 0.79 mmol, 92% yield) as a beige solid.
MS (m / z): 61.1.5 (M + H).
Step 3 and 4 N1- (3-fluoro-4- (2- (5 - ((2-methoxyethylamino) methyl) pyridin-2-yl) thienof3,2-blpyridin-7-yl
(methylsulfonyl) phenyl) malonamide (345)
To a solution of compound 343 (120 mg, 0.197 mmol), 3-methylsulfonylaniline hydrochloride (82 mg, 0.393 mmol) and DIPEA (172 μ ?, 0.983 mmol) in DMF (4 mL) was added BOP ractive (261 mL, 0.59). mmol) and the mixture is stirred at room temperature for 18 hours. A saturated aqueous solution of ammonium chloride is added and the aqueous phase is extracted twice with ethyl acetate. The combined organic extracts are washed with brine, dried over anhydrous sodium sulfate and the solvent is removed under reduced pressure. The residue is purified via Biotage (linear gradient 0-20%, methanol / dichloromethane, Snap column 25 g) to produce compound 344 as yellow solid (not characterized) which is dissolved in DCM (10 ml) and treated with TFA ( 4.5 mL, 59 mmol). The mixture is stirred for 18 hours at room temperature. The solvent is removed under reduced pressure, the residue is diluted with ethyl acetate and the organic layer is extracted with 1 N NaOH. The aqueous phase is extracted three times with ethyl acetate and the combined organic layers are concentrated. The residue is purified via Biotage (linear gradient 0-30%, methanol / dichloromethane, Snap column 50 g) to yield compound 345 (39 mg, 0.059 mmol, 29.9% yield) as a beige solid.
1 H NMR (400 MHz, DMSO-d 6) d (ppm): 10.65 (s, 1 H), 10.61 (s, 1 H), 8.57 (d, J = 1.6 Hz, 1 H), 8.52 (d, J = 5.2 Hz, 1 H), 8.33 (s, 1 H), 8.28 (s, 1 H), 8.24 (d, J = 8.0 Hz, 1 H), 7.92-7.85 (m, 3 H), 7.66-7.60 (m , 2H), 7.51 (t, J = 8.8 Hz, 1 H), 7.45 (dd, J = 9.2, 1.6 Hz, 1 H), 6.68 (dd, J = 5.2, 0.8 Hz, 1 H), 3.79 (s) , 2H), 3.57 (s, 2H), 3.41 (t, J = 5.6 Hz, 2H), 3.24 (s, 3H), 3.21 (s, 3H), 2.66 (t, J = 5.6 Hz, 2H).
MS (m / z): 664.5 (M + H).
Step 5 N1- (3-Fluoro-4- (2- (5 - ((N- (2-methoxyethyl) acetamido) methyl) pyridin-2-yl) thienol [3,2-b1pyridin-7-yloxy) phen
(methylsulfonyl) phenyl) malonamide (346)
A solution of compound 345 (18.5 mg, 0.028 mmol) in acetic anhydride (1.31 ml, 13.9 mmol) is stirred at room temperature for 60 hours. The solvent is removed under reduced pressure and the residue is triturated with water for 3 hours. The solid suspension is filtered, the precipitate is rinsed with water and dried under high vacuum to yield compound 346 (6.4 mg, 9.07 μ? T ??, 32.5%) as a beige solid.
1 H NMR (400 MHz, DMSO-d 6) d (ppm): mixture rotamers, 1 0.64 (s, 1 H), 10.60 (s, 1 H), 8.55-8.49 (m, 2 H), 8.38-8.21 (m, 3H), 7.91-7.86 (m, 2H), 7.78 (td, J = 8.8, 2.0 Hz, 1 H), 7.66-7.60 (m, 2H), 7.51 (t, J = 8.8 Hz, 1 H), 7.44 (dd, J = 9.2, 1.6 Hz, 1 H), 6.71 -6.67 (m, 1 H), 4.71 and 4.59 (2s, 2H), 3.58-3.23 (m, 14H), 3.21 (s, 3H), 2.13 and 2.05 (2s, 3H).
MS (m / z): 706.5 (M + H).
SCHEME 26
do not
N - ((2- (7- (4- (3-cyclopropylidene) -2-fluorophenoxy) thienof3,2-b1-pyridin-2-yl) -1-methyl-1 H-imidazol-5-yl) methyl) -N- (2-methoxyethyl) methanesulfonamido (349)
Step 1: (2- (7- (4- (3-cyclopropylureido) -2-fluorophenoxy) thienof3.2-b1-pyridin-2-yl) -1-methyl-H-imidazol-5-yl) methyl (2-methoxyethyl) tere-butyl carbamate (347)
To a solution of the aniline 46 (400 mg, 0.758 mmol) is added triphosgene (1125 mg, 5 eq, 3.79 mmol) and Pr2NEt (490 mg, 5 eq 3.79 mmol) and the reaction mixture is stirred at room temperature for one hour. Cyclopropylamine (6103 mg, 141 eq 107 mmol) is added and the reaction mixture is stirred at room temperature overnight. The mixture is concentrated, then diluted with DCM and washed with water. The organic phase is collected, dried over Na 2 SO 4, filtered and evaporated. The residue is purified by column chromatography (eluent 20% MeOH in EtOAc) to yield the desired compound 347 as a yellow oil (426 mg, 92% yield).
MS (m / z) = 61 1.4 (M + H)
Step 2j 1-cyclopropyl-3- (3-fluoro-4- (2- (5 - ((2-methoxyethylamino) methyl) -1-methyl-H-imidazol-2-yl) thieno [3,2-b1pyridin- 7-yloxy) phenyl urea (348)
To a solution of 347 (426 mg, 0.698 mmol) in DCM (10 mL) is added HCI in dioxane (0.7 mL, 4.01 eq., 2.80 mmol, 4M in dioxane) and the reaction mixture is stirred at room temperature for 3 hours. hours. The mixture is diluted with water and solid NaHCO3 is added. The reaction mixture is extracted well with EtOAc then the organic phase is collected, dried over Na2SO4, filtered and concentrated. The residue is purified by column chromatography (eluent: 25% MeOH in EtOAc to 50% MeOH in EtOAc) to yield the desired compound 348 as a yellow powder (21 mg, 59% yield).
MS (m / z) = 51 1.4 (M + H).
Step 3j N - ((2- (7- (4- (3-cyclopropylureido) -2-fluorophenoxy) thieno [3,2-blpyridin-2-yl) -1-methyl-1 H-imidazol-5-yl) methyl) -N- (2-methoxyethyl) methanesulfonamido (349)
To a suspension of the amine 348 (61 mg, 0.119 mmol) in DCM (5 mL) was added methanesulfonyl chloride (20.53 mg, 1.5 eq., 0.179 mmol) and Pr2NEt (46.3 mg, 3 eq., 0.358 mmol). ) and the reaction mixture is stirred at room temperature for 3 hours. The mixture is diluted with EtOAc then washed with saturated NH 4 Cl solution, saturated NaHCO 3 solution and brine. The organic phase is collected, dried over Na 2 SO 4, filtered and concentrated. The residue is purified by column chromatography (eluent to 25% MeOH in EtOAc) to yield the desired compound 349 as a pale yellow solid (34 mg, 48%).
1 H NMR (d 6 DMSO) 8.27 (s, 1 H), 8.10 (d, J = 5.48 Hz, 1 H), 7.53 (s, 1 H), 7.25 (m, 1 H), 6.95 (t, J = 9.0 Hz, 1 H), 6.76 (m, 1 H), 6.71 (s, 1 H), 6.24 (d, J = 5.48 Hz, 1 H), 6.14 (s, 1 H), 4.06 (s, 2H), 3.49 (s, 3H), 2.72 (s, 3H), 2.63 (s, 3H), 2.12 (m, 3H), 0.23 (m, 2H), 0.00 (s, 2H).
SCHEME 27
353: Example 216
Step 1: (2- (7- (4- (3- (2,4-difluorophenyl) ureido) -2-fluorophenoxy) thieno [3,2-blpyridin-2-yl) -1-methyl-1 H-imidazole -5-l) tere-butyl methyl (2-methoxyethylcarbamate (350)
To a solution of aniline 46 (500 mg, 0.948 mmol) in DCM (0 mL) is added 2,4-difluoro-1-isocyanatobenzene (441 mg, 3 eq., 2.84 mmol) and the reaction mixture is stirred at room temperature. environment for 24 hours. The mixture is concentrated and purified via column chromatography (eluent 10% MeOH in EtOAc) to yield 350 (600 mg, 93%) as a white solid.
MS (m / z) = 683.7 (M + H)
Step 2: 1 - (2,4-difluoropheni -3- (3-fluoro-4- (2- (5- (f2-methoxyethylamino) methyl) -1-methyl-H-imidazol-2-yl) thieno [3,2 -b1pi
iloxy) phenyl) urea (351)
To a solution of 350 (600 mg, 0.879 mmol) in DCM (15 mL) is added HCl in dioxane (2 mL, 7.17 eq., 8 mmol, 4M in dioxane) and the reaction mixture is stirred at room temperature for 3 hours. hours. The mixture is diluted with water and solid NaHCO3 is added. The reaction mixture is extracted with EtOAc then the organic phase is collected, dried over Na2SO4, filtered and concentrated. Trituration of the residue with EtOAc yields the desired compound 351 as an off-white solid (314 mg, 61% yield).
1 H NMR (d 6 -DMSO): 10.90 (s, 1 H), 8.89 (s, 1 H), 8.50 (d, J = 5.48 Hz, 1 H), 7.98 (m, 1 H), 7.95 (s, 1 H), 7.72 (m, 1 H), 7.41 (m, 1 H), 7.28 -7.20 (m, 3H), 7.04 (m, 1 H), 6.68 (d, J = 5.28 Hz, 1 H), 4.28 (s, 2H), 3.92 (s, 3H), 3.61 (m, 2H), 3.27 (s, 3H), 3.13 (m, 2H).
Step 3: 1 - (((2- (7- (4- (3- (2,4-difluorophenyl) ureido) -2-fluorophenoxy) thieno [3,2-blpyridin-2-yl) -1-methyl-1 H (S-Midazol-5-yl) methyl) (2-methoxyethyl) amino) -3-methyl-1-oxobutan-2-ylcarbamate of (S) -tert-butyl (352)
To a solution of compound 351 (280 mg, 0.481 mmol) in
DMF (10 mL) is added (S) -2- (tert-butoxycarbonylamino) -3-methylbutanoic acid (209 mg, 2 eq., 0.961 mmol), iPr2NEt (0.252 mL, 3 eq., 1442 mmol) and HATU (365 mg, 2 eq., 0.961 mmol) and the reaction mixture is stirred
all night. The reaction mixture is diluted with EtOAc and washed with water, saturated solution of NAHCO3 then brine. The organic phase is collected, dried over Na 2 SO 4, filtered and then concentrated. Purification of the residue by column chromatography (eluent 20% MeOH in EtOAc) affords the desired compound 352 as an off-white solid (200 mg, 53% yield).
MS (m / z) = 782.7 (M + H).
Step 4: (S) -2-amino-N - ((2- (7- (4- (3- (2,4-difluorophenyl) ureido) -2-fluorophenoxy) thieno [3,2-blpyridin-2- il) -1-methyl-1 H-imidazol-5-yl) methyl) -N- (2-methoxyethi-3-methylbutanamide (353)
To a suspension of compound 352 (200 mg, 0.256 mmol) in DCM (10 mL) is added HCI in dioxane (0.7 mL, 10.95 eq., 2.80 mmol, 4M in dioxane) and the reaction mixture is stirred at room temperature for 3 hours. The mixture is diluted with water and NaHCO3 is added. The reaction mixture is extracted with EtOAc then the organic phase is collected, dried over Na2SO4, filtered and concentrated. Purify it from the residue by column chromatography (eluent 30% MeOH in EtOAc) to yield the desired compound 353 as a pale yellow powder (155 mg, 89% yield).
1 H NMR (Ó 6 -DMSO) 9.36 (s, 1 H), 8.60 (s, 1 H), 8.49 (m, 1 H), 8.01 (m, 1 H), 7.87 (s, 1 H), 7.71 (m , 1 H), 7.41 (t, J = 8.99 Hz, 1 H), 7.31 (m, 1 H), 7.20 (m, 1 H), 7.02 (m, 1 H), 6.98 (s, 1 H), 6.65 (d, J = 5.09 Hz, 1 H), 4.83 (d, J = 15.65 Hz, 1H), 4.48 (d, J = 15.65 Hz, 1H), 3.81 (s, 1H), 3.80 (s, 3.40 ( m, 1H), 3.39-3.295 (m, 6H), 1.71 (m, 2H), 0.81 (m, 6H).
SCHEME 28
EXAMPLE 217
N1 - (3-fluoro-4- (2- (5 - ((2-methoxyethylamino) methyl) -1-methyl-1 H-imidazol-2-yl) thieno [3,2-b1pyridin-7-yloxy) phenyl ) -N3- (2-fluorophenyl) malonamide (355)
Step 1j (2- (7- (2-fluoro-4- (3- (2-fluorophenylamino) -3-oxopropanamido) phenoxy) thieno [3,2-bipyridin-2-yl) -1-methyl -1 H-imidazol-5-yl) methyl (2-methoxyethyl) carbamate (354)
To the solution of aniline 46 (300 mg, 0.569 mmol), acid 2 (224 mg, 1137 mmol), and DIPEA (0.397 mL, 2.274 mmol) in DMF (15 mL) is added HATU (540 mg, 1422 mmol). The reaction mixture is stirred for 16 hours at room temperature, then divided between ethyl acetate and water; the organic layer is collected, washed with water, 1 M NaOH, and brine, dried (Na2SO4) then filtered and concentrated. The residue is purified by Biotage (eluent 1 -30% MeOH / EA, silicone column 12 g) to give 354 (230 mg, 0.325 mmol, 57.2% yield) as a beige solid.
TLC: Rf = 0.35 (eluent 10% MeOH / EtOAc).
Step 2: N1 - (3-fluoro-4- (2- (5 - ((2-methoxyethylamino) methyl) -1-methyl-1 H-imidazol-2-yl) thieno [3,2-blpyridin-7-] iloxy) phenyl) -N3- (2-fluorophenyl) malonamide (355)
To a solution of 354 (230 mg, 0.325 mmol) in DCM (3 mL) is added TFA (0.5 mL). The reaction mixture is stirred at room temperature
the whole night afterwards he concentrates. The residue is partitioned between EtOAc and saturated NaHCO 3 solution. The organic layer is collected, dried and concentrated. The residue is purified via Biotage (0-50% MeOH / EA, 10 g SNAP column) to yield the reddish residue which is further purified by column chromatography (eluent MeOH / EA, 20-25%) to give a solid yellow which is triturated with ether to yield the title compound 355 (80 mg, 0.132 mmol, 40.5% yield) as an off-white solid.
HRMN (dmso) d (ppm) 1 H: 10.53 (s, 1 H), 10.01 (s, 1 H), 8.47 (d, 1 H, J = 5.5 Hz), 7.95 (m, 1 H), 7.85- 7.81 (m, 2H), 7.46 (t, 1 H, J = 8.8Hz), 7.39 (d, 1 H, J = 10.9Hz), 7.15-7.09 (m, 2H), 6.91 (s, 1 H), 6.65 (d, 1 H, J = 5.5Hz), 3! 81 (s, 3H), 3.72 (s, 2H), 3.58 (s, 2H), 3.35 (t, 2H, J = 5.6Hz), 3.20 ( s, 3H), 2.64 (t, 2H, J = 5.6Hz).
MS: 607.2 (MH) +.
EXAMPLE 218
2-fluoro-N- (3-fluoro-4- (2- (5 - ((2-methoxyethylamino) methyl) -1-methyl-1H-imidazol-2-yl) thienof3,2-b1pyridin-7-yloxy) phenyl) benzamide (357)
Step 1 (2- (7- (2-Fluoro-4- (2-fluorobenzamido) phenoxy) thieno [3,2-blpyridin-2-yl) -1-methyl-1 H-imidazol-5-yl) methyl) Tere-butyl (2-methoxyethyl) carbamate (356)
To a solution of aniline 46 (300 mg, 0.569 mmol) in DCM 810 ml) at 0 ° C is added DIPEA (0.199 ml, 1137 mmol) and 2-fluorobenzoyl chloride (135 mg, 0.853 mmol) and the suspension is stirred overnight at room temperature. The reaction mixture is concentrated and the residue is partitioned between EtOAc and water. The organic layer is collected, dried and concentrated. The residue is purified using Biotage (eluent EtOAc, HR column of silicone 25 g) to provide the title compound 356 (400 mg, 0.616 mmol, quantitative yield) as a white solid.
MS: 650 (MH) +.
Step 2: 2-Fluoro-N- (3-fluoro-4- (2- (5 - ((2-methoxyethylamino) methyl) -1-methyl-1 H-imidazol-2-yl) thieno [3,2- b1pyridin-7-yloxy) phenyl) benzamide (357)
To a solution of 356 (400 mg, 0.616 mmol) and TFA (0.047 mL, 0.616 mmol) in DCM (15 mL) is added overnight at room temperature then concentrated. The residue is partitioned between EtOAc and saturated NaHCO 3 solution. The product is found in both layers. The layers are combined and concentrated. The residue is extracted with MeOH and inorganic solid is filtered. The filtrate is concentrated and the residue is purified using Btotage (eluent MeOH / EtOAc, 10-50%, silicone column of 25 g) to provide a solid which is triturated with a mixture of EtOAc / ether to produce 358 (40 mg, 0.073 mmol, 1 1.82% yield) as a white solid.
HRMN: (dmso) d (ppm) 1 H: 10.77 (s, 1 H), 8.51 (d, 1 H, J = 5.5Hz), 7.94-7.91 (m, 2H), 7.68-7.63 (m, 1 H ), 7.60-7.56 (m, 2H), 7.49 (t, 1 H), J = 8.8Hz), 7.36-7.30 (m, 2H), 7.15 (s, 1 H), 6.70 (d, 1 H, J = 5.5Hz), 4.13 (s, 2H), 3.89 (s, 3H), 3.51 (t, 2H, J = 5.3Hz), 3.26 (s, 3H), 3.01 (m, 2H).
MS: 550 (MH) +
SCHEME 29
EXAMPLE 219
1-cyclopropyl-3- (3-fluoro ^ - (2- (5- (morpholinomethyl) pyridin-2-yl) thieno [3,2-blpyridin-7-yloxy) phenyl) urea (360)
Step 1: 4 - ((6- (7- (2-fluoro-4-nitro-phenoxy) -thienor-3,2-blp-iridin-2-yl) pyridin-3-yl) methyl) morpholine (358)
To a suspension of carbaldehyde 321 (0.5 g, 1.265 mmol) in DCM (12.65 ml) is added morpholine (0.220 ml, 2.53 mmol) and acetic acid (0.145 ml, 2.53 mmol) and the mixture is stirred for 1 hour at room temperature. before triacetoxy sodium borohydride (0.804 g, 3.79 mmol) is added. The agitation continues throughout the night. The mixture is then partitioned between DCM and 1 N NaOH. The phases are separated, the organic layer is collected, dried over sodium sulfate and concentrated. The residue is purified via Biotage (linear gradient 0-20%, MeOH / EtOAc; SNAP column 10g) to yield the title compound 358 (341 mg, 0.731 mmol, 57.8% yield) as a beige solid.
MS: 467 (MH) +
Step 2: 3-Fluoro-4- (2- (5- (morpholinomethyl) pyridin-2-yl) thieno [3,2-blpyridin-7-yloxy) aniline (359)
A mixture of nitro compound 358 (432 mg, 0.926 mmol), iron powder (440 mg, 7.87 mmol), and ammonium chloride (42.6 mg, 0.796 mmol) in a mixture of water (3.00 ml) and ethanol (6 ml) ) is heated at 80 ° C for 30 minutes. The reaction mixture is then filtered while heating through a pad of Celite. The filtrate is concentrated and the residue is purified using Biotage (eluent: 0-20% EtOAc / MeOH, SNAP column 10 g) to yield amine 359 (136 mg, 0.312 mmol, 33.6% yield) as a white solid.
MS: 437 (MH) +.
Step 3: 1-cyclopropyl-3- (3-fluoro-4- (2- (5- (morpholinomethyl) pyridin-2-yl) thienof3,2-blpyridin-7-yloxy) phenyl) urea (360 )
The solution of aniline 359 (136 mg, 0.312 mmol) and DIPEA
(0.218 mL, 1.246 mmol) in THF (6 mL) is cooled to 0 ° C, and then triphosgene (46.2 mg, 0.156 mmol) is added and the reaction mixture is stirred for 1 hour at 0 ° C followed by the addition of cyclopropylamine (89 mg, 1558 mmol).
The reaction mixture is stirred at room temperature for additional 3 hours then concentrated, partitioned between water and ethyl acetate. A sticky solid is formed which is isolated by suction filtration, rinsed with water and ethyl acetate, and dried in vacuo. This material is then purified using Gilson (eluent 20-95% MeOH / H 2 O, 1 h) to give the title compound 360 (30 mg, 0.058 mmol, 18.53% yield) as a white solid.
1H: HRMN 9.16 (s, br, 1 H), 8.16 (d, 1 H, J = 1.6 Hz), 8.1 1 (d, 1 H, J = 5.4 Hz), 7.91 (s, 1 H), 7.83 ( d, 1 H, J = 8.2Hz), 7.46 (dd, 1 H, J1 = 2.1 Hz, J2 = 8.2Hz), 7.34 (dd, 1 H, J 1 = 2.6Hz, J2 = 13.9Hz), 6.97- 7.45 (m, 2H), 6.84-6.81 (m, 1 H), 6.23 (d, 1 H, J = 4.7Hz), 3.18 (t, 4H), 3.14 (s, 2H), 2.15-2.12 (m, 1 H), 1.98 (m, 4H), 0.23-0.19 (m, 2H), 0.02-0.005 (m, 2H).
MS: 520.4 (MH) +.
SCHEME 30
368: Example 220
EXAMPLE 220
1 - . 1 - (4- (2- (4-5,8,11-trioxa-2-azadodecylphenyl) thienor3,2-blpyridin-7-yloxy) -3-fluorophenyl) -3- (5-methylisoxazole-3-) il) urea (368)
Step 1: 4- (7- (2-fluoro-4-nitrophenoxy) thienof3,2-b1pyridin-2-D-benzaldehyde (362)
Yodothienopyridine 361 (US 2006/0287343) (2.10 g, 5.05 mmol), 4-formylphenylboronic acid (1.51 g, 10.1 mmol) is dissolved, and tetrakis (triphenylphosphine) palladium (0.29 g, 0.25 mmol) is dissolved in dry dioxane (80 my). Cesium fluoride (0.92 g, 6.1 mmol) and sodium bicarbonate (2.12 g, 25.2 mmol) are dissolved in water (5 ml each) and added to the reaction mixture, which is degassed with a stream of N2, then heat to reflux for 3 hours, cool and concentrate. The residue is partitioned between ethyl acetate and water, resulting in a thin precipitate. This is isolated by suction filtration and rinsed with water and ethyl acetate to yield 362 (1.92 g, 96%).
LREM (M + H): 395.2
Step 2: N, N- (4- (7- (2-fluoro-4-nitrophenoxy) thieno [3,2-b1pyridin-2-yl) benzyl) -2- (2- (2-methoxyethoxy) ethoxy) ethanamine (364)
A suspension of 362 (0.90 g, 2.3 mmol), 363 amine (0.93 g, 5.7 mmol) [363 amine has been synthesized according to the procedures used for the synthesis of amines (322 (scheme 18) and 326 (scheme 20) ) and acetic acid (0.26 ml, 4.6 mmol) in dichloromethane (50 ml) is stirred for 1 hour at room temperature. Then sodium triacetoxyborohydride (1.45 g, 6.85 mmol) is added and the mixture is stirred at room temperature for 16 hours. An additional amount of sodium triacetoxyborohydride (1.5 g) is then added, and the stirring is continued for 2 hours. The reaction mixture is partitioned between dichloromethane and 1 N HCl. The organic phase is discarded. The aqueous phase is basified (pH = 13) with 3M NaOH, and extracted with dichloromethane. The organic extract is dried over anhydrous sodium sulfate, filtered and concentrated to yield 364 (0.72 g, 58%) as a yellow solid.
LREM (M + H): 542.4.
Stage 3: 4- (7- (2-fluoro-4-nitrophenoxy) thieno [3,2-blpyridin-2-yl] benzyl (tere-butyl 2- (2- (2-methoxyethoxy) ethoxy) ethyl) carbamate (365)
To a solution of 364 (0.72 g, 1.3 mmol) in dichloromethane (100 ml) at room temperature is added DMAP (0.041 g, 0.33 mmol) and Boc20 (0.58 g, 2.7 mmol). The reaction mixture is stirred at room temperature for 2 hours then the mixture is washed consecutively with water, brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue is purified by chromatography on silica gel (eluent EtOAc then 1% MeOH in EtOAc) to yield compound 365 (0.51 g, 60% yield).
LREM (M + H): 642.5
Stage 4: 4- (7- (4-amino-2-fluorophenoxy) thieno [3,2-blpyridin-2-yl) benzyl (tere-butyl 2- (2- (2-methoxyethoxy) ethoxy) carbamate) (366 )
To a solution of 365 (0.49 g, 0.76 mmol) in MeOH (100 mL) is added iron powder (0.43 g, 7.6 mmol) and ammonium chloride (0.12 g, 2.3 mmol) in water (5 mL). The resulting mixture is refluxed for 4 hours, then cooled, filtered through celite pad and concentrated. The residue is divided between dichloromethane and water; the organic phase is collected, washed with brine, dried over magnesium sulfate
Anhydrous, filtered and concentrated. The residue is purified by chromatography on silica gel (eluent 2% MeOH in EtOAc) to provide 366 (0.41 g, 88% yield).
LREM (M + H). 612.6
Step 5j 4- (7- (2-fluoro-4- (3- (5-methylisoxazol-3-yl) ureido) phenoxy) thienof3,2-blpyridin-2-yl) benzyl (2- (2- (2- tert-butyl methoxyethoxy) ethoxy) ethyl) carbamate (367)
To a solution of 366 (0.15 g, 0.25 mmol) and DIPEA (0.1 ml, 0.080 g, 0.61 mmol) in tetrahydrofuran (50 ml) at 0 ° C is added triphosgene (0.029 g, 0.098 mmol) and the resulting solution stir for 1 hour at 0 ° C. 3-Amino-5-methylisoxazole (0.025 g, 0.25 mmol) is added and the mixture is heated to room temperature and stirred for 3 hours, then quenched with 1 ml of water and concentrated under reduced pressure. The residue is partitioned between ethyl acetate and water; The organic phase is collected, washed with brine, dried over MgSO 4, filtered and concentrated. The product is purified by chromatography on silica gel (eluent: 2% MeOH in EtOAc) to give 367 (0.074 g, 4% yield).
Step 7: 1- (4- (2- (4, 5,8,1 1-trioxa-2-azadodecylphenyl) thienor 3,2-blpyridin-7-yloxy) -3-fluorophenyl) -3- (5-methylisoxazole- 3-yl) urea (368)
To a solution of 367 (0.074 g, 0.10 mmol) in dichloromethane (50 mL) is added trifluoroacetic acid (1.0 mL). The reaction mixture is stirred for 3 hours at room temperature then it is concentrated and the residue is partitioned between dichloromethane and saturated NaHCO3. The organic phase is collected, washed with brine, dried over MgSO 4, filtered and concentrated. The residue is purified by Gilson reverse phase HPLC (35-75% MeOH / H20, Aquasil Cie, 30 min) and lyophilized. The purified product (which contains some form of HPLC formic acid) is divided between dichloromethane and 1 M NaOH). The organic phase is collected, dried (MgSO 4), filtered and concentrated to give compound 368 (0.033 g, 0.052 mmol, 52% yield).
1 H: 9.71 (s, 1 H); 9.31 (s, 1 H); 8.48 (d, J = 5.5, 1 H); 8.01 (s, 1 H);
7. 82-7.79 (m, 2H); 7.73 (dd, J = 13.1, 2.5, 1 H) 7.46-7.41 (m, 3H) 7.28-7.26 (m, 1 H); 6.60 (d, J = 5.5, 1 H); 6.54 (d, J = 0.8, 1 H); 3.75 (s, 2H); 3.51 -3.45 (m, 8H); 3.41 -3.35 (m, 2H); 3.20 (s, 3H); 2.63 (t, J = 5.7, 2H); 2.35 (d, J = 0.6, 3H).
LREM (M + H): 636.5
SCHEME 31
EXAMPLE 221
N- (4- (7- (2-fluoro-4- (3- (5-methylisoxazol-3-yl) ureido) phenoxy) thienor3,2-blpyridin-2-yl) benzyl) -N- (2- ( 2- (2-methoxyethoxy) ethoxy) ethyl) acetamide (371)
Step 1: N- (4- (7- (2-fluoro-4-nitrophenoxy) thieno [3,2-blpyridin-2-yl] benzyl) -N- (2- (2- (2-methoxyethoxy) ethoxy) ethyl) acetamide (369)
To a solution of 364 (0.50 g, 0.92 mmol) in dry tetrahydrofuran (50 mL) is added acetic anhydride (1.0 mL, 11 mmol). The reaction mixture is stirred for 24 hours at room temperature then concentrated. The residue is partitioned between ethyl acetate and water; The organic phase is collected, washed with NaHCO3, brine, dried (MgSO4), filtered and concentrated. The residue is purified by chromatography on silica gel (eluent EtOAc) to give 369 (0.36 g, 67% yield).
LREM (M + H): 584.4
Step 2 N- (4- (7- (4-amino-2-fluorophenoxy) thieno [3,2-b1-pyridin-2-yl] benzyl) -N- (2- (2- (2-methoxyethoxy) ethoxy) ethyl) acetamide (370)
To a solution of 369 (0.36 g, 0.62 mmol) in MeOH (100 mL) is added iron powder (0.68 g, 12 mmol) and ammonium chloride (0.13 g, 2.5 mmol) in water (5 mL). The resulting mixture is refluxed for 4 hours, then cooled through celite and concentrated. The residue is divided between dichloromethane and water; The organic phase is collected, washed with brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The product is purified by chromatography on silica gel (eluent 2% MeOH in EtOAc) to provide 370 (0.35 g, 100% yield).
LREM (M + H): 554.4
Step 3 N- (4- (7- (2-Fluoro-4- (3- (5-methylisoxazol-3-yl) ureido) phenoxy) thienor3,2-b] pyridin-2-yl) benzyl) -N- (2- (2- (2-methoxyethoxy) ethoxy) etl) acetamide (371)
To a solution of 370 (0.14 g, 0.25 mmol) and DIPEA (0.11 mL, 0.080 g, 0.61 mmol) in tetrahydrofuran (50 mL) at 0 ° C is added triphosgene (0.030 g, 0.10 mmol) and the resulting solution is stirred for 0.5 hours at 0 ° C. 3-Amino-5-methylisoxazole (0.074 g, 0.76 mmol) is added and the mixture is warmed to room temperature and stirred for 3 hours, then quenched with 1 ml of water and concentrated under reduced pressure. The residue is partitioned between ethyl acetate and water, the organic phase is collected, washed with brine, dried over MgSO 4, filtered and concentrated. The product is purified by chromatography on silica gel (10% MeOH in EtOAc), followed by Gilson reverse phase HPLC (35-65% acetonitrile / H20, Aquasil Cie, 30 min) and lyophilized. The residue (which contains some formic acid of HPLC) is divided between dichloromethane and 1 M NaOH. The organic phase is dried (MgSO4), filtered and concentrated to provide 371 (65 mg, 38% yield) as a mixture. 2: 1 of rers by
1 H NMR. 1 H NMR (DMSO-d 6) d (ppm) 1 H: 9.64 (s, 1 H); 9.19 (s, 1 H); 8.50-8.48 (m, 1 H); 8.04 (s, 0.4H); 8.01 (s, 0.6H); 7.89 (d, J = 8.2, 0.4H); 7.82 (d, J = 8.2, 0.6H); 7.72 (dd, J = 12.9, 2.5, 1 H) 7.45 (t, J = 9.2, 1 H); 7.33 (d, J = 8.4, 2H); 7.27-7.24 (m, 1 H); 6.61-6.59 (m, 1 H); 6.54 (d, J = 0.8, 1 H); 4.68 (s, 0.4H); 4.59 (s, 0.6H); 3.52-3.38 (m, 12H); 3.21 (s, 1.8H); 3.20 (s, 1.2H); 2.35 (d, J = 0.4, 3H); 2.12 (s, 1 .8H); 2.00 (1.2 H).
LREM (M + H): 678.8.
SCHEME 32
EXAMPLE 222
3-Fluoro-4- (2- (5 - ((2-methoxyethylamino) methyl) pyridin-2-yl) thieno [3,2-b1pyridin-7-yloxy) phenylcarbamate of 2,2,2-trifluoroethyl (373)
Step 1: 4- (2- (5 - ((tert-Butoxycarbonyl (2-methoxyethyl) amino) methyl) pyridin-2-yl) thieno [3,2-blpyridin-7-yloxy) -3-fluoropheni-methylcarbamate , 2,2-trifluoroethyl (372)
Diphosgene (0.017 ml, 0.143 mmol) is added to a solution of aniline 126 (0.15 g, 0.286 mmol) in THF (2.86 ml) and the reaction mixture is stirred vigorously for 2 hours. To the reaction mixture is added
2,2,2-trifluoroethanol (0.042 mL, 0.572 mmol) and a solution of DIPEA (0.100 mL, 0.572 mmol) in THF (2.86 mL). The reaction mixture is stirred vigorously overnight, diluted with DCM, washed with saturated ammonium chloride solution, dried over anhydrous sodium sulfate and concentrated to dryness. The residue is purified by flash chromatography (Biotage, 10 Snap column, gradient: 3% of 10 CV, 3% to 5% of 2 CV, and 5% of 10 CV of MeOH in DCM) yielding 372 (0.1097 g, 0.169 mmol , 59.0% yield) as a light brown solid,
m / z: 651.4 (M + H) +.
Step 2j 3-Fluoro-4- (2- (5 - ((2-methoxyethylamino) methoxy-ethylamino) methyl) pyridin-2-yl) thieno [3,2-blpyridin-7-yloxy) phenylcarbamate 2.2, 2-trifluoroethyl (373)
To a suspension of 372 (0.1097 g, 0.169 mmol) in DCM (1.0 mL) is added TFA (1.0 mL, 12.98 mmol) and the reaction mixture is stirred at room temperature for 2 hours. The reaction mixture is concentrated under reduced pressure, the residue is dissolved in DCM, washed with 1 N NaH solution, dried over anhydrous sodium sulfate and concentrated under pressure to yield 373 (0.0543 g, 0.097 mmol, 57.3% of performance) as a white solid.
1 H NMR (DMSO-D 6, 400 MHz) 10.55 (s, 1 H), 8.57 (s, 1 H), 8.52 (d, J = 5.62 Hz, 1 H), 8.32 (s, 1 H), 8.23 ( d, J = 8.1 Hz, 1 H), 7.90 (d, J = 8.10 Hz, 1 H), 7.63 (d, J = 9 Hz, 1 H), 7.52 (d, J = 13.5 Hz, 1 H), 7.39 (t, J = 9.0Hz, 1H), 6.66 (d, J = 6.7Hz, 1H), 4.85 (q, J = 9.0Hz, 2H), 3.79 (s, 2H), 3.41 (t, J = 5.5 Hz, 2H), 3.24 (s, 3H), 2.66 (t, J = 5.5Hz, 2H).
m / z: (M + H) + 551.4
SCHEME 33
TO
376: Example 223
EXAMPLE 223
N- (3-Fluoro-4- (2- (5 - ((2-methoxyethylamino) methyl) pyridin-2-yl) thienor3,2- b] pyridin-7-yloxy) phenylcarbamoyl) cyclopropanesulfonamide (376)
Step 1: Ethyl cyclopropylsulfonylcarbamate (374) To a solution of cyclopropanesulfonamide (Li, J et al., Synlett 2006, 5, 725-728) (800 mg, 6.60 mmol) in acetone (25 ml) is added potassium carbonate ( 2738 g, 3 eq 19.81 mmol) and ethyl chloroformate (1.075 g, 1.5 eq, 9.90 mmol) and the reaction mixture is stirred at room temperature overnight. The reaction mixture is poured into water and made acidic (pH 1) with concentrated HCl then extracted with EtOAc. The extract is collected, dried over Na 2 SO 4, filtered and concentrated. Purification of the residue by column chromatography (eluent 30% EtOAc in hexanes) yields 374 as a colorless oil (800 mg, 63%).
1 H NMR (DMSO, d.6) 1 1 .47 (s, 1 H), 4.10 (q, J = 10.27 Hz, 2H), 2.90 (m, 1 H), 1 .19 (t, J = 7.24 Hz , 3H), 1.039 (m, 4H).
Step 2j (6- (7- (4- (3- (cyclopropylsulfonyl) ureido) -2-fluorophenoxy) t'enof3,2-blpyridin-2-yl) pyridin-3-yl) methyl (2-methoxyethyl) tere-butyl carbamate (375)
To a solution of the amine 126 (500 mg, 0.953 mmol) in DME (4 ml) is added carbamate 374 (460 mg, 2.5 eq 2.383 mmol) and the reaction mixture is heated at 120 ° C for 1 day. The mixture is cooled to room temperature, diluted with EtOAc and water and the organic phase is collected, dried over Na 2 SO 4, filtered and concentrated. Purification of the residue by column chromatography (eluent of EtOAc to 50% acetone in EtOAc) yields 375 as a brown oil (130 mg, 55%).
MS (miz) = 672.5 (M + H)
Step 3: N- (3-Fluoro-4- (2- (5- (82-methoxyethylamino) methyl) pyridin-2-yl) thieno [3,2-b] pyridin-7-yloxy) phenylcarbamoyl) cyclopropanesulfonamido (376)
To a solution of 375 (140 mg0.208 mmol) in DCM (5 mL) is added HCI in dioxane (0.5 mL, 2 mmol, 9.6 eq 4M in dioxane) and the reaction mixture is stirred for 4 hours. The mixture is diluted with EtOAc, made basic with NaHCO 3 solution and extracted with EtOAc / acetone. The organic phase is collected and discarded. The aqueous phase is concentrated and the residue is suspended in a mixture of DCM and acetone. The solution phase is collected, dried over Na2SO4, filtered and concentrated to yield 376 as a beige solid after further trituration with Et20 (yield 8 mg 7%).
1 H NMR (DMSO-d 6): 8.67 (s, 1 H), 8.56 (s, 1 H), 8.47 (d, J = 5.28, 1 H), 8.27 (s, 1 H), 8.19 (d, J = 8.02 Hz, 1 H), 7.85 (m, 2H), 7.80 (s, 1 H), 7.22 (m, 2H), 6.59 (d, J = 5.28 Hz, 1 H), 3.76 (s, 2H), 3.40 (m, 2H), 3.20 (s, 3H), 2.76 (m, 1 H), 2.60 (m, 2H), 0.75 (m, 2H), 0.65 (m, 2H).
LREM (ESI): (calculated) 571.64 (found) 572.58 (MH) +.
Additional compounds according to the present invention include those in Table 2.
TABLE 2
] H NMR (DMSO-d6) d (ppm):
9. 55 (s, 1H), 8.92 (s, 1H), 8.48 (m, 1H), 8.0) m, 1H), 7.85 (s, 1H), 7.72 (m, 1H), 7.42 (t, J = 8.9 Hz) , 1H), 7.30 - 7.20 (m, 2H), 6.91 (s, 1H),
227 N 6.81 (m, 1H), 6.64 (d, J = 5.48
Hz, 1H), 3.87 (s, 3H), 3.72 (s,
1- (2,5-difluorophenyl) -3- (3-fluoro-4- (2- (5-2H), 3.36 (t, J = 5.67 hz, 2H), ((2-methoxyethylamino) methyl) -1 -methyl-1 H- 3.20 (s, 3H), 2.64 (t, J = 5.67 imidazol-2-yl) thieno [3,2-b] pyridine-7 Hz, 2H).
iloxy) phenyl) urea LREM (ESI): (calc.) 582.60
(encont.) 583.5 (MH) +
NMR (DMSO-d6) d (ppm): 8.96 (s, 1H), 8.59 (s, 1H), 8.47 (d, 1H, J = 5.5Hz), 7.85 (s,
1 0 OMe 1H), 7.70 (dd, 1H, J1 = 2.3Hz,
J2 = 13.3Hz), 7.38 (t, 1H, J = 9.0Hz), 7.33-7.31 (m, 2H), N N
7. 21-7.18 (171, 1H), 6.91 (s, 1H),
228
6. 85-6.83 (m, 2H), 6.63 (d, 1H, J = 5.3Hz), 3.87 (s, 3H), 3.72 (s,
1- (3-fluoro-4- (2- (5 - ((2- 2H), 3.67 (s, 3H), 3.36 (t, 2H, methoxyethylamino) methyl) -1-methyl-1 H- J = 5.6 Hz), 3.19 (s, 3H), 2.65 (t, imidazol-2-yl) thieno [3,2-b] pyridin-7-2H, J = 5.5Hz).
iloxy) phenyl) -3- (4-methoxyphenyl) urea
LREM (ESI): (calc.) 576.2 (encont.) 577.5 (MH) +
NMR (DMSO-d6) d (ppm): 9.15 (s, 1H), 9.02 (s, 1H), 8.48 (d, J = 5.28 Hz, 1H), 7.86 (s, 1H), 7.81 (m, 1H) , 7.70 (m, 1H), 7.41 (t, J = 8.99 Hz, 1H), 7.31 (m, 1H), 7.24 (m, 3H),
229 H 1 / > _ J 7.14 (m, 1H), 6.94 (s, 1H),
6. 64 (d, J = 5.28 Hz, 1H), 3.87
1- (3-bromophenyl) -3- (3-fluoro-4- (2- (5 - ((2- (s, 3H), 3.77 (s, 2H), 3.375 (t, methoxyethylamino) methyl) -1 -methyl-1 H- J = 5.48 hz, 2H), 3.20 (s, 3H), imidazol-2-yl) thieno [3,2-b] pyridin-7- 2.69 (t, J = 5.48 Hz, 2H) iloxy) phenyl) urea
LREM (ESI): (calc.) 625.51 (encont.) 625.4 / 627.4 (MH) +
Additional compounds according to the present invention include those in Table 3
TABLE 3
Additional compounds according to the present invention include those in Table 4.
TABLE 4
Additional compounds according to the present invention include those in Table 5.
TABLE 5
Additional compounds according to the present invention include those in Table 5a.
TABLE 5A
Pharmaceutical compositions
In some embodiments, the invention provides pharmaceutical compositions comprising a compound according to the invention and a pharmaceutically acceptable carrier, excipient or diluent. Compositions of the invention can be formulated by any method well known in the art and can be prepared for administration by any route, including, without limitation, parenteral, oral, sublingual, transdermal, topical intranasal, intratracheal, or intrarectal. In some embodiments, the compositions of the invention are administered intravenously in a hospital setting. In some modalities, the administration can be by the oral route.
The characteristics of the carrier, excipient or diluent will depend on the route of administration. As used herein, the term "pharmaceutically acceptable" means a non-toxic material that is compatible with a biological system such as cell, cell culture, tissue or organism, and that does not interfere with the effectiveness of the biological activity of the active ingredient (s). . In this manner, the compositions according to the invention may contain, in addition to the inhibitor, diluents, fillers, salts, stabilizers, solubilizers, or other materials well known in the art. The preparation of pharmaceutically acceptable formulations is described in, for example, Remington's Pharmaceuticals Sciences, 18th edition, ed. A. Gennaro, Mack Publishing Co., Easton, Pa, 1990.
The active compound is included in the pharmaceutically acceptable carrier, excipient or diluent in an amount sufficient to deliver a therapeutically effective amount to a patient without causing serious toxic effects in the treated patient. The effective dosage range of a pharmaceutically acceptable derivative can be calculated based on the weight of the source compound to be delivered. If the derivative exhibits activity in itself, the effective dosage can be estimated as above using the weight of the derivative, or by other means known to those of skill in the art.
Inhibition of VEGF receptor signaling
In some embodiments, the invention provides a method for inhibiting VEGF receptor signaling in a cell, comprising contacting a cell in which the inhibition of VEGF receptor signaling is desired with an inhibitor of VEGF receptor signaling according to the invention. with the invention Because the compounds of the invention inhibit VEGF receptor signaling, these are useful research tools for in vitro study of the function of VEGF receptor signaling in biological procedures.
In some embodiments, the inhibition of VEGF receptor signaling causes an inhibition of cell proliferation of contacted cells.
EXAMPLE OF ASSAY
Inhibition of VEGF activity
The following protocol is used to test the compounds of the invention.
EXAMPLE OF ASSAY 1
Assay of the tyrosine kinase receptor in vitro (VEGF KDR receptor)
This test measures the ability of the compounds to inhibit the enzymatic activity of the enzymatic activity of the recombinant human VEGF receptor.
A 1.6-kb cDNA corresponding to the catalytic domain of VEGFR2 (KDR) (Genbank accession number AF035121 amino acid 806 to 1 356) is cloned into the Pst 1 site of the Gateway vector pDEST20 (Invitrogen) for the production of a GST-version. labeled of this enzyme. This construct is used to generate recombinant baculovirus using the Bac-toBac ™ system according to the manufacturer's instructions (Invitrogen).
The GST-VEGFR2806-1356 protein is expressed in Sf9 cells
(Spodoptera frugiperda) in infection with recombinant baculovirus construct. Briefly, sf9 cells grow in suspension and are maintained in serum-free medium (sf900 II supplemented with gentamicin) at a cell density of approximately 2 X 10 6 cells / ml are infected with viruses mentioned above at a multiplicity of infection (MOI) of 0.1. for 72 hours at 27 ° C with agitation at 120 rpm on a rotary shaker. Infected cells are collected by centrifugation at 398 g for 15 minutes. Cell pellets are frozen at -80 ° C until the purification is performed.
All the steps described in cell extraction and purification are carried out at 4 ° C. Sf9 cell pellets infected with GST-baculovirus recombinate VEGFR2806-1356 are thawed and gently resuspended in buffer pH A (PBS pH 7.3 supplemented with 1 ng / ml pepstatin, 2 g / ml aprotinin and leupeptin, 50 μg / ml) of PMSF, 50 μ9 / λ of TLCK and 10 μ of E64 and 0.5 mM of DTT) using 3 ml of pH regulator per gram of cells. The suspension is homogenized by Dounce and 1% Triton X-100 is added to the homogenate after which it is centrifuged at 22500 g, 30 minutes, 4 ° C. The supernatant (cell extract) is used as the starting material for the purification of GST-VEGFR2806-356.
The supernatant is loaded onto a GST-agarose column (Sigma) equilibrated with PBS pH 7.3. Following four column volume washes (CV) with PBS pH 7.3 + 1% Triton X-100 and 4 CV washes with pH regulator B (50 mM Tris pH 8.0, 20% glycerol and 100 mM naCl), proteins bound are eluted in stages with 5 CV of pH buffer supplemented with 5 mM DTT and 15 mM glutathione. Fractions
enriched with GST-VEGFR2806-1356 from this chromatography step is combined based on UV traces ie fractions with O.D. 280 high. Concentrations of final GST-VEGFR2806-1356 protein preparation are approximately 0.7 mg / ml with purity of approximately 70%. Purified GST-VEGFR2806-1356 protein samples are aliquoted and frozen at -80 ° C before being used in the enzyme assay.
Inhibition of VEGFR / KDR is measured in a DELFIATM assay (Perkin Elmer). The poly (Glu4, Tyr) substrate is immobilized in 96-well black high-styrofoam plates. The coated plates are washed and stored at 4 ° C. During the assay, the enzyme is pre-incubated with inhibitor and MgATP on ice in 96-well polypropylene plates for 4 minutes, and then transferred to the coated plates. The consecutive kinase reaction takes place at 30 ° C for 10-30 minutes. The concentrations of ATP in the assay are 0.6 μp? for VEGFR / KDR (2Xel Km). The enzyme concentration is 5 nM. After incubation, the kinase reactions are quenched with EDTA and the plates washed. The phosphorylated product is detected by incubation with anti-phosphotyrosine Europium-labeled MoAb. After washing the plates, MoAb binding is detected by fluorescence resolved in time in a Gemini SpectraMax reader (Molecular Devices). Compounds are evaluated over the range of concentrations of and CI150's (concentration of compounds that provide 50% inhibition of enzymatic activity) are determined. The results are shown in table 6. In the table, "a" indicates inhibitory activity at a concentration of less than 250 nanomolar; "b" indicates inhibitory activity at a concentration > 500 but < 1000 nanomolar, and "d" indicates inhibitory activity > 1000 nanomolar.
EXAMPLE OF ASSAY 2
Erk phosphorylation dependent on VEGF
Cells and growth factor: HUVEC cells were purchased from Cambrex Bio Science Walkersville, Inc and are grown according to the vendor's instructions. The sequence encoding the full length of VEGF165 is cloned using Cloning Technology gateway (Invitrogen) for Sf9 baculovirus expression cells. VEGF165 is purified from conditioned medium using a NaCl elution gradient from a HiTrap heparin column (GE Healthcare Life Sciences) followed by an imidazole elution gradient from a HiTrap chelation column (GE Healthcare Life Sciences), then stored pH regulator in PBS supplemented with 0.1% BSA and sterilized filter.
Cell assays, the cells are seeded in 8000 cells / well of a 96-well plate and grown for 48 hours. The cells are then grown overnight in serum and growth factor-free medium and exposed for 1.5 hours to dilutions of compounds. Following a 15-minute incubation in the medium, VEGF 65 cells (150 ng / ml) are lysed in an ice-cooled pH buffer (50 mM HEPES, pH 7.4, 150 mM NaCl !, 1.5 mM MgCl2, 1% Triton X-100, 10% glycerol) containing 1 mM of 4- (2-aminoethyl) benzenesulfonyl fluoride hydrochloride, 100 μg sodium orthovanadate, 1 mM sodium fluoride, 10 ng / ml of leupeptin, 10 g / ml of aprotinin, 1 μg / ml of pepstatin and 50 μg / ml of Na-p-tosyl-L-lysine chloromethyl ketone hydrochloride and processed as Western blots to detect anti-phospho ERK1 / 2 (T202 / Y204) (Cell Signaling Technologies).
Western blot analysis: Single treatment well lysate samples are separated on 5-20% SDS-PAGE gels and immunoblotted using Immobilon polyvinylidene difluoride membranes (Amersham) according to the manufacturer's instructions. The spots are washed in Tris pH regulated saline with 0.1% Tween 20 detergent (TBST) and tested for antibodies against Thr202 / Tyr204-ERK (Cell signaling technologies, Chemiluminescence detection (Amersham, ECL plus) is performed in accordance with manufacturer's instructions using Store densitometer (GE Healthcare; 800 MT, 100 nM resolution) for image formation and densitometry analysis.The values on the dissolution interval are used to prepare IC50 curves using parameter adjustment model 4. These Curves are calculated using software GraFit 5.0 The results are shown in table 6. In the table, "a" indicates the inhibitory activity at a concentration of less than 250 nanomolar, "b" indicates the inhibitory activity at a concentration of > 250 but <500 nanomolar, "c" indicates the inhibitory activity at> 500 but 1000 nanomolar, and "d" indicates inhibitory activity> 1000 nanomolar.
TABLE 6
EXAMPLE OF ASSAY 2
Solid tumor disease model in vivo
This test measures the compound's ability to inhibit solid tumor growth.
Tumor xenografts are established on the flank of female CD1 atimic mice (Charles River Inc.) by subcutaneous injection of 1 X106 U87, A431 or SKLMS / mouse cells. Once it is established, tumors are then passed serially. in guests of nude mice. Tumor fragments from these host animals are used in subsequent compound evaluation experiments. For nude female mice from compound evaluation experiments. For
Female nude mice from compound evaluation experiments weighing approximately 20 g are implanted s.c. by surgical implantation with tumor fragments of ~ 30 mg of donor tumors. When the tumors are approximately 100 mm3 in size (-7-10 days after implantation), the animals are randomly chosen and separated into the treatment and control groups. Each group contains 6-8 tumor-bearing mice, each of which is labeled on the ear and then individually through the experiment.
Mice are weighed and tumor measurements are taken by calibrators three times weekly starting at day 1. These tumor measurements are converted to tumor volume by the well-known formula (L / W / 4) 3 4 / 3p. The experiment ends when the control tumors reach a size of approximately 1500 mm3. In this model, the change in mean tumor volume for a group treated with compound / the change in mean tumor volume of the control group (untreated or vehicle treated) x 100 (AT / AC) is subtracted from 100 to provide the percentage of inhibition of tumor growth (% TGI) for each test compound. In addition to tumor volumes, the body weight of animals is monitored twice weekly for up to 3 weeks.
EXAMPLE OF ASSAY 3
Choroidal in vivo neovascularization model (CNV)
This test measures the ability of compounds to inhibit CNV progression. CNV is the leading cause of severe vision loss in patients suffering from age-related macular degeneration (AMD).
Rats Brown-Norway (Japan Clea Co., Ltd) is used in these studies.
Rats are anesthetized by intraperitoneal injection of pentobarbital, and the right pupil is dilated with 0.5% tropicamide and 0.5% phenylephrinephine hydrochloride. The right eye receives 6 laser burns between the retinal vessels using a slit lamp supply system from Green Laser Photocoagulator (Nidex Inc., Japan), and a microscope slide with Healon ™ (AMO Inc) is used as a lens. Contact. The laser energy is 100 to 200 mW for 0.1 seconds and the diameter of the spot is 100 μ. At the time of the laser beam, the production of bubbles is observed, which is an indication of rupture of the Bruch membrane that is important for the generation of CNV.
Rats are divided into groups based on their body weight using SAS software (Japan SAS Institute R8.1) after laser irradiation (Day 0). After the animals are anesthetized, and the right pupil is dilated (as mentioned above), the animal's right eye receives the compound or vehicle by injection (10 μ? / Eye) at a dose of 30 nmol / eye per day 3. The compounds are dissolved or suspended in CBS, PBS or other suitable vehicles before injection.
On day 10, the animals are anesthetized with ether, and fluorescein isocyanate (FITC) - high molecular weight dextran (SIGMA, 2 x 106 PM) is injected via a tail vein (20 mg / rat). Approximately 30 minutes after the injection of FITC-dextran, the animals are painlessly killed by ether or carbon dioxide, and the eyes are removed and fixed with 10% neutral pH buffer of 10% formalin. After around fixation, flat supports of RPE-choroid-sclera are obtained by recovering the cornea, lenses and retina of the eyeballs. The flat supports are mounted in 50% glycerol on one microscopic side, and the laser burned portion is photographed using a fluorescent microscope (Nikon Corporation, excitation filter: 465-495 nm, absorption filter: 515-555 nm). The CNV area is obtained by measuring the hyper-fluorescent area observed in the photograph using Scion image.
The average CNV area of 6 burns is used as an individual value of the CNV area, and the average CNV area of the compound treated group is compared to that of the vehicle treated group. The results with some compounds of the present invention are shown in table 7 and are indicated as% inhibition of CNV progression ("A" indicates more than equal to 60% inhibition, and "B" indicates> 40% a <60% inhibition).
TABLE 7
Claims (35)
- NOVELTY OF THE INVENTION CLAIMS 1. - A compound of formula (I): D M (I) and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and their complexes, and racemic and stepmic mixtures, diastereomers and enantiomers thereof, wherein, D is selected from group consisting of an aromatic ring system, heteroaromatic, cycloalkyl or heterocyclic, each of which is optionally replaced with 1 to 5 independently selected R38; M is a optionally substituted heterocyclic fused radical; Z is -O-; Ar is a 5 to 7 member aromatic ring system, which is optionally substituted with 0 to 4 groups R2, and G is a group B-L-T, where B is -N (R13) - or -C (= S) -; L is selected from the group consisting of -C (= 0) N (R13) -, -C (= O) C0-C1alkyl-C (= O) N (R13) -, and -C (= 0) -, wherein an alkyl group of the group L mentioned above is optionally substituted, and T is selected of the group consisting of -Co.Calkyl, -C0-C5alkyl-Q, -O-C0-C5alkyl-Q, -O-Co- C5alkyl, -C (= S) -N (R13) -C0-C5alkyl-Q, -C0-C5alkyl-S (O) 2-Q, and -C (= S) -N (R13) - Co-C5alkyl, wherein each Co-Csalkyl is optionally substituted; wherein each R38 is independently selected from the group consisting of halo, C C6 optionally substituted alkyl, -C0-C6alkyl- (optionally substituted heterocycle), -C2-C6alkenyl = N-heterocycle-CrC6alkyl optionally substituted, -CH = N-heterocycle optionally substituted, - (CH ^ NR ^ CH ^ R36, -C (0) (CH2) jNR39 (CH2) nR36, - (CH2) jNR39 (CH2) ¡[O (CH2) 1] x (CH2) iR99, - (CH2) jNR39C (0) (CH2) iO (CH2) jOR3, - (CH2) jNR39 (CH2) j (CH) (NH2) (COOH), - (CH2) iNR39CH (CH3) (CH2) jR99 and - ( CH2) jNR39 (CH2) jCOOH, where each j is an integer independently ranging from 0 to 4, n is an integer that varies from 0 to 6, x is an integer ranging from 0-6, each i is independent 2 or 3, and the radicals (CH2) n-of the above groups R38 are optionally substituted with Cr C6alkyl, R36 is H or - (CH2) n30R37, where n3 is an integer ranging from 0 to 6; except that when R36 and R39 are both bound to the same nitrogen, then R36 and R39 are not both bonded to the nitrogen directly through an oxygen; each R37 is independently selected from H, C C6 alkyl, - (CH2) nO (CH2) aO-CrC6alkyl, - (CH2) nCH (NH) (CH2) nO-Ci-C6alkyl, - (CH2) nCH (NH) ( CH2) nC1-C6alkyl, - (CH2) nO (CH2) aO-C3-C10cycloalkyl, - (CH2) nCH (NH) (CH2) nO-C3-C ^ cycloalkyl and - (CH2) nCH (NH) ( CH2) nC3-C1-cycloalkyl, where each n is an integer independently varying from 0 to 6 is already an integer ranging from 2 to 6, wherein the alkyl and cycloalkyl radicals of the above R37 groups are optionally substituted by one or more substituents selected independently; R39 is selected from the group consisting of H, C C6 alkyl, -S02-CrC6alkyl, -C (0) -CrC6 alkyl, -C (0) 0-CrC6alkyl, -C (O) -CrC6alkyl-NR3R3, -CrC6alkyl-0 -C -C6alkyl, -C (O) (CH2) o -4O (CH2) 1.40Ci-C6alkyl, -C (O) -C C6alkyl-OH, -C (0) -CF3 and -C (0) CH [CH (C C6alkyl) 2] NR3R3 and a protecting group used to protect secondary amino groups with the proviso that when R36 and R39 are both bound to the same nitrogen, then R36 and R39 are not both bound to nitrogen directly through an oxygen; R99 in each occurrence is independently -H, -NH2 or -OR3; R2 at each occurrence is independently selected from -H and halogen; each R3 is independently selected from the group consisting of -H and R4; R4 is (Ci-C6) alkyl; each R13 is independently selected from the group consisting of -H, -C (0) NR3R3 and Ci-C6 alkyl; Q is a ring system of three to ten members, optionally substituted with between zero and four of R20; and each R20 is independently selected from the group consisting of -H, halogen, trihalomethyl, -OR3, -S (O) 0.2R3, -S (O) 2NR3R3, -C (O) OR3, -C (O) NR3R3, - (CH2) o-5 (heteroaryl), CrC6alkyl, wherein n is an integer ranging from 0 to 6, and the heteroaryl and dC6 alkyl are optionally substituted. 2 - . 2 - The compound according to claim 1, further characterized in that D is an aromatic or heteroaromatic ring system, each of which is substituted with 1 or 2 independently selected R38 groups. 3. - The compound according to claim 1, further characterized because D is a heteroaromatic ring system of 5 or 6 members, each of which is replaced with 1 or 2 R38 groups selected independently 4. The compound according to claim 1, further characterized in that D is a 6-membered aromatic ring system or a 6-membered heteroaromatic ring system, each of which is substituted with 1 or 2 independently selected R38 groups. 5. The compound according to claim 1, further characterized in that D is a 6-membered aromatic ring system, substituted with 1 or 2 R38 groups selected independently. 6. - The compound according to claim 1, further characterized in that D is a heteroaromatic ring system of 6 members, replaced by 1 or 2 R38 groups selected independently. 7 -. 7 - The compound according to claim 1, further characterized in that D is a 5-membered heteroaromatic ring system, substituted by 1 or 2 independently selected R38 groups. 8. The compound according to claim 1, further characterized in that D is phenyl, pyridyl, imidazolyl or tetrahydropyridyl, each of which is substituted with 1 or 2 independently selected R38 groups. 9. The compound according to claim 1, further characterized in that each R38 is independently selected from the group consisting of dC6 alkyl, - (CH2) jNR39 (CH2) j (CH) (NH2) (COOH), - (CH2) ) jNR39 (CH2) jCOOH, (CH2) jNR39 (CH2) nR36 and -C0-C6alkyl- (optionally substituted heterocycle). 10. - The compound according to claim 1, further characterized in that R39 is selected from the group consisting of H, -C (0) -C C6 alkyl, -C (O) 0-C-C6alkyl, -C (0) -CrC6alk L-NH2, -S02-Me, -C (O) (CH2) 0-4O (CH2) 1-4OC1-C6alkyl and -C (O) CH [CH (C1-C6alkyl) 2] NR3R3 11. - The compound according to claim 1, further characterized in that R36 is -OMe. 12. - The compound according to claim 1, further characterized in that R99 is -OMe. 13. - The compound according to claim 1, further characterized in that M is where * represents the point of attachment to D, and † represents the point of attachment to Z. 14. The compound according to claim 1, further characterized in that Ar is selected from the group consisting of phenyl, pyrazine, pyridazine, pyrimidine and pyridine, wherein each of said phenyl, pyrazine, pyridazine, pyrimidine and pyridine is optionally substituted by 0 to 4 groups R2. 15. - The compound according to claim 1, further characterized in that G is selected from the group consisting of R13 R13 13 R 13 R 13 Q O o o O 0 16 -. 16 - The compound according to claim 1, further characterized in that G is selected from the group consisting of 17. - The compound according to claim 1, further characterized in that Q is selected from the group consisting of phenyl, cyclopropyl, isoxazolyl, cyclohexyl, thiazolyl, tetrahydrofuran, pyrazolyl, cyclobutyl and cyclopentyl, optionally substituted with between zero and two R20. 18. - The compound according to claim 1, further characterized because each R20 is independently selected between the group consisting of -P (= 0) (Me) 2, methyl, halo, trihalomethyl, methoxy, - C (0) NH2, heteroaryl, COOH, -S02NH2, -C (0) NH2, COOMe-, -C (0) N (H) (Me), -C (0) N (Me) 2 and -S02Me. 19 -. 19 - The compound according to claim 1, further characterized in that D is phenyl, pyridyl, imidazolyl or tetrahydropyridyl, each of which is substituted with 1 or 2 independently selected R38 groups; Month Z is -O-; Ar is phenyl optionally substituted by 0 to 4 halo; and G is selected from the group formed by R13 R 13 R 13 R13 R13 Q o o o o wherein Q is optionally substituted with from 0 to 4 R20 selected independently. twenty - . 20 - The compound according to claim 1, further characterized in that D is pyridyl substituted with (CH2) jNR39 (CH2) nR35, - (CH2) jNR39 (CH2) [0 (CH2),] x (CH2) jR99, -C0-C6alkyl- (heterocycle optionally substituted with an oxo), - (CH2) jNR39 (CH2) jCOOH, - (CH2) jNR39CH (CH3) (CH2) jR99 or - (CH2) iNR39 (CH2) j (CH) (NH2) (COOH); Month Z is -0-; Ar is phenyl optionally substituted by an F, and G is R13 wherein Q is optionally substituted with 0 to 4 R selected independently. 21. The compound according to claim 1, characterized in that D is pyridyl substituted with - (CH2) jNR39 (CH2) nR36, - (CH2) jNR39 (CH2) ¡[0 (CH2) ¡] x (CH2) iR99, - C0-C6alkyl- (heterocycle substituted with oxo), - (CH2) jNR39 (CH2) jCOOH or - (CH2) jNR39 (CH2) j (CH) (NH2) (COOH); R "is OMe; M is Z is -0-; Ar is phenyl optionally substituted by an F, and G is where R13 is H; and Q is phenyl optionally substituted with 1 or 2 R20 selected independently, wherein each R20 is independently selected from the group consisting of -P (= 0) (Me) 2, methyl, halo (eg, F), trihalomethyl , methoxy, -C (0) NH2, heteroaryl, -COOH, -S02HN2, -C (0) NH2, -COOMe, -C (0) N (H) (Me), -C (0) N (Me) 2 and -S02Me or Q is pyrazolyl optionally substituted with methyl, or Q is cyclopropyl, cyclobutyl or tetrahydrofuran, or Q is isoxazolyl substituted with methyl. 22. The compound according to claim 1, further characterized in that D is imidazolyl substituted with a C Cealkyl and a - (CH 2) j NR 39 (CH 2) j R 36 M is Z is -O-; Ar is phenyl optionally substituted with an F, and G is where Q is optionally substituted with 0 to 4 selected R independently. 23. The compound according to claim 1, further characterized in that D is imidazolyl substituted with a Ci-C6alkyl and a - (CH2) jNR39 (CH2) nR36; Month Z is -O-; Ar is phenyl optionally substituted with an F, and G is where R13 is H, and Q is phenyl optionally substituted with 0 to 4 R20 independently selected. 24. - The compound according to claim 1, further characterized in that D is imidazolyl substituted with a Ci-C6alkyl 36. and a - (CH2) jNRJ9 (CH2) nRJO; is Z is -O-; Ar is phenyl optionally substituted with an F and G is wherein R 13 is H, and Q is phenyl optionally substituted with one or two groups independently selected from the group consisting of -P (0) Me 2, methyl, F, trifluoromethyl, methoxy, -C (0) NH 2 and oxazolyl, or Q is cyclopropyl. 25. The compound according to claim 1, further characterized in that D is pyridyl substituted with (CH2) jNR39 (CH2) nR36, - (CH2) jNR39 (CH2) i [O (CH2) i] x (CH2) jR "1 -C0-C6alkyl- (heterocycle substituted with an oxo), - (CH2) jNR39 (CH2) jCOOH or - (CH2) jNR39 (CH2) j (CH) (NH2) (COOH); R99 is OMe; M is Z is -O-; Ar is phenyl optionally substituted with an F, and G is where R 3 is H; and Q is cyclopropyl. 26. The compound according to claim 1, further characterized in that D is pyridyl substituted with -C0-C6alkyl- (optionally substituted heterocycle); Month Z is -O-; Ar is phenyl optionally substituted with an F, and G is R13 R13 where R13 is H; and Q is cyclopropyl. 27. The compound according to claim 1, further characterized in that D is pyridyl substituted with -CH 2 - (5- or 6-membered heterocyclyl) wherein the 5- or 6-membered heterocyclyl is substituted with 0, 1 or 2 oxo); Month Z is -O-; Ar is phenyl substituted with an F, and G is R13 R13 O o wherein R13 is H, and Q is cyclopropyl. 28. - The compound according to claim 1, further characterized in that D is pyridyl substituted with Month Z is -O-; Ar is phenyl substituted with an F, and G is R13 R13 I i 0 or where R13 is H; and Q is cyclopropyl. 29. The compound according to claim 1, further characterized in that D is pyridyl substituted with - (CH 2) j NR 39 (CH 2) - [0 (CH 2) 1] x (CH 2) j R 99; R99 is OMe; Month Z is -O-; Ar is phenyl substituted with an F, and G is R13 R13 wherein R13 is H; and Q is cyclopropyl. 30. - A composition comprising a compound of any of claims 1 to 29. 31- An in vitro method for inhibiting kinase activity, the method comprising contacting kinase with a compound of any of claims 1 to 29 or a composition thereof. 32. The use of a compound of any of claims 1 to 29 or a composition thereof in the manufacture of a medicament for inhibiting angiogenesis in a patient. 33. The use of a compound of any one of claims 1 to 29 or a composition thereof in the manufacture of a medicament for treating a disease sensitive to inhibition of kinase activity in a patient. 34. The use of a compound of any of claims 1 to 29 or a composition thereof in the manufacture of a medicament for treating a cell proliferative disease in a patient. 35. The use of a compound of any one of claims 1 to 29 or a composition thereof in the manufacture of a medicament for treating an ophthalmic disease, condition or disorder in a patient.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3400508P | 2008-03-05 | 2008-03-05 | |
PCT/CA2009/000228 WO2009109035A1 (en) | 2008-03-05 | 2009-02-27 | Inhibitors of protein tyrosine kinase activity |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010009729A true MX2010009729A (en) | 2010-12-21 |
Family
ID=41055503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010009729A MX2010009729A (en) | 2008-03-05 | 2009-02-27 | Inhibitors of protein tyrosine kinase activity. |
Country Status (19)
Country | Link |
---|---|
US (3) | US8729268B2 (en) |
EP (2) | EP2262815A4 (en) |
JP (2) | JP2011513339A (en) |
KR (2) | KR20100132068A (en) |
CN (2) | CN102161663B (en) |
AR (2) | AR070539A1 (en) |
AU (2) | AU2009221583B2 (en) |
BR (2) | BRPI0908573A2 (en) |
CA (2) | CA2763168A1 (en) |
CO (1) | CO6290684A2 (en) |
IL (2) | IL207946A0 (en) |
MX (1) | MX2010009729A (en) |
NZ (2) | NZ589336A (en) |
RU (2) | RU2498988C2 (en) |
SG (1) | SG182146A1 (en) |
TW (2) | TWI438205B (en) |
UA (2) | UA101362C2 (en) |
WO (1) | WO2009109035A1 (en) |
ZA (2) | ZA201005868B (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2010009729A (en) * | 2008-03-05 | 2010-12-21 | Methylgene Inc | Inhibitors of protein tyrosine kinase activity. |
SG178965A1 (en) | 2009-09-03 | 2012-04-27 | Allergan Inc | Compounds as tyrosine kinase modulators |
US9340555B2 (en) | 2009-09-03 | 2016-05-17 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
KR20130100234A (en) * | 2010-04-16 | 2013-09-10 | 메틸진 인코포레이티드 | Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders |
CN103003283A (en) * | 2010-06-09 | 2013-03-27 | Abbvie公司 | Crystalline forms of kinase inhibitors |
TWI492949B (en) * | 2010-06-09 | 2015-07-21 | Abbvie Bahamas Ltd | Crystalline forms of kinase inhibitors |
TWI482770B (en) * | 2010-06-09 | 2015-05-01 | Abbvie Bahamas Ltd | Crystalline forms of kinase inhibitors |
SG187956A1 (en) * | 2010-08-27 | 2013-03-28 | Merck Patent Gmbh | Furopyridine derivatives |
AR083023A1 (en) * | 2010-09-17 | 2013-01-23 | Purdue Pharma Lp | PIRIDINE COMPOUNDS AND A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM |
BRPI1004176A2 (en) * | 2010-10-25 | 2015-08-11 | Univ Rio De Janeiro | Functionalized aryl and / or heteroaryl urea compounds; synthesis process of these compounds; pharmaceutical composition containing such compounds and uses |
US20130090327A1 (en) * | 2011-09-30 | 2013-04-11 | Methylgene Inc. | Inhibitors of Protein Tyrosine Kinase Activity |
US20130096135A1 (en) * | 2011-09-30 | 2013-04-18 | Methylgene Inc. | Selected Inhibitors of Protein Tyrosine Kinase Activity |
US20130096088A1 (en) * | 2011-09-30 | 2013-04-18 | Methylgene Inc. | Inhibitors of Protein Tyrosine Kinase Activity |
SG10201911585XA (en) * | 2014-12-09 | 2020-01-30 | Abbvie Inc | Bcl xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same |
FR3037957B1 (en) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | NOVEL HYDROXYESTER DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
CN118416236A (en) | 2018-01-31 | 2024-08-02 | 德西费拉制药有限责任公司 | Combination therapy for the treatment of gastrointestinal stromal tumors |
WO2019152719A1 (en) | 2018-01-31 | 2019-08-08 | Deciphera Pharmaceuticals, Llc | Combination therapy for the treatment of mastocytosis |
MX2022001863A (en) | 2019-08-12 | 2022-05-30 | Deciphera Pharmaceuticals Llc | Ripretinib for treating gastrointestinal stromal tumors. |
TW202122082A (en) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | Methods of treating gastrointestinal stromal tumors |
HRP20231699T1 (en) | 2019-12-30 | 2024-05-10 | Deciphera Pharmaceuticals, Llc | Amorphous kinase inhibitor formulations and methods of use thereof |
AU2020417282B2 (en) | 2019-12-30 | 2023-08-31 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
WO2023155777A1 (en) * | 2022-02-15 | 2023-08-24 | Beigene (Suzhou) Co., Ltd. | N- [ (6-bromopyridin-3-yl) methyl] -2-methoxyethan-1-amine salts and preparation thereof |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7000A (en) * | 1850-01-08 | Smut-machine | ||
US7019A (en) * | 1850-01-15 | Improvement in obstetrical supporters | ||
US6107300A (en) * | 1996-03-27 | 2000-08-22 | Dupont Pharmaceuticals | Arylamino fused pyrimidines |
KR100446363B1 (en) | 1997-11-11 | 2004-09-01 | 화이자 프로덕츠 인코포레이티드 | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
CA2333770A1 (en) | 1998-06-04 | 1999-12-09 | Abbott Laboratories | Cell adhesion-inhibiting antinflammatory compounds |
EP1181296A1 (en) | 1999-06-03 | 2002-02-27 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
ATE277933T1 (en) | 2000-06-06 | 2004-10-15 | Pfizer Prod Inc | THIOPHENE COMPOUNDS FOR USE AS ANTICANCER AGENTS |
US20020004511A1 (en) * | 2000-06-28 | 2002-01-10 | Luzzio Michael Joseph | Thiophene derivatives useful as anticancer agents |
RU2264389C3 (en) * | 2000-10-20 | 2018-06-01 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | NITROGEN-CONTAINING AROMATIC DERIVATIVES, THEIR APPLICATION, MEDICINE ON THEIR BASIS AND METHOD OF TREATMENT |
US6995171B2 (en) * | 2001-06-21 | 2006-02-07 | Agouron Pharmaceuticals, Inc. | Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents |
GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
AU2003206068A1 (en) * | 2002-03-01 | 2003-09-16 | Pfizer Inc. | Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents |
US20030199525A1 (en) | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
CL2003002287A1 (en) | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPOUNDS DERIVED FROM TIENO [3,2-b] -PIRIDINA-6-CARBONITRILOS AND TIENEO [2,3-b] -PIRIDINA-5-CARBONITRILS, PHARMACEUTICAL COMPOSITION, PROCEDURE OF PREPARATION AND INTERMEDIARY COMPOUNDS, AND THEIR USE IN THE TREATMENT OF CANCER, APOPLEJIA, OSTEOPOROSIS |
US20050065171A1 (en) | 2003-06-25 | 2005-03-24 | Shakespeare William C. | Substituted purine derivatives |
CA2536321A1 (en) | 2003-08-29 | 2005-03-10 | Pfizer Inc. | Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents |
WO2005052872A1 (en) * | 2003-11-21 | 2005-06-09 | Facil, Llc | Financial transaction system and method |
EP1711495A2 (en) | 2004-01-23 | 2006-10-18 | Amgen Inc. | Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer |
US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
WO2005121125A1 (en) * | 2004-06-09 | 2005-12-22 | Pfizer Inc. | Ether-linked heteroaryl compounds |
US20050288290A1 (en) * | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
US7439246B2 (en) * | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
EP1773826A4 (en) | 2004-07-02 | 2009-06-03 | Exelixis Inc | C-met modulators and method of use |
CA2573999A1 (en) | 2004-07-16 | 2006-04-06 | Sunesis Pharmaceuticals, Inc. | Thienopyrimidines useful as aurora kinase inhibitors |
EP1781664B1 (en) * | 2004-07-30 | 2013-09-04 | MethylGene Inc. | Inhibitors of vegf receptor and hgf receptor signaling |
MX2007006230A (en) * | 2004-11-30 | 2007-07-25 | Amgen Inc | Quinolines and quinazoline analogs and their use as medicaments for treating cancer. |
AU2006229343A1 (en) * | 2005-03-28 | 2006-10-05 | Kirin Pharma Kabushiki Kaisha | Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency |
US20080161305A1 (en) | 2005-04-06 | 2008-07-03 | Exelixis, Inc. | C-Met Modulators and Methods of Use |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Substituted Amid derivatives & methods of use |
WO2008041053A2 (en) * | 2005-05-20 | 2008-04-10 | Methylgene, Inc. | Inhibitors of vegf receptor and hgf receptor signaling |
US7790729B2 (en) | 2005-05-20 | 2010-09-07 | Methylgene Inc. | Inhibitors of VEGF receptor and HGF receptor signaling |
TW200740820A (en) * | 2005-07-05 | 2007-11-01 | Takeda Pharmaceuticals Co | Fused heterocyclic derivatives and use thereof |
JP2009526761A (en) | 2006-01-30 | 2009-07-23 | アレイ バイオファーマ、インコーポレイテッド | Heterobicyclic thiophene compounds and methods of use |
WO2007107005A1 (en) | 2006-03-22 | 2007-09-27 | Methylgene, Inc. | Inhibitors of protein tyrosine kinase activity |
US7298968B1 (en) * | 2007-01-05 | 2007-11-20 | Rheem Manufacturing Company | Pumpless combination instantaneous/storage water heater system |
PL2183254T3 (en) * | 2007-08-29 | 2017-10-31 | Methylgene Inc | Inhibitors of protein tyrosine kinase activity |
MX2010009729A (en) * | 2008-03-05 | 2010-12-21 | Methylgene Inc | Inhibitors of protein tyrosine kinase activity. |
KR20130100234A (en) * | 2010-04-16 | 2013-09-10 | 메틸진 인코포레이티드 | Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders |
-
2009
- 2009-02-27 MX MX2010009729A patent/MX2010009729A/en not_active Application Discontinuation
- 2009-02-27 NZ NZ589336A patent/NZ589336A/en not_active IP Right Cessation
- 2009-02-27 WO PCT/CA2009/000228 patent/WO2009109035A1/en active Application Filing
- 2009-02-27 UA UAA201011785A patent/UA101362C2/en unknown
- 2009-02-27 RU RU2010145459/04A patent/RU2498988C2/en not_active IP Right Cessation
- 2009-02-27 CA CA2763168A patent/CA2763168A1/en not_active Abandoned
- 2009-02-27 EP EP09716596A patent/EP2262815A4/en not_active Withdrawn
- 2009-02-27 KR KR1020107025059A patent/KR20100132068A/en not_active Application Discontinuation
- 2009-02-27 SG SG2012040093A patent/SG182146A1/en unknown
- 2009-02-27 JP JP2010548992A patent/JP2011513339A/en active Pending
- 2009-02-27 BR BRPI0908573-4A patent/BRPI0908573A2/en not_active IP Right Cessation
- 2009-02-27 TW TW099142241A patent/TWI438205B/en not_active IP Right Cessation
- 2009-02-27 CN CN201010549696.5A patent/CN102161663B/en not_active Expired - Fee Related
- 2009-02-27 NZ NZ588355A patent/NZ588355A/en not_active IP Right Cessation
- 2009-02-27 BR BRPI0923670-8A patent/BRPI0923670A2/en not_active IP Right Cessation
- 2009-02-27 AU AU2009221583A patent/AU2009221583B2/en not_active Ceased
- 2009-02-27 CN CN200980107358.1A patent/CN102015723B/en not_active Expired - Fee Related
- 2009-02-27 UA UAA201013462A patent/UA100262C2/en unknown
- 2009-02-27 US US12/920,676 patent/US8729268B2/en not_active Expired - Fee Related
- 2009-02-27 TW TW098106618A patent/TW200940549A/en unknown
- 2009-02-27 EP EP10015089A patent/EP2332536A1/en not_active Withdrawn
- 2009-02-27 CA CA2717816A patent/CA2717816A1/en not_active Abandoned
- 2009-02-27 RU RU2010140668/04A patent/RU2533827C2/en not_active IP Right Cessation
- 2009-02-27 AR ARP090100693A patent/AR070539A1/en unknown
- 2009-02-27 KR KR1020107022142A patent/KR20100137495A/en not_active Application Discontinuation
-
2010
- 2010-08-17 ZA ZA2010/05868A patent/ZA201005868B/en unknown
- 2010-09-02 IL IL207946A patent/IL207946A0/en unknown
- 2010-10-01 CO CO10121775A patent/CO6290684A2/en active IP Right Grant
- 2010-10-21 IL IL208882A patent/IL208882A0/en unknown
- 2010-10-21 ZA ZA2010/07517A patent/ZA201007517B/en unknown
- 2010-11-26 AR ARP100104383A patent/AR079208A2/en unknown
- 2010-11-30 AU AU2010246540A patent/AU2010246540B2/en not_active Ceased
- 2010-12-09 US US12/964,289 patent/US8759522B2/en not_active Expired - Fee Related
-
2011
- 2011-01-21 JP JP2011010326A patent/JP5661485B2/en not_active Expired - Fee Related
-
2014
- 2014-02-28 US US14/194,155 patent/US20140179632A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010009729A (en) | Inhibitors of protein tyrosine kinase activity. | |
US8404846B2 (en) | Inhibitors of protein tyrosine kinase activity | |
AU2011241420B2 (en) | Inhibitors of protein tyrosine kinase activity and use thereof to treat ophthalmic disorders | |
US20130096088A1 (en) | Inhibitors of Protein Tyrosine Kinase Activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |